POLIPEPTÍDEOS DE FUSÃO, COMPOSIÇÕES IMUNOGÊNICAS, MÉTODOS E USOS DOS MESMOS

Abstract

Fusion polypeptides, and their use in subunit vaccine compositions to elicit immune responses against two or more pathogens are described, as well as polynucleotides encoding therefor. Also described are methods for treating and preventing infection by two or more pathogens.

Description

115 Fusion polypeptides, immunogenic compositions, methods and uses thereof. Technical Area

[0001] The present invention relates generally to pathogens. In particular, the invention relates to fusion polypeptides, immunogenic compositions comprising fusion polypeptides, and methods for the simultaneous treatment and / or prevention of one or more pathogen-related conditions or pathogen infections. Fundamentals

[0002] The emergence of new pathogens and new variants of existing pathogens with increased transmission or the potential to circumvent vaccine-acquired immunity are significant barriers to ending pandemics, such as SARS-CoV-2, as well as preventing future outbreaks. Even more concerning is the significant potential for new pathogens, such as Coronaviridae, to spread from an animal reservoir and initiate an entirely new pandemic. Broadly protective or pan-pathogenic vaccines that can protect against a variety of bacterial, fungal, and / or viral species, such as Betacoronaviruses, simultaneously offer a solution to the continuous emergence of new pathogens and / or new variants of pathogens.

[0003] Antigen design and the time required for vaccine production are two constraints for the development and implementation of vaccines for the treatment and / or prevention of infectious diseases. Current vaccination strategies for the treatment and prevention of viruses, for example, require the provision of a vaccine that matches circulating strains to keep pace with emerging new and potentially harmful variants. This strategy is limited because it targets only a single viral variant, which may result in reduced or absent protection against a wide range of viral variants and / or species. Furthermore, the significant time required for the production of many current vaccine formulations hinders the ability to rapidly produce new formulations targeting any new or potential variants. In addition, each vaccine is produced separately, representing a significant expenditure of time and money for the manufacturer and / or developer.Furthermore, delays in the acquisition of... Petition 870250095390, dated 10 / 19 / 2025, page 5 / 166 / 115 vaccines in low- and middle-income countries may be further aggravated with conventional approaches, contributing to greater vaccine disparity.

[0004] Subunit vaccines, which are vaccine compositions that include one or more selected antigens, but not all antigens, derived from or homologous to an antigen of a pathogen of interest, provide a system conducive to faster and more economical vaccine manufacturing; however, the use of fewer potentially antigenic proteins has limited the effectiveness of these subunit vaccines compared to their traditional vaccine counterparts.

[0005] Multivalent vaccines are those that elicit an immune response to two or more antigens; however, current multivalent vaccines are limited in their effectiveness in neutralizing two or more antigens to prevent disease, as well as in their ability to be produced and / or modified quickly.

[0006] Current multivalent vaccines, such as those for the treatment and / or prevention of diphtheria, tetanus and / or pertussis, comprise separately prepared pathogenic components, such as inactivated toxins, which are combined to produce a final immunogenic composition.

[0007] Bivalent vaccines targeting the SARS-CoV-2 virus that induces COVID-19 and its variants comprise separately prepared mRNA directed against the ancestral SARS-CoV-2 virus and against the BA.4 / BA.5 variants. The use of these bivalent vaccines for the prevention of COVID-19 has not resulted in significant differences in the ability to neutralize any variant of SARS-CoV-2 compared to monovalent vaccines targeting the ancestral strain from which the variants were derived.

[0008] The ability to provide two or more antigens and a delivery system for them that facilitates the neutralization of multiple pathogens and / or pathogen variants in a single composition is required. Specifically, there is a need to develop broadly protective, rapidly editable, low-cost, and temperature-stable vaccines that protect against current and emerging viruses, such as coronaviruses, and a platform for their preparation. Petition 870250095390, dated 10 / 19 / 2025, page 6 / 166 / 115 Summary of the Invention

[0009] In certain embodiments described herein, a fusion polypeptide is provided which may comprise an amino acid sequence encoding, in sequence, a first antigen, a ligand and at least one additional antigen.

[0010] In certain embodiments, the at least one additional antigen may comprise a plurality of antigens and each antigen of the plurality of antigens may be linked to the preceding antigen with a linker peptide comprising the ligand.

[0011] In certain embodiments, the sequence of the first antigen may comprise a greater number of amino acids than the sequence of at least one or more antigens.

[0012] In certain embodiments, the first antigen may comprise an antigenic peptide or fragment thereof from a first pathogen.

[0013] In certain embodiments, the first antigen may comprise a first prokaryotic antigen, a first viral antigen, or a first fungal antigen.

[0014] In certain embodiments, the first viral antigen may comprise a component of a viral surface glycoprotein, a lipoprotein, or an extracellular domain of a transmembrane protein.

[0015] In certain embodiments, the first viral antigen may comprise a first coronavirus antigen comprising a MERS-CoV antigen, a SARS-CoV-1 antigen, a SARS-CoV-2 antigen (for example, but not limited to a Wuhan coronavirus antigen, e.g coronavirus antigen BA.1, a coronavirus antigen BA.2 or a coronavirus antigen B.1,351), an HCoV-HKU1 antigen, an HCoV-OC43 antigen, a BtCoV-RaTG13 antigen, a Bt antigen SL-CoV-WIV1, an antigen HKU4-CoV, a HKU5-CoV antigen, a PDF-2108 CoV antigen, a SHC014-CoV antigen, a BtSCoV-RsSHC014 antigen, a BtSCoV-Rs3367 antigen, a BANAL-52 antigen, a BANAL-236 antigen, and so on Pangolin-CoV GX / P2V antigen, a morsel CDPHE15 coronavirus antigen, a morsel HKU10 coronavirus antigen, a HuB-2013 alphacoronavirus antigen of Rhinolophus ferrumequinum, a human coronavirus antigen 229E, a coronavirus antigen of mouse Lucheng Rn, Petition 870250095390, of 19 / 10 / 2025, p. 7 / 166 / 115 a mink coronavirus 1 antigen, a ferret coronavirus antigen, a Miniopterus bat coronavirus 1 antigen, a Miniopterus bat HKU8 coronavirus antigen, a Myo-2011 alphacoronavirus antigen, an alphacoronavirus antibody SC-2013 of Nyctalus velutinus, a coronavirus antigen 3398 of Pipistrellus kuhlii, a swine epidemic diarrhea virus antigen, a Scotophilus bat coronavirus 512 antigen, a HKU2 coronavirus antigen, a bat NL36 antigen human coronavirus, an NL63-related bat coronavirus strain BtKYNL63-9b antigen, a Sorex araneus T14 coronavirus antigen, a Suncus murine X74 coronavirus antigen, an Alphacoronavirus 1 antigen, a canine coronavirus antigen, a coronavirus antigen feline, a human antigen CCoV-HuPn-2018, a swine transmissible gastroenteritis coronavirus antigen,an antigen of the porcine acute diarrheal syndrome coronavirus (SADSCoV), an HCoV-NL63 antigen, a Khosta2 sarbecovirus antigen, a Kenya bat coronavirus BtKY72 antigen, a bat SARS coronavirus HKU3 antigen, an antigen of the NL63-related bat coronavirus strain BtKYNL63-9b, an HCoV-229E antigen, or any combination thereof.

[0016] In certain embodiments, the first coronavirus antigen may comprise a spike (S) protein or a fragment thereof. In certain embodiments, the first coronavirus antigen may comprise a SARS-CoV-2 spike protein or a protein encoded by a nucleotide sequence with at least 70% identity to the SARS-CoV-2 spike protein. In certain embodiments, the first coronavirus antigen may comprise an S1 protein or a fragment thereof. In certain embodiments, the first coronavirus antigen may comprise a SARS-CoV-2 S1 protein or a protein encoded by a nucleotide sequence with at least 70% identity to the SARS-CoV-2 S1 protein.

[0017] In certain embodiments, the linkage sequence may comprise from 6 to 24 amino acids. In certain embodiments, the linkage sequence may comprise glycine (G), serine (S), alanine (A), or any Petition 870250095390, dated 10 / 19 / 2025, page 8 / 166 / 115 combination thereof. In certain embodiments, an amino acid sequence of the ligand may comprise GSGSGS or GAAASG.

[0018] In certain embodiments, the at least one additional antigen may comprise at least one additional antigenic peptide or fragment thereof from at least one additional pathogen.

[0019] In certain embodiments, at least one additional antigen may comprise an amino acid sequence of at least 8 amino acids.

[0020] In certain embodiments, the at least one additional antigenic protein may comprise at least one additional prokaryotic antigen, at least one additional viral antigen, at least one additional fungal antigen, or any combination thereof.

[0021] In certain embodiments, the at least one additional viral antigen may comprise at least one coronavirus antigen, wherein the at least one coronavirus antigen is a Coronaviridae antigen.

[0022] In certain embodiments, at least one coronavirus antigen may comprise a MERS-CoV antigen, a SARS-CoV-1 antigen, a SARS-CoV-2 antigen (for example, but not limited to, a Wuhan coronavirus antigen, a BA.1 coronavirus antigen, a BA.2 coronavirus antigen or a B.1 coronavirus antigen.351), on HCoV-HKU1 antigen, on HCoV-OC43 antigen, on BtCoVRaTG13 antigen, on Bt SL-CoV-WIV1 antigen, on HKU4-CoV antigen, on HKU5-CoV antigen, on PDF-2108 CoV antigen, on SSVHC0 antigen, on BtSCoV-RsSHC014, a BtSCoV-Rs3367 antigen, a BANAL-52 antigen, a BANAL-236 antigen, a Pangolin-CoV GX / P2V antigen, a bat CDPHE15 coronavirus antigen, a HKU10 coronavirus antigen, a morphological alpha coronavirus antigen HuB-2013 of Rhinolophus ferrumequinum, a human coronavirus antigen 229E, a mouse coronavirus antigen Lucheng Rn, a mink coronavirus 1 antigen, a ferret coronavirus antigen, a bat coronavirus 1 antigen, a Hterus coronavirus antigen Hterus8 bat Miniopterus, an alphacoronavirus antigen Sax-2011 from Myotis ricketti, an alphacoronavirus SC-2013 antigen from Nyctalus velutinus, a coronavirus 3398 antigen from Pipistrellus kuhlii, a diarrhea virus antigen. Petition 870250095390, dated 10 / 19 / 2025, page. 9 / 166 / 115 swine epidemic, an antigen of the Scotophilus bat coronavirus 512, an antigen of the Rhinolophus bat coronavirus HKU2, an antigen of the human NL63 coronavirus, an antigen of the NL63-related bat coronavirus strain BtKYNL63-9b, an antigen of the Sorex araneus coronavirus T14, an antigen of the Suncus murinus coronavirus X74, an antigen of the alphacoronavirus 1, a canine coronavirus antigen, a feline coronavirus antigen, a human CCoV-HuPn-2018 antigen, a porcine transmissible gastroenteritis coronavirus antigen, a porcine acute diarrheal syndrome coronavirus (SADS-CoV) antigen, an HCoV-NL63 antigen, an antigen of the NL63-related bat coronavirus strain BtKYNL63-9b, an HCoV-229E antigen, a sarbecovirus antigen Khosta2, an antigen of the bat coronavirus BtKY72 from Kenya, a bat SARS HKU3 coronavirus antigen, or any combination thereof.

[0023] In certain embodiments, at least one coronavirus antigen may comprise a receptor-binding domain, a fragment thereof, or a nucleotide-encoded protein with at least 70% identity to a Coronaviridae receptor-binding domain.

[0024] In certain embodiments, the first antigen and at least one additional antigen may each independently comprise a prokaryotic antigen, a viral antigen, or a fungal antigen.

[0025] In certain embodiments, the fusion polypeptide may also comprise, in sequence, a third antigen and the upstream binding sequence of the first antigen.

[0026] In certain embodiments, the plurality of antigens may comprise prokaryotic antigens, viral antigens, fungal antigens, or any combination thereof.

[0027] In certain forms, viral antigens may comprise coronavirus antigens.

[0028] In certain embodiments, coronavirus antigens may comprise MERS-CoV antigens, SARS-CoV-1 antigens, SARS-CoV-2 antigens (e.g., but not limited to Wuhan coronavirus antigens, BA.1 coronavirus antigens, BA.2 coronavirus antigens, or B.1.351 coronavirus antigens), HCoV-HKUI antigens, HCoV-OC43 antigens, Petition 870250095390, of 19 / 10 / 2025, p. 10 / 166 / 115 BtCoV-RaTG13 antigens, Bt SL-CoV-WIVI antigens, HKU4-CoV antigens, HKU5-CoV antigens, PDF-2108 CoV antigens, SHC014-CoV antigens, BtCoV-RaTG13 antigens, HCS014 antigens BtSCoV-Rs3367, BANAL52 antigens, BANAL-236 antigens, Pangolin-CoV GX / P2V antigens, bat CDPHE15 coronavirus antigens, bat HKU10 coronavirus antigens, Rs. human coronavirus antigens 229E, Lucheng Rn mouse coronavirus antigens, mink coronavirus 1 antigens, ferret coronavirus 1 antigens, bat coronavirus 1 antigens, Miniopterus bat coronavirus 1 antigens, double coronavirus antigens, Miniopterus bat antibodies Myotis ricketti sax-2011, Nyctalus velutinus SC-2013 alphacoronavirus antigens, Pipistrellus kuhlii coronavirus 3398 antigens, swine epidemic diarrhea virus antigens,Antigens of Scotophilus bat coronavirus 512, antigens of Rhinolophus bat coronavirus HKU2, human NL63 coronavirus antigens, antigens of the NL63-related bat coronavirus strain BtKYNL63-9b, antigens of Sorex araneus coronavirus T14, antigens of Suncus murinus coronavirus X74, antigens of alphacoronavirus 1, canine coronavirus antigens, feline coronavirus antigens, a human CCoV-HuPn-2018 antigen, antigens of swine transmissible gastroenteritis coronavirus, antigens of swine acute diarrheal syndrome coronavirus (SADS-CoV), HCoV-NL63 antigens, antigens of the NL63-related bat coronavirus strain BtKYNL63-9b, antigens of HCoV-229E, antigens of Khosta2 sarbecovirus, antigens of Kenyan bat coronavirus BtKY72, antigens of bat SARS coronavirus HKU3, or any combination thereof. of these.

[0029] In certain embodiments, the coronavirus antigen may comprise a receptor-binding domain, a fragment thereof, or a nucleotide-encoded protein with at least 70% identity to a Coronaviridae receptor-binding domain.

[0030] In certain embodiments, the first antigen and at least one additional antigen may each independently comprise a prokaryotic antigen, a viral antigen, or a fungal antigen. Petition 870250095390, dated 10 / 19 / 2025, page 11 / 166 / 115

[0031] In certain embodiments, a fusion polypeptide is provided which may comprise an amino acid sequence encoding a plurality of antigens in series, wherein each of the plurality of antigens is linked to a preceding antigen-binding sequence.

[0032] In certain modalities, the plurality of antigens may comprise two or more antigens.

[0033] In certain embodiments, each of the plurality of antigens may independently comprise a prokaryotic antigen, a viral antigen, or a fungal antigen.

[0034] In certain embodiments, the linkage sequence may comprise from 6 to 24 amino acids. In certain embodiments, the linkage sequence may comprise glycine (G), serine (S), alanine (D), or any combination thereof.

[0035] In certain embodiments, the fusion polypeptide may comprise a Wuhan coronavirus antigen and a B.1.617.2 coronavirus antigen.

[0036] In certain embodiments, the fusion polypeptide may comprise a Wuhan coronavirus antigen and a BA.2 coronavirus antigen.

[0037] In certain embodiments, the fusion polypeptide may comprise a Wuhan coronavirus antigen and a BA.1 coronavirus antigen.

[0038] In certain embodiments, the fusion polypeptide may comprise a B.1.351 coronavirus antigen, a Wuhan coronavirus antigen, and a BA.2 coronavirus antigen.

[0039] In certain embodiments, the fusion polypeptide may comprise a B.1.351 coronavirus antigen, a Wuhan coronavirus antigen, and a BA.1 coronavirus antigen.

[0040] In certain embodiments, the fusion polypeptide may comprise a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen, and a bat SARS-like WIV1 coronavirus antigen.

[0041] In certain embodiments, the fusion polypeptide may comprise a BA.2 coronavirus antigen, a coronavirus antigen BtKY72 from Kenyan bats and a BtSCoV-RsSHC014 antigen. Petition 870250095390, dated 10 / 19 / 2025, page 12 / 166 / 115

[0042] In certain embodiments, the fusion polypeptide may comprise a Wuhan coronavirus antigen, a Pang17 pangolin coronavirus antigen, and a SARS-like bat coronavirus WIV1 antigen.

[0043] In certain embodiments, the fusion polypeptide may comprise a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen, a BtSCoV-RsSHC014 antigen, and a bat SARS-like WIV1 coronavirus antigen.

[0044] In certain embodiments, the fusion polypeptide may comprise a BA.2 coronavirus antigen, an HKU3 bat SARS coronavirus antigen, a Kenya bat BtKY72 coronavirus antigen, and a bat SARS-like coronavirus antigen WIV1.

[0045] In certain embodiments, the fusion polypeptide may comprise a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen, a BtSCoV-RsSHC014 antigen, and an Urbani SARS coronavirus antigen.

[0046] In certain embodiments, the fusion polypeptide may comprise a Wuhan coronavirus antigen, a RaTG13 bat coronavirus antigen, a Kenyan bat coronavirus BtKY72 antigen, and a SARS-like bat coronavirus WIV1 antigen.

[0047] In certain embodiments, the antigen may comprise a receptor-binding domain or an S1 domain.

[0048] In certain embodiments, the antigen may comprise a selected sequence from the group consisting of SEQ ID NOs:12-24.

[0049] In certain embodiments described herein, a fusion polypeptide of SEQ ID NO:1 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:1 is provided.

[0050] In certain embodiments described herein, a fusion polypeptide with SEQ ID NO:2 or a sequence with at least Petition 870250095390, dated 10 / 19 / 2025, page 13 / 166 10 / 115 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:2.

[0051] In certain embodiments described herein, a fusion polypeptide of SEQ ID NO:3 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:3 is provided.

[0052] In certain embodiments described herein, a fusion polypeptide of SEQ ID NO:4 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:4 is provided.

[0053] In certain embodiments described herein, a fusion polypeptide of SEQ ID NO:5 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:5 is provided.

[0054] In certain embodiments described herein, a fusion polypeptide of SEQ ID NO:6 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:6 is provided. Petition 870250095390, dated 10 / 19 / 2025, page 14 / 166 / 115

[0055] In certain embodiments described herein, a fusion polypeptide of SEQ ID NO:7 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:7 is provided.

[0056] In certain embodiments described herein, a fusion polypeptide of SEQ ID NO:8 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:8 is provided.

[0057] In certain embodiments described herein, a fusion polypeptide of SEQ ID NO:9 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:9 is provided.

[0058] In certain embodiments described herein, a fusion polypeptide of SEQ ID NO:10 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:10 is provided.

[0059] In certain embodiments described herein, a fusion polypeptide with SEQ ID NO:11 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least is provided. Petition 870250095390, dated 10 / 19 / 2025, page 15 / 166 12 / 115 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:11.

[0060] In certain embodiments, an immunogenic composition is provided comprising a fusion polypeptide as described herein and a pharmaceutically acceptable salt, carrier or adjuvant.

[0061] In certain embodiments, the use of a fusion polypeptide or immunogenic compound, as described herein, is provided for in the manufacture of a medicament for the treatment or prevention of a pathogenic infection in a subject who requires it.

[0062] In certain embodiments, the use of a fusion polypeptide or immunogenic compound, as described herein, is provided for the treatment or prevention of a pathogenic infection in a subject who requires it.

[0063] In certain embodiments, a method of treating or preventing a pathogenic infection is provided, comprising administering an effective amount of a fusion polypeptide or an immunogenic composition, as described herein, to a subject in need thereof. In certain embodiments, the pathogenic infection may comprise a viral infection, a bacterial infection, or a fungal infection.

[0064] In certain embodiments of a use or method, the pathogenic infection may comprise a viral infection. In certain embodiments of a use or method, the viral infection may comprise a Coronaviridae virus.

[0065] In certain embodiments of a use or method, the coronavirus can comprise MERS-CoV, SARS-CoV-1, SARS-CoV-2, HCoV-HKU1, HCoV-OC43, BtCoV-RaTG13, Bt SL-CoV-WIV1, HKU4-CoV-CoV, PKU-CoV-218 CoV, SHC014-CoV, BtSCoV-RsSHC014, BtSCoV-Rs3367, BANAL-52, BANAL-236, Pangolin-CoV GX / P2V, bat CDPHE15 coronavirus, bat HKU10 coronavirus, Rhinofernovirus derumen, antibody human coronavirus 229E, a Lucheng Rn mouse coronavirus antigen, a mink coronavirus 1 antigen, a ferret coronavirus 1 antigen, a bat Miniopterus coronavirus 1 antigen, a bat HKU8 coronavirus antigen, a 2011 Saxon coronavirus antigen Myotis ricketti, a Nyctalus velutinus alphacoronavirus SC-2013 antigen, a Pipistrellus kuhlii coronavirus 3398 antigen, a swine epidemic diarrhea virus antigen, Petition 870250095390, of 19 / 10 / 2025, p. 16 / 166 13 / 115 Scotophilus brood coronavirus 512, Rhinolophus brood coronavirus HKU2, human coronavirus NL63, BtKYNL63-9b strain of NL63-related brood coronavirus, Sorex araneus coronavirus T14, Suncus murinus coronavirus X74, Alphacoronavirus 1, canine coronavirus, feline coronavirus, human CCoV-HuPn-2018, swine transmissible gastroenteritis coronavirus, swine acute diarrhea syndrome coronavirus (SADS-CoV), HCoVNL63, NL63-related morsel coronavirus strain BtKYNL63-9b, HCoV-229E, sarbecovirus Khosta2, coronavirus WIV1 SARS type mortality, coronavirus BtKY72from Kenya mortality, coronavirus SHC014, coronavirus pangolim Pang17, coronavirus HKU3 SARS mortality, coronavirus SARS Urbani, coronavirus RaTG13 mortality, coronavirus Wuhan, coronavirus BA.1, coronavirus BA.2, coronavirus B.1,351 or any combination of the same; or a virus with at least 70% nucleotide identity with MERS-CoV, SARS-CoV-1, SARS-CoV-2, HCoV-HKLH,HCoV-OC43, BtCoV-RaTG13, Bt SL-CoV-WIV1, HKU4-CoV, HKU5-CoV, PDF2108 CoV, SHC014-CoV, BtSCoV-RsSHC014, BtSCoV-Rs3367, BANAL-52, BANAL-236, Pangolin-CoV GX / P2V, morsel coronavirus CDPHE15, morsel HKU10 coronavirus, Rhinolophus ferrumequinum alphacoronavirus HuB-2013, human coronavirus 229E, Lucheng Rn mouse coronavirus, mink coronavirus 1, furan coronavirus, Miniopterus morsel coronavirus 1, coronavirus HKLI8 of Miniopterus morsel Sax2011 alphacoronavirus of Myotis ricketti, Nyctalus velutinus alphacoronavirus SC-2013, coronavirus 3398 Pipistrellus kuhlii, swine epidemic diarrhea virus, coronavirus 512 of Scotophilus morsel, HKLI2 coronavirus of morcego Rhinolophus, human coronavirus NL63, NL63-related morcego strain BtKYNL63-9b, coronavirus T14 of Sorex araneus, coronavirus X74 of Suncus murinus, Alphacoronavirus 1, canine coronavirus, feline coronavirus, CCoV-HuPn-2018 human, coronavirus da swine transmissible gastroenteritis,swine acute diarrhea syndrome coronavirus (SADS-CoV), HCoVNL63, NL63-related morsel BtKYNL63-9b coronavirus strain, HCoV-229E, Khosta2 sarbecovirus, morsel SARS-type WIV1 coronavirus, Kenya morsel BtKY72 coronavirus, coronavirus SHC014 morsel, pangolim coronavirus Pang17, coronavirus HKU3 SARS morsel, coronavirus SARS Urbani, coronavirus RaTG13 morsel, coronavirus, Petition 870250095390, 10 / 19 / 2025, p. 17 / 1 14 / 115 Wuhan, coronavirus BA.1, coronavirus BA.2, coronavirus B.1.351 or any combination thereof; or a virus with at least 70% nucleotide identity with MERS-CoV, SARS-CoV-1, SARS-CoV-2, HCoV-HKLH, HCoV-OC43, BtCoV-RaTG13, Bt SL-CoV-WIV1, HKU4-CoV, HKU5-CoV-CoV, PVDF2, 108, CoV SHC014-CoV, BtSCoV-RsSHC014, BtSCoV-RsS3367, BANAL-52, BANAL-236, Pangolin-CoV GX / P2V, bat coronavirus CDPHE15, bat coronavirus HKU10, alphacoronavirus HuB-2013, Rhinoferum ferrous Corona virus human 229E, Lucheng Rn mouse coronavirus, mink coronavirus 1, ferret coronavirus, bat Miniopterus coronavirus 1, Miniopterus bat HKLI8 coronavirus, Myotis ricketti alphacoronavirus 229E, Myotis ricketti alphacoronavirus 2013, N. veluctus alphacoronavirus 2013 Pipistrellus kuhlii coronavirus 3398, swine epidemic diarrhea virus, bat Scotophilus coronavirus 512, bat Rhinolophus coronavirus HKLI2, human coronavirus NL63,NL63-related morsel BtKYNL63-9b coronavirus strain, Sorex araneus coronavirus T14, Suncus murinus coronavirus X74, Alphacoronavirus 1, canine coronavirus, feline coronavirus, human CCoV-HuPn-2018, porcine transmissible gastroenteritis coronavirus, da swine acute diarrhea syndrome (SADS-CoV), HCoV-NL63, NL63-related mortality BtKYNL63-9b coronavirus strain, HCoV229E, Khosta2 sarbecovirus, WIV1 mortality SARS-like coronavirus, Kenya mortgage coronavirus BtKY72, coronavirus SHC014 of morsel, pangolim coronavirus Pang17, coronavirus HKU3 SARS morsel, coronavirus SARS Urbani, coronavirus RaTG13 morsel, Wuhan coronavirus, coronavirus BA.1, coronavirus BA.2, coronavirus B.1,351 or any combination of these.,

[0066] In certain embodiments of one use or method, the fusion polypeptide or immunogenic composition is for administration one or more times.

[0067] In certain embodiments of a use or method, the fusion polypeptide or immunogenic composition neutralizes two or more different pathogens, two or more different antigens, or both.

[0068] In certain embodiments of a use or method, the two or more different pathogens comprise two or more protein variants derived from the same parental pathogen. Petition 870250095390, dated 10 / 19 / 2025, page 18 / 166 15 / 115

[0069] In certain embodiments of a use or method, the two or more pathogens comprise two or more Coronaviridae, two or more variants of Coronaviridae, or any combination thereof.

[0070] In certain embodiments of a use or method, the fusion polypeptide or immunogenic compound may reduce the amount of a pathogen in the subject.

[0071] In certain embodiments, a nucleic acid is provided that encodes a fusion polypeptide as described herein or that encodes the fusion polypeptide with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with a fusion protein as described herein;or a nucleic acid encoding a fusion polypeptide comprising a sequence selected from the group consisting of: SEQ ID NO:25-67 or encoding a fusion polypeptide with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with any of the SEQ ID NOs:25-67.;

[0072] In certain embodiments, a transformed cell is provided with a nucleic acid described herein or expressing a fusion polypeptide as described herein. In certain embodiments, the cell may comprise a mammalian cell, a yeast cell, a plant cell, a bacterial cell, or an insect / arthropod cell. In certain embodiments, the mammalian cell may comprise a Chinese hamster ovary (CHO) cell. Brief Description of the Drawings

[0073] These and other features of the invention will become clearer from the following description, which refers to the accompanying drawings, in which:

[0074] Figure 1 is a schematic of exemplary fusion polypeptides, as described herein. Figure 1A provides a fusion polypeptide. Petition 870250095390, dated 10 / 19 / 2025, page 19 / 166 Figure 1B provides a fusion polypeptide comprising, in sequence, a first antigen, a ligand, and an additional antigen, wherein the additional antigen is a plurality of antigens, wherein n is an integer corresponding to the number of antigens comprising the “at least one additional antigen” in the fusion polypeptide, and each antigen is linked to the preceding antigen by a ligand sequence.

[0075] Figure 2 is a schematic of exemplary fusion polypeptides, as described herein. Figure 2A provides a fusion polypeptide comprising, in sequence, a third antigen, a ligand, a first antigen, a ligand, and an additional antigen. Figure 2B provides a fusion polypeptide comprising, in sequence, a third antigen, a ligand, a first antigen, a ligand, and an additional antigen, wherein the additional antigen is a plurality of antigens, wherein n is an integer corresponding to the number of antigens comprising the “at least one additional antigen” in the fusion polypeptide and each antigen is linked to the preceding antigen by a linkage sequence.

[0076] Figure 3 is a schematic of an exemplary fusion polypeptide as described herein. Figure 3 provides a fusion polypeptide comprising a plurality of antigens, wherein n is an integer corresponding to the number of antigens in the fusion polypeptide and each antigen is linked to the preceding antigen by a linkage sequence.

[0077] Figure 4 is a schematic of exemplary vaccines and a study model. The vaccine candidates and challenge virus were altered between studies, but the overall study model and timeline remained the same. Figure 4A provides exemplary vaccines comprising fusion polypeptides as described herein. Figure 4B provides an exemplary study model for the treatment and / or prevention of a pathogen infection with fusion polypeptides, as described herein.

[0078] Figure 5 provides neutralizing titers for 3 pathogen variants (SARS-CoV-2: Beta, Delta, and Omicron) treated with COVAC-2 (control, unbound WuhanS1), 4296 (WuhanS1-dRBD), or 4304 (WuhanS1oRBD). Virus neutralization titers (VN) of hamsters vaccinated with Petition 870250095390, dated 10 / 19 / 2025, p. 20 / 166 17 / 115 PBS or COVAC-2 control (line 1), or S1Wu-dRBD (line 2), or S1WuoRBD (line 3) challenged with a variant of concern Beta (column 1), Delta (column 2), or Omicron (column 3). RBD: receptor-binding domain; dRBD: SARS-CoV-2 delta variant RBD; oRBD: SARS-CoV-2 omicron variant RBD; S1Wu: SARS-CoV-2 Wuhan S1.

[0079] Figure 6 provides weight loss data after a two-dose vaccination with COVAC-2 (WuhanS1), 4304 (WuhanS1-oRBD) or 4296 (WuhanS1-dRBD), followed by challenge with worrisome Beta, Delta or Omicron variants of SARS-CoV-2 (VOCs). RBD: receptor-binding domain. dRBD: Delta variant of SARS-CoV-2 RBD; oRBD: Omicron variant of SARS-CoV-2 RBD; S1Wu: SARS-CoV-2 Wuhan S1.

[0080] Figure 7 provides levels of infectious virus in the nasal cavity after a two-dose vaccination with COVAC-2 (WuhanS1), 4304 (WuhanS1-oRBD) or 4296 (WuhanS1-dRBD), followed by challenge with beta, delta or omicron variants of SARS-CoV-2 of concern (VOCs). RBD: receptor-binding domain; dRBD: SARS-CoV-2 delta variant RBD; oRBD: SARS-CoV-2 RBD omicron variant; S1Wu: SARS-CoV-2 Wuhan S1.

[0081] Figure 8 provides levels of infectious virus in the lung after a two-dose vaccination with COVAC-2 (WuhanS1), 4304 (WuhanS1-omicronRBD) or 4296 (WuhanS1-deltaRBD), followed by challenge with worrisome Beta, Delta or Omicron variants of SARS-CoV-2 (VOCs). RBD: receptor-binding domain; deltaRBD: SARS-CoV-2 RBD delta variant; oRBD: SARS-CoV-2 RBD omicron variant; S1Wu: SARS-CoV-2 Wuhan S1.

[0082] Figure 9 provides exemplary vaccines comprising three fused (linked) or three unlinked antigens, wherein the linked and unlinked vaccines differ only in that the antigens are fused in the linked vaccine. Figure 9A provides anti-S1 titers after a two-dose vaccination for three antigens delivered as a fusion (linked) or unlinked. Figure 9B provides virus neutralization titers for the Delta SARS-CoV-2 variant after a two-dose vaccination with three antigens delivered as a fusion (linked) or unlinked. Figure 9C provides the body weights of animals challenged with the concerning Delta SARS-CoV-2 variant after a two-dose vaccination with three antigens delivered as a fusion. Petition 870250095390, dated 10 / 19 / 2025, page 21 / 166 18 / 115 (bound) or unbound. Ag: Antigen; RBD: receptor-binding domain. omiRBD: omicron variant of SARS-CoV-2 RBD; betaRBD: beta variant of SARS-CoV-2 RBD; WhS1: SARS-CoV-2 Wuhan S1.

[0083] Figure 10 provides an exemplary bioinformatics pipeline used to select viral sequences for candidate antigen model on the polypeptide fusion subunit platform.

[0084] Figure 11 is a schematic of exemplary vaccines comprising fusion polypeptides as described herein and their phylogenetic relationship in clades 1a, 1b, 2 and 3.

[0085] Figure 12 provides an exemplary study model for vaccines and immunogenicity assessment and its results. Figure 12A provides an exemplary study model for immunogenicity assessment of animals administered with fusion polypeptides, as described herein. Figure 12B provides an exemplary serum binding ELISA of animals administered with fusion polypeptides as described herein. Significant differences from PBS are marked in blue (above the value), while significant differences from Pfizer are marked in red (below the value). Pfizer: Pfizer-BioNTech Comiranty®Original and Omicron BA.4 / .5, bivalent COVID-19 vaccine, 4499: WhS1-Khosta2-WIV1, 4500: WhS1-Pang17-WIV1, 4501: WhS1-Khosta2-RsSHCO14-WIV1, 4502: WhS1Khosta2- RsSHCO14-Urbani, 4503: WhS1-RatG13-BtKY72-WIV1.

[0086] Figure 13 provides an exemplary ELISPOT IFNγ / IL-5 group of animals administered fusion polypeptides as described herein at a dose of 5 pg. All groups were stimulated with S1 from the ancestral SARS-CoV-2 strain and Urbani's RBD. In addition, the candidate vaccines were stimulated with their own antigen. Significant differences from PBS are marked in blue, while significant differences from Pfizer are marked in red. Pfizer: Pfizer-BioNTech Comiranty®Original and Omicron BA.4 / .5, bivalent COVID-19 vaccine, 4499: WhS1-Khosta2WIV1, 4500: WhS1-Pang17-WIV1, 4501: WhS1-Khosta2- RsSHCO14-WIV1, 4502: WhS1-Khosta2-RsSHCO14-Urbani, 4503: WhS1-RatG13-BtKY72-WIV1.

[0087] Figure 14 is a scheme of exemplary model study vaccines and immunogenicity assessment. Hamsters were vaccinated on Day 0 and Day 28 with the respective antigens. The hamsters were challenged Petition 870250095390, dated 10 / 19 / 2025, page 22 / 166 19 / 115 intranasally on day 48 with the Delta variant of SARS-CoV-2 (1x10⁵TCID₅₀). Serum was collected for ELISA and viral neutralization assays on days 0, 28, and 48. Nasal wash samples were collected on days 1, 3, 5, 7, and 10 post-challenge. Animals were sacrificed on days 5 and 10 post-challenge for respiratory tissue collection.

[0088] Figure 15 provides an exemplary analysis of the percent change in body weight of animals administered with fusion polypeptides, as described herein. Significant differences from PBS are marked in blue (above the value), while significant differences from Pfizer are marked in red (below the value). Pfizer: PfizerBioNTech Comiranty®Original and Omicron BA.4 / .5, bivalent COVID-19 vaccine, 4499: WhS1-Khosta2-WIV1, 4500: WhS1-Pang17-WIV1, 4501: WhS1-Khosta2-RsSHCO14-WIV1, 4502: WhS1-Khosta2-RsSHCO14-Urbani, 4503: WhS1-RatG13-BtKY72-WIV1.

[0089] Figure 16 provides an exemplary ELISA of animals administered with fusion polypeptides as described herein. Significant differences from PBS are marked in blue (above the value), while significant differences from Pfizer are marked in red (below the value). Pfizer: Pfizer-BioNTech Comiranty® Original and Omicron BA.4 / .5, bivalent COVID-19 vaccine, 4499: WhS1-Khosta2WIV1, 4500: WhS1-Pang17-WIV1, 4501: WhS1-Khosta2-RsSHCO14-WIV1, 4502: WhS1-Khosta2-RsSHCO14-Urbani, 4503: WhS1-RatG13-BtKY72-WIV1. Detailed description

[0090] Fusion polypeptides, immunogenic compositions comprising fusion polypeptides, and methods and uses thereof are described herein. It should be noted that the embodiments and examples provided herein are for illustrative purposes only, intended for specialists in the field, and are in no way intended to be limiting.

[0091] The practice of the present invention will employ, unless otherwise indicated, conventional methods of microbiology, virology, chemistry, biochemistry, recombinant DNA techniques, and immunology, within the capabilities of the technique. Such techniques are fully explained in the literature. See, for example, Fundamental Virology, Current Edition, vols. I and II (BN Fields and DM Knipe, eds.); Handbook of Experimental Immunology, Vols. I-IV (DM Weir and Petition 870250095390, dated 10 / 19 / 2025, p. 23 / 166 20 / 115 CC Blackwell eds., Blackwell Scientific Publications); TE Creighton, Proteins: Structures and Molecular Properties (WH Freeman and Company); AL Lehninger, Biochemistry (Worth Publishers, Inc., current edition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (current edition); Methods In Enzymology (S. Collowick and N. Kaplan eds., Academic Press, Inc.).

[0092] All publications, patents and patent applications cited herein, above or below, are incorporated herein by reference in their entirety.

[0093] It should be noted that, as used in this description and the accompanying claims, the singular forms “a”, “an” and “the” include plural referents, unless the content clearly indicates otherwise. Thus, for example, reference to “an antigen” may include a mixture of two or more such antigens and the like.

[0094] As used herein, the term “coronavirus” may refer to any virus of the Coronaviridae family or to an antigen derived therefrom. As would be known to the expert, common names for members of the coronavirus family, such as “Omicron”, may be referred to as such or by alternative names known to the expert, such as “BA.1” or “BA.2”. It is also contemplated that sublineages of members of the coronavirus family, such as BA.4, BA.5, XBB.1.5 or any other sublineages known to the expert, may be provided in fusion proteins as described herein. As would be known to the expert, a sublineage may comprise the same and / or different antigens as the parental strain or other sublineages thereof.

[0095] In certain embodiments, a fusion polypeptide comprising an amino acid sequence encoding, in sequence, a first antigen (1), a ligand (2) and at least one additional antigen (3) is provided here.

[0096] The terms “polypeptide” and “protein,” as used herein, refer to a polymer of amino acid residues and are not limited to a minimum length, and peptides, oligopeptides, dimers, multimers, and the like may be included in the definition. Both full-length proteins and fragments thereof are covered by the definition. The terms may also include post-translational modifications of the polypeptide or Petition 870250095390, dated 10 / 19 / 2025, page 24 / 166 / 115 protein, such as glycosylation, acetylation, phosphorylation and the like. Furthermore, for the purposes of the present invention, a “polypeptide” may refer to a protein that includes modifications, such as deletions, additions and substitutions, in the native sequence, provided that the protein maintains the desired activity, such as recognition by a B cell. These modifications may be deliberate, such as through site-directed mutagenesis, or may be unintentional, such as through mutations in the host genome that produce the proteins or errors due to PCR amplification.

[0097] The term “peptide,” as used herein, refers to a fragment of a polypeptide. Thus, a peptide may include a C-terminal deletion, an N-terminal deletion, and / or an internal deletion of the native polypeptide, provided that the entire protein sequence is not present. A peptide will generally include at least about 3 to 10 contiguous amino acid residues of the full-length molecule and may include at least about 15 to 25 contiguous amino acid residues of the full-length molecule, or at least about 20 to 50 or more contiguous amino acid residues of the full-length molecule, or any whole number between 3 amino acids and the number of amino acids in the full-length sequence, provided that the peptide in question retains the ability to elicit the desired biological response.

[0098] As used herein, the phrase fusion polypeptide may refer to a single polypeptide encoded by two or more different amino acid sequences, wherein the different amino acid sequences may be derived from and comprise: i) different polypeptides from a pathogen, such as, by way of non-limiting example, a spike protein from SARS-CoV-2 and a nucleocapsid protein from SARS-CoV-2; ii) different antigens of a pathogen, such as, by way of non-limiting example, an antigenic fragment of a SARS-CoV-2 spike protein and an antigenic fragment of a SARS-CoV-2 nucleocapsid protein; iii) different variants of a pathogen polypeptide, such as, by way of non-limiting example, a receptor-binding domain of SARS-CoV-2 comprising delta variant mutations, a receptor domain Petition 870250095390, dated 10 / 19 / 2025, page 25 / 166 22 / 115 of a SARS-CoV-2 receptor-binding domain comprising omicron variant mutations and / or a receptor-binding domain of a SARS-CoV-2 receptor-binding domain comprising beta variant mutations; iv) polypeptides from different pathogens, such as, by way of non-limiting example, a Coronaviridae virus, an Orthomyxoviridae virus and / or a Pneumoviridae virus, or may include, for example, a Betacoronavirus and an Alphacoronavirus; (v) an amino acid sequence from a genus, lineage, species, variant, serotype, and / or strain different from the ancestral or parental pathogen or microorganism; or any combination thereof;

[0099] As used herein, an “antigen” refers to a molecule, such as a protein, polypeptide, or fragment thereof, containing one or more epitopes (linear, conformational, or both) that will stimulate the host’s immune system to produce a specific humoral and / or cellular response to the antigen. The term may be used interchangeably with the term “immunogen.” Antibodies such as anti-idiotype antibodies, or fragments thereof, and synthetic peptide mimotopes, which may mimic an antigen or antigenic determinant, are also encompassed by the definition of antigen as used herein. Similarly, an oligonucleotide or polynucleotide that expresses an antigen or antigenic determinant in vivo, as in nucleic acid immunization applications, is also included in the definition of antigen herein.As used herein, a “plurality of antigens” may refer to one or more antigens, where the one or more antigens may be different antigens, different variants of an antigen, antigens from different pathogenic organisms, or any combination thereof.

[0100] As used herein, a “linker” or “linking sequence” may refer to a peptide or polypeptide containing one or more amino acid residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or more amino acid residues) linked by one or more peptide bonds. Linkers may provide rotational freedom that allows each component of the fusion protein to interact with its intended target, such as a B cell, without hindrance. These linkers may be mixtures of glycine (G), alanine (A), and serine (S), Petition 870250095390, dated 10 / 19 / 2025, page 26 / 166 23 / 115 as (GSGSGS)n or (GAAASG)n, where n is 1, 2, 3, 4, 5, 6 or greater. In certain embodiments where the fusion polypeptide comprises two or more ligands, each ligand may independently be a different ligand sequence or the same ligand sequence.

[0101] In certain embodiments, it is contemplated that the first antigen and one or more additional antigens are different antigens, wherein the different antigens may comprise sequences derived from a different organism, protein, family, genus, lineage, species, variant, serotype, strain, or any combination thereof. In certain embodiments, the first antigen and one or more additional antigens may comprise antigens from different organisms, such as a virus and a prokaryote, or may comprise antigens from the same organism, such as two different viral antigens. In certain embodiments, the first antigen and one or more additional antigens may comprise antigens from the same virus family, such as Coronaviridae, or may comprise antigens from different virus families, such as Coronaviridae and Orthomyxoviridae.In certain embodiments, the first antigen and one or more additional antigens may comprise antigens of different genera, such as a Betacoronavirus and an Alphacoronavirus. In certain embodiments, the first antigen and one or more additional antigens may comprise antigens of different proteins, such as a SARS-CoV-2 spike protein and a SARS-CoV-2 nucleocapsid protein. In certain embodiments, the first antigen and one or more additional antigens may comprise different variants, such as a SARS-CoV-2 delta variant or a SARS-CoV-2 omicron variant.

[0102] As used herein, a “fungus” may comprise any organism of the kingdom Fungi, and a “fungal antigen” may comprise any antigenic sequence thereof. In certain embodiments, the fungal antigen may be derived from a fungal organism that contributes to or causes a disease or condition in a vertebrate subject, such as Candida, Cryptococcus, or Aspergillus.

[0103] As used herein, a “prokaryote” may comprise any prokaryotic organism, and a “prokaryotic antigen” may comprise any antigenic sequence thereof. In certain embodiments, the prokaryotic antigen may be derived from a prokaryotic organism that Petition 870250095390, dated 10 / 19 / 2025, page 27 / 166 / 115 contributes to or causes a disease or condition in a vertebrate subject, such as Pneumococcus, Corynebacterium, or Clostridium.

[0104] As used herein, a “virus” may comprise any submicroscopic organism or agent that replicates only within the living cells of an organism, and a “viral antigen” may comprise any antigenic sequence thereof. In certain embodiments, the viral antigen may be derived from a virus that contributes to or causes a disease or condition in a vertebrate subject, such as Coronaviridae, Orthomyxoviridae, or Pneumoviridae.

[0105] In certain embodiments, the at least one additional antigen may comprise a plurality of antigens, and each antigen of the plurality of antigens may be linked to the preceding antigen with a linker peptide comprising the ligand. In certain embodiments, the plurality of antigens may comprise two or more antigens, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 antigens. In certain embodiments, the plurality of antigens may each independently comprise a different antigen, wherein the different antigen may comprise an antigen derived from an organism, phylum, genus, family, lineage, species, variant, serotype, and strain different from an ancestral pathogen, a parental pathogen, microorganism, or antigenic sequence.

[0106] As used herein, the terms preceding and upstream in reference to a polypeptide, an amino acid sequence, or a nucleotide sequence may refer to an element, such as an amino acid sequence encoding, for example, an antigen, antigenic fragment, or ligand, that is at the N-terminal position of the element to which it “precedes” or is “upstream” in the polypeptide or the resulting polypeptide encoded by the nucleotide sequence. As used herein, the terms “proceeding” and “downstream” in reference to a polypeptide, an amino acid sequence, or a nucleotide sequence may refer to an element, such as an antigenic amino acid sequence, that is at the C-terminal position of the element to which it “proceeds” or is “downstream.”

[0107] In certain embodiments, the amino acid sequence of the first antigen may comprise a greater number of amino acids than the amino acid sequence of at least one or more of the others. Petition 870250095390, dated 10 / 19 / 2025, p. 28 / 166 25 / 115 antigens. In certain embodiments, a greater number of amino acids may consist of 1 or more additional amino acids in the first antigen compared to at least one of the other antigens, such as, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132,133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148,149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164,165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180,181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196,197, 198, 199, 200, 201,202, 203, 204, 205, 206, 207, 208, 209, 210, 211,212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244,245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260,261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276,277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292,293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308,309, 310, 311 , 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339,340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355,356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371,372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387,388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403,404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419,420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435,436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516 Petition 870250095390, dated 10 / 19 / 2025, p. 29 / 166 26 / 115 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601,602, 603, 604, 605, 606, 607, 608, 609, 610, 611,612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627,628, 629, 630, 631,632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643,644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659,660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675,676, 677, 678, 679, 680, 681,682, 683, 684, 685, 686, 687, 688, 689, 690, 691,692, 693, 694, 695, 696, 697, 698, 699, 700, 701,702, 703, 704, 705, 706, 707,708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721,722, 723,724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739,740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751,752, 753, 754, 755,756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771,772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787,788, 789, 790, 791,792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803,804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819,820, 821,822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835,836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851,852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867,868, 869, 870, 871,872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883,884, 885, 886, 887, 888, 889, 890, 891,892, 893, 894, 895, 896, 897, 898, 899,900, 901,902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915,916, 917, 918, 919, 920, 921,922, 923, 924, 925, 926, 927, 928, 929, 930, 931,932, 933, 934, 935, 936, 937, 938, 939, 940, 941,942, 943, 944, 945, 946, 947,948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000 or more amino acids.

[0108] In certain embodiments, the first antigen may comprise an antigenic peptide or fragment thereof from a first pathogen. In certain embodiments, the first pathogen may comprise a vertebrate pathogen. Petition 870250095390, dated 10 / 19 / 2025, page 30 / 166 27 / 115 comprising a viral pathogen, a prokaryotic pathogen, or a eukaryotic pathogen, such as a fungal pathogen.

[0109] In certain embodiments, the first viral pathogen may comprise: adeno-associated virus, Aichi virus, Australian bat lyssavirus, Banna virus, Barmah forest virus, BK polyomavirus, Bunyamwera virus, La Crosse Bunyavirus, snow hare virus (Bunyavirus), Cercopithecine herpesvirus, Chandipura virus, Chikungunya virus, Cosavirus A, Cowpox virus, Coxsackievirus, Crimean-Congo hemorrhagic fever virus, dengue virus, Dhori virus, Dugbe virus, Duvenhage virus, eastern chimpanzee foamy virus, eastern equine encephalitis virus, Ebola virus, Echovirus, encephalomyocarditis virus, Epstein-Barr virus, European bat lyssavirus, GB C virus / hepatitis G virus, Hantaan virus, Hendra virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis delta virus, Hepatitis E virus, horsepox virus, human adenovirus, human astrovirus, human coronavirus, human cytomegalovirus.Human Enterovirus 68,70, Human Herpesvirus 1, Human Herpesvirus 2, Human Herpesvirus 6, Human Herpesvirus 7, Human Herpesvirus 8, Human Immunodeficiency Virus, Human Papillomavirus 1, Human Papillomavirus 16,18, Human Papillomavirus 2, Human Parainfluenza, Human Parvovirus B19, Human Respiratory Syncytial Virus, Human Rhinovirus, Human SARS Coronavirus, Human T-lymphotropic Virus, Human Torovirus, Influenza A Virus, Influenza B Virus, Influenza C Virus, Isfahan Virus, Japanese Encephalitis Virus, JC Polyomavirus, Junin Arenavirus, KI Polyomavirus, Lagos Bat Virus, Lake Victoria Marburgvirus, Langat Virus, Lassa Virus, Louping Disease Virus, Lymphocytic Choriomeningitis Virus.Machupo virus, mammalian orthorubulavirus 5 (simian virus 5), Mayaro virus, measles virus, Merkel cell polyomavirus, MERS coronavirus, Mokola virus, Molluscum contagiosum virus, monkeypox virus, mumps virus, Murray Valley encephalitis virus, New York virus, Nipah virus, Norwalk virus, O'nyong-nyong virus, Orf virus, Oropouche virus, Pichinde virus, poliovirus, Punta Toro sandfly, Puumala virus, rabies virus, Rift Valley fever virus, Rosavirus A, Ross River virus, Rotavirus A, Rotavirus B, Rotavirus C, rubella virus, Sagiyama virus, Salivirus A, mosquito gunpowder fever, Naples sandfly (Toscana virus), Sicilian fever virus. Petition 870250095390, dated 10 / 19 / 2025, page 31 / 166 28 / 115 powdery mildew, Sapporo virus, SARS coronavirus, SARS 2 coronavirus, Semliki forest virus, Seoul virus, foamy monkey virus, Sindbis virus, Southampton virus, St. St. Louis, tick-transmitted powassan virus, torque teno virus, Uukuniemi virus, vaccinia virus, varicella-zoster virus, smallpox virus, vesicular equine encephalitis virus, vesicular stomatitis virus, West Nile virus, human encephalitis virus, WUU polyvirus Yaba monkey tumor, Yaba-like disease virus, yellow fever virus, Zika virus, Khosta2 sarbecovirus, bat SARS-like WIV1 coronavirus, Kenya bat BtKY72 coronavirus, pangolin coronavirus Pang17, bat SARS SARS coronavirus, bat SARS Urbani, bat RaTG13 coronavirus, Wuhan coronavirus, BA.1 coronavirus, BA.2 coronavirus, B.1.351 coronavirus, any serotype, any variant or any combination thereof.

[0110] In certain embodiments, the first antigen may comprise a first viral antigen. In certain embodiments, the first viral antigen may be derived from a viral pathogen. In certain embodiments, the first viral antigen may comprise any antigen derived from a first viral pathogen.

[0111] In certain embodiments, the first prokaryotic pathogen may comprise: Actinomyces israelii, Bacillus anthracis, Bacteroides fragilis, Bordetella pertussis, Borrelia, Brucella, Campylobacter jejuni, Chlamydia, Chlamydophila psittaci, Clostridium, Corynebacterium diphtheriae, Ehrlichia, Enterococcus, Escherichia, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira, Listeria monocytogenes, Mycobacterium, Mycoplasma pneumoniae, Neisseria, Pseudomonas aeruginosa, Nocardia asteroides, Rickettsia rickettsii, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema pallidum, Vibrio cholerae, Yersinia pestis or any combination thereof.

[0112] In certain embodiments, the first antigen may comprise a first prokaryotic antigen. In certain embodiments, the first prokaryotic antigen may be derived from a prokaryotic pathogen. In certain embodiments, the first prokaryotic antigen may comprise any antigen derived from a first prokaryotic pathogen. Petition 870250095390, dated 10 / 19 / 2025, page 32 / 166 29 / 115

[0113] In certain embodiments, the first eukaryotic pathogen may comprise: Trypanosoma brucei, Entamoeba histolytica, Babesia bovis, Babesia divergens, Candida albicans, Trypanosoma cruzi, Giardia lamblia, Acanthamoeba culbertsoni, Necator americanus, Leishmania major, Bruga malayi, Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trichomonas vaginalis, Aedes aegypti or any combination thereof.

[0114] In certain embodiments, the first antigen may comprise a first eukaryotic antigen. In certain embodiments, the first eukaryotic antigen may be derived from a eukaryotic pathogen. In certain embodiments, the first eukaryotic antigen may comprise any antigen derived from the first eukaryotic pathogen.

[0115] In certain embodiments, the first viral antigen may comprise a component of a viral surface glycoprotein, a lipoprotein, or an extracellular domain of a transmembrane protein. As used herein, a “surface glycoprotein” may refer to a molecule comprising a polypeptide and a carbohydrate chain. A “component of a surface glycoprotein” may comprise a full-length glycoprotein or a fragment thereof. In certain embodiments, the component of the surface glycoprotein, lipoprotein, or extracellular domain of the transmembrane protein may be an antigenic component.

[0116] In certain embodiments, the first viral antigen may comprise a first coronavirus antigen. In certain embodiments, the first coronavirus antigen may comprise an antigen of a Coronaviridae virus. In certain embodiments, the first coronavirus antigen may comprise an antigen of a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. In certain embodiments, the first coronavirus antigen may comprise a MERS-CoV antigen, a SARS-CoV-1 antigen, a SARS-CoV-2 antigen (for example, but not limited to Wuhan coronavirus antigens, BA.1 coronavirus antigens, BA.2 coronavirus antigens, or B.1.351 coronavirus antigens), an HCoVHKUI antigen, an HCoV-OC43 antigen, a BtCoV-RaTG13 antigen, a BtSL-CoV-WIV1 antigen, an HKU4-CoV antigen, an HKU5-CoV antigen, an antigen Petition 870250095390, dated 10 / 19 / 2025, page 33 / 166 30 / 115 PDF-2108 CoV, a SHC014-CoV antigen, a BtSCoV-RsSHC014 antigen, a BtSCoV-Rs3367 antigen, a BANAL-52 antigen, a BANAL236 antigen, a Pangolin-CoV antigen GX / P2V, an antigen of coronavirus CDPHE15 of morsel, a coronavirus HKU10 antigen of morsel, an alphacoronavirus HuB-2013 antigen of Rhinolophus ferrumequinum, a human coronavirus 229E antigen, a mouse coronavirus antigen Lucheng Rn, a coronavirus 1 antigen of mink, um furrow coronavirus antigen, a Miniopterus morsel coronavirus 1 antigen, a Miniopterus morsel coronavirus HKU8 antigen, a Sax-2011 alphacoronavirus antigen of Myotis ricketti, a SC-2013 alphacoronavirus antigen of Nyctalus velutinus, um coronavirus 3398 antigen of Pipistrellus kuhlii, a swine epidemic diarrhea virus antigen, a coronavirus 512 antigen of Scotophilus carcass, a coronavirus HKU2 antigen of Rhinolophus carcass, a human coronavirus NL63 antigen,an antigen from the NL63-related bat coronavirus strain BtKYNL63-9b, an antigen from Sorex araneus coronavirus T14, an antigen from Suncus murinus coronavirus X74, an alphacoronavirus 1 antigen, a canine coronavirus antigen, a feline coronavirus antigen, a human CCoV-HuPn-2018 antigen, an antigen from porcine transmissible gastroenteritis coronavirus, an antigen from porcine acute diarrheal syndrome coronavirus (SADS-CoV), an HCoV-NL63 antigen, an antigen from the NL63-related bat coronavirus strain BtKYNL63-9b, an HCoV-229E antigen, a Khosta2 sarbecovirus antigen, an antigen from Kenya bat coronavirus BtKY72, an antigen from bat SARS coronavirus HKU3, or any combination thereof. In certain embodiments, the first coronavirus antigen may comprise an antigen derived from a Coronaviridae spike protein, S1 protein, receptor-binding domain (RBD), and / or any fragment thereof. In certain embodiments,The first coronavirus antigen may comprise a sequence selected from SEQ IDs NOS: 12 to 24 or a nucleic acid selected from SEQ IDs NOS: 25 to 67 that encodes the antigen. In certain embodiments, the antigen sequence may have at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, Petition 870250095390, dated 10 / 19 / 2025, page 34 / 166 31 / 115 identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with a sequence selected from SEQ ID Nos: 12 to 24 or the nucleic acid encoding the fusion polypeptide selected from SEQ ID Nos: 25-67.

[0117] In certain embodiments, the first coronavirus antigen may comprise a spike (S) protein or a fragment thereof. As used herein, a coronavirus spike (S) protein may comprise a spike protein or a fragment thereof from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. In certain embodiments, the spike protein may comprise any Coronaviridae spike protein or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae spike protein. In certain embodiments, the spike (S) protein, or a fragment thereof, may be a receptor-binding domain (RBD) from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof.In certain embodiments, the RBD may comprise any Coronaviridae RBD or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae RBD. In certain embodiments, the spike (S) protein, or a fragment thereof, may be an S1 protein from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. In certain embodiments, the spike protein may comprise any Coronaviridae S1 protein or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae S1 protein.

[0118] In certain embodiments, the linker may comprise a sequence of 6 or more amino acids in length. In certain embodiments, the linker may comprise a sequence of 6 to 24 amino acids. In certain embodiments, the linker may comprise a sequence consisting of one or more glycine, serine, and alanine. In certain embodiments, the linker may comprise a sequence that, when operatively linked to the preceding antigen, does not impair the ability of either antigen in the fusion polypeptide to interact with its intended target, such as, for example, Petition 870250095390, dated 10 / 19 / 2025, p. 35 / 166 / 115 a B cell. In certain embodiments, the linker may comprise 1 or more repeating units of GSGSGS or GAAASG, such as 1, 2, 3, 4, 5, or 6 repeating units. In certain embodiments, the linker may comprise GSGSGS, GSGSGS GSGSGS, GSGSGS GSGSGS GSGSGS, GSGSGS GSGSGS GSGSGS GSGSGS GSGSGS GSGSGS GSGSGS GSGSGS GSGSGS, GSGSGS GSGSGS GSGSGS GSGSGS GSGSGS GSGSGS, GAAASG, GAAASG GAAASG, GAAASG GAAASG GAAASG GAAASG, GAAASG GAAASG GAAASG GAAASG, or GAAASG GAAASG GAAASG GAAASG GAAASG GAAASG GAAASG. In certain embodiments, where the fusion polypeptide may comprise more than one ligand, each ligand may independently comprise the same ligand sequence or a different ligand sequence.

[0119] In certain embodiments, the at least one additional antigen comprises at least one additional antigenic peptide or fragment thereof from at least one additional pathogen. In certain embodiments, the first pathogen may comprise a vertebrate pathogen comprising a viral pathogen, a prokaryotic pathogen, or a eukaryotic pathogen, such as a fungal pathogen. In certain embodiments, the at least one additional antigen may comprise an antigen as disclosed for the first antigen, wherein the at least one additional antigen is different from the first antigen.

[0120] In certain embodiments, at least one additional antigen may comprise an amino acid sequence of at least 8 amino acids.

[0121] In certain embodiments, the at least one additional antigen may comprise a vertebrate pathogen comprising at least one additional prokaryotic antigen, at least one additional viral antigen, at least one additional fungal antigen, or any combination thereof.

[0122] In certain embodiments, at least one viral pathogen may comprise: adeno-associated virus, Aichi virus, Australian bat lyssavirus, Banna virus, Barmah forest virus, BK polyomavirus, Bunyamwera virus, La Crosse Bunyavirus, snow hare virus (Bunyavirus), Cercopithecine herpesvirus, Chandipura virus, Chikungunya virus, Cosavirus A, Cowpox virus, Coxsackievirus, Crimean-Congo hemorrhagic fever virus, dengue virus, Dhori virus, Dugbe virus, Duvenhage virus, foamy virus Petition 870250095390, dated 10 / 19 / 2025, page 36 / 166 33 / 115 Eastern chimpanzee virus, Eastern equine encephalitis virus, Ebola virus, EcHovirus, encephalomyocarditis virus, Epstein-Barr virus, European bat lyssavirus, GBC virus / hepatitis G virus, Hantaan virus, Hendra virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis delta virus, hepatitis E virus, horsepox virus, human adenovirus, human astrovirus, human coronavirus, human cytomegalovirus, Enterovirus 68.Human 70, Human Herpesvirus 1, Human Herpesvirus 2, Human Herpesvirus 6, Human Herpesvirus 7, Human Herpesvirus 8, Human Immunodeficiency Virus, Human Papillomavirus 1, Human Papillomavirus 16,18, Human Papillomavirus 2, Human Parainfluenza, Human Parvovirus B19, Human Respiratory Syncytial Virus, Human Rhinovirus, Human SARS Coronavirus, Human T-lymphotropic Virus, Human Torovirus, Influenza A Virus, Influenza B Virus, Influenza C Virus, Isfahan Virus, Japanese Encephalitis Virus, JC Polyomavirus, Junin Arenavirus, KI Polyomavirus, Lagos Bat Virus, Lake Victoria Marburgvirus, Langat Virus, Lassa Virus, Louping Disease Virus, Lymphocytic Choriomeningitis Virus.Machupo virus, mammalian orthorubulavirus 5 (simian virus 5), Mayaro virus, measles virus, Merkel cell polyomavirus, MERS coronavirus, Mokola virus, Molluscum contagiosum virus, monkeypox virus, Mumps virus, Murray Valley encephalitis virus, New York virus, Nipah virus, Norwalk virus. O'nyong-nyong virus, Orf virus, Oropouche virus, Pichinde virus, Poliovirus, Punta Toro sandfly virus, Puumala virus, rabies virus, Rift Valley fever virus, Rosavirus A, Ross River virus, Rotavirus A, Rotavirus B, Rotavirus C, rubella virus, Sagiyama virus, Salivirus A, Naples sandfly virus (Toscana virus), Sicilian sandfly virus, Sapporo virus, SARS coronavirus, SARS-CoV-2 coronavirus, Semliki Forest virus, Seoul virus, simian foamy virus, Sindbis virus, Southampton virus, St. John's encephalitis virus.Louis, tick-borne powassan virus, torque teno virus, Uukuniemi virus, vaccinia virus, varicella-zoster virus, smallpox virus, Venezuelan equine encephalitis virus, vesicular stomatitis virus, West Nile virus, western equine encephalitis virus, WU polyomavirus, Yaba monkey tumor virus, Yaba-like disease virus, yellow fever virus, Zika virus, Khosta2 sarbecovirus, bat SARS-like coronavirus WIV1, BtKY72 coronavirus. Petition 870250095390, dated 10 / 19 / 2025, page 37 / 166 / 115 Kenyan bat, pangolin Pang17 coronavirus, bat SARS HKU3 coronavirus, SARS Urbani coronavirus, bat RaTG13 coronavirus, Wuhan coronavirus, BA.1 coronavirus, BA.2 coronavirus, B.1.351 coronavirus, any serotype, any variant or any combination thereof.

[0123] In certain embodiments, the at least one antigen may comprise at least one viral antigen. In certain embodiments, the at least one viral antigen may be derived from a viral pathogen. In certain embodiments, the at least one viral antigen may comprise any antigen derived from a viral pathogen described herein.

[0124] In certain embodiments, the at least one prokaryotic pathogen may comprise: Actinomyces israelii, Bacillus anthracis, Bacteroides fragilis, Bordetella pertussis, Borrelia, Brucella, Campylobacter jejuni, Chlamydia, Chlamydophila psittaci, Clostridium, Corynebacterium diphtheriae, Ehrlichia, Enterococcus, Escherichia, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira, Listeria monocytogenes, Mycobacterium, Mycoplasma pneumoniae, Neisseria, Pseudomonas aeruginosa, Nocardia asteroides, Rickettsia rickettsii, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema pallidum, Vibrio cholerae, Yersinia pestis or any combination thereof.

[0125] In certain embodiments, the at least one antigen may comprise at least one prokaryotic antigen. In certain embodiments, the at least one prokaryotic antigen may be derived from a prokaryotic pathogen. In certain embodiments, the at least one prokaryotic antigen may comprise any antigen derived from the at least one prokaryotic pathogen.

[0126] In certain embodiments, at least one eukaryotic pathogen may comprise Trypanosoma brucei, Entamoeba histolytica, Babesia bovis, Babesia divergens, Candida albicans, Trypanosoma cruzi, Giardia lamblia, Acanthamoeba culbertsoni, Necator americanus, Leishmania major, Bruga malayi, Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trichomonas vaginalis, Aedes aegypti, or any combination thereof.

[0127] In certain embodiments, at least one antigen may comprise at least one eukaryotic antigen. In certain embodiments, the Petition 870250095390, dated 10 / 19 / 2025, page 38 / 166 35 / 115 at least one eukaryotic antigen may be derived from a eukaryotic pathogen. In certain embodiments, the at least one eukaryotic antigen may comprise any antigen derived from the at least one eukaryotic pathogen.

[0128] In certain embodiments, at least one viral antigen may comprise at least one coronavirus antigen. In certain embodiments, at least one coronavirus antigen may comprise an antigen of a Coronaviridae virus. In certain embodiments, at least one coronavirus antigen may comprise a MERS-CoV antigen, a SARS-CoV-1 antigen, a SARS-CoV-2 antigen (for example, but not limited to Wuhan coronavirus antigens, BA.1 coronavirus antigens, BA.2 coronavirus antigens, or B.1.351 coronavirus antigens), an HCoV-HKU1 antigen, an HCoV-OC43 antigen, a BtCoV-RaTG13 antigen, a BtSL-CoV-WIV1 antigen, an HKU4-CoV antigen, an HKU5-CoV antigen, a PDF-2108 CoV antigen, an SHC014-CoV antigen, a BtSCoV-RsSHC014 antigen, a BtSCoV-Rs3367 antigen, a BANAL-52 antigen, a BANAL236 antigen, a Pangolin-CoV GX / P2V antigen, a bat coronavirus CDPHE15 antigen, a bat coronavirus HKU10 antigen,a Rhinolophus ferrumequinum HuB-2013 alphacoronavirus antigen, a human coronavirus 229E antigen, a Lucheng Rn mouse coronavirus antigen, a monkey coronavirus 1 antigen, a ferret coronavirus 1 antigen, a Mini coronavirus antigen, a mouse coronavirus 1 antigen Miniopterus bat HKU8 coronavirus antigen, Myotis ricketti alphacoronavirus antigen Sax-2011, Nyctalus velutinus SC-2013 alphacoronavirus antigen, Nyctalus velutinus coronavirus 3398 antigen, Pipistrellus kuhlivirus antigen pig, a Scotophilus bat coronavirus 512 antigen, a Rhinolophus bat HKU2 coronavirus antigen, a human coronavirus NL63 antigen, an antigen of a bat coronavirus strain BtKYNL63-9b related to NL63, a mouse coronavirus antigen T14 araneus, a Suncus murine X74 coronavirus antigen, an Alphacoronavirus 1 antigen, a canine coronavirus antigen,a feline coronavirus antigen, a human CCoV-HuPn-2018 antigen, a swine transmissible gastroenteritis coronavirus antigen, a syndrome coronavirus antigen, Petition 870250095390, dated 10 / 19 / 2025, page 39 / 166 36 / 115 porcine acute diarrheal disease (SADS-CoV), an HCoV-NL63 antigen, an antigen from the NL63-related bat coronavirus strain BtKYNL63-9b, an HCoV-229E antigen, a Khosta2 sarbecovirus antigen, a Kenyan bat coronavirus BtKY72 antigen, a bat SARS coronavirus HKU3 antigen, or any combination thereof. In certain embodiments, at least one viral antigen may comprise a sequence selected from SEQ ID Nos: 12 to 24 or a nucleic acid selected from SEQ ID Nos: 25 to 67 that encodes the antigen. In certain embodiments, at least one antigen may comprise an antigen derived from a Coronaviridae spike protein, S1 protein, receptor-binding domain (RBD), and / or any fragment thereof.In certain embodiments, the antigen sequence may have at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with a sequence selected from SEQ ID NOs:12 to 24 or the nucleic acid encoding the fusion polypeptide selected from SEQ ID NOs:25-67.

[0129] In certain embodiments, at least one coronavirus antigen may comprise a spike (S) protein or a fragment thereof. As used herein, a coronavirus spike (S) protein may comprise a spike protein or a fragment thereof from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. In certain embodiments, the spike protein may comprise any Coronaviridae spike protein or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae spike protein. In certain embodiments, the spike (S) protein, or a fragment thereof, may be a receptor-binding domain (RBD) from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof.In certain embodiments, the RBD may comprise any Coronaviridae RBD or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae RBD. In certain embodiments, a. Petition 870250095390, dated 10 / 19 / 2025, page 40 / 166 37 / 115 The spike protein (S), or a fragment thereof, may be an S1 protein from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. In certain embodiments, the spike protein may comprise any Coronaviridae S1 protein or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae S1 protein.

[0130] In certain embodiments, the first antigen and at least one additional antigen each independently comprise a prokaryotic antigen, a viral antigen, or a fungal antigen. In certain embodiments, the first antigen may comprise a viral antigen and at least one additional antigen may comprise a prokaryotic antigen. In certain embodiments, the first antigen may comprise a viral antigen and at least one additional antigen may comprise a viral antigen, for example, the first antigen may comprise an S1 protein of SARS-CoV-2 and at least one additional antigen may comprise a SARS-CoV-2 receptor-binding domain. In certain embodiments, the first antigen may comprise a delta variant of SARS-CoV-2 and at least one additional antigen may comprise an omicron variant of SARS-CoV-2.

[0131] In certain embodiments, the fusion polypeptide may further comprise, in sequence, a third antigen (4) and the binding sequence (2) upstream of the first antigen protein.

[0132] In certain embodiments, the third antigen may comprise a vertebrate pathogen comprising a third prokaryotic antigen, a third viral antigen, a third fungal antigen, or any combination thereof.

[0133] In certain embodiments, the third viral pathogen may comprise: adeno-associated virus, Aichi virus, Australian bat lyssavirus, Banna virus, Barmah forest virus, BK polyomavirus, Bunyamwera virus, La Crosse Bunyavirus, snow hare virus (Bunyavirus), Cercopithecine herpesvirus, Chandipura virus, Chikungunya virus, Cosavirus A, Cowpox virus, Coxsackievirus, Crimean-Congo hemorrhagic fever virus, Dengue virus, Dhori virus, Dugbe virus, Duvenhage virus, foamy virus Petition 870250095390, dated 10 / 19 / 2025, p. 41 / 166 38 / 115 Eastern chimpanzee virus, Eastern equine encephalitis virus, Ebola virus, Echovirus, encephalomyocarditis virus, Epstein-Barr virus, European bat lyssavirus, GBC virus / hepatitis G virus, Hantaan virus, Hendra virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis delta virus, hepatitis E virus, horsepox virus, human adenovirus, human astrovirus, human coronavirus, human cytomegalovirus, human enterovirus 68, 70, human herpesvirus 1, human herpesvirus 2, human herpesvirus 6, human herpesvirus 7, human herpesvirus 8, human immunodeficiency virus, human papillomavirus 1, human papillomavirus 16, 18, human papillomavirus 2, human parainfluenza, human parvovirus B19, human respiratory syncytial virus, human rhinovirus, human SARS coronavirus, virus Human T-lymphotropic virus, Human torovirus, Influenza A virus, Influenza B virus, Influenza C virus, Isfahan virus, Japanese encephalitis virus, JC polyomavirusJunin Arenavirus, KI Polyomavirus, Lagos Bat Virus, Lake Victoria Marburgvirus, Langat Virus, Lassa Virus, Louping Disease Virus, Lymphocytic Choriomeningitis Virus, Machupo Virus, Mammalian Orthorubulavirus 5 (Simian Virus 5), Mayaro Virus, Measles Virus, Merkel Cell Polyomavirus, MERS Coronavirus, Mokola Virus, Molluscum Contagiosum Virus, Monkeypox Virus, Mumps Virus, Murray Valley Encephalitis Virus, New York Virus, Nipah Virus, Norwalk Virus. O'nyong-nyong virus, Orf virus, Oropouche virus, Pichinde virus, Poliovirus, Punta Toro sandfly virus, Puumala virus, rabies virus, Rift Valley fever virus, Rosavirus A, Ross River virus, Rotavirus A, Rotavirus B, Rotavirus C, rubella virus, Sagiyama virus, Salivirus A, Naples sandfly virus (Toscana virus), Sicilian sandfly virus, Sapporo virus, SARS coronavirus, SARS-CoV-2 coronavirus, Semliki Forest virus, Seoul virus,Simian foamy virus, Sindbis virus, Southampton virus, St. Louis encephalitis virus, tick-borne powassan virus, Torque teno virus, Uukuniemi virus, Vaccinia virus, Varicella-zoster virus, smallpox virus, Venezuelan equine encephalitis virus, vesicular stomatitis virus, West Nile virus, western equine encephalitis virus, WU polyomavirus, Yaba monkey tumor virus, Yaba-like disease virus, yellow fever virus, Zika virus, Khosta2 sarbecovirus, bat SARS-like coronavirus WIV1, BtKY72 coronavirus, Petition 870250095390, dated 10 / 19 / 2025, page 42 / 166 39 / 115 Kenyan bat coronavirus, pangolin Pang17 coronavirus, bat SARS HKU3 coronavirus, SARS Urbani coronavirus, bat RaTG13 coronavirus, Wuhan coronavirus, BA.1 coronavirus, BA.2 coronavirus, B.1.351 coronavirus, any serotype thereof, any variant thereof, or any combination thereof.

[0134] In certain embodiments, the third antigen may comprise a third viral antigen. In certain embodiments, the third viral antigen may be derived from a viral pathogen. In certain embodiments, the third viral antigen may comprise any antigen derived from the third viral pathogen.

[0135] In certain embodiments, the third prokaryotic pathogen may comprise: Actinomyces israelii, Bacillus anthracis, Bacteroides fragilis, Bordetella pertussis, Borrelia, Brucella, Campylobacter jejuni, Chlamydia, Chlamydophila psittaci, Clostridium, Corynebacterium diphtheriae, Ehrlichia, Enterococcus, Escherichia, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira, Listeria monocytogenes, Mycobacterium, Mycoplasma pneumoniae, Neisseria, Pseudomonas aeruginosa, Nocardia asteroides, Rickettsia rickettsii, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema pallidum, Vibrio cholerae, Yersinia pestis or any combination thereof.

[0136] In certain embodiments, the third antigen may comprise a third prokaryotic antigen. In certain embodiments, the third prokaryotic antigen may be derived from a prokaryotic pathogen. In certain embodiments, the third prokaryotic antigen may comprise any antigen derived from a third prokaryotic pathogen.

[0137] In certain embodiments, the third eukaryotic pathogen may comprise: Trypanosoma brucei, Entamoeba histolytica, Babesia bovis, Babesia divergens, Candida albicans, Trypanosoma cruzi, Giardia lamblia, Acanthamoeba culbertsoni, Necator americanus, Leishmania major, Bruga malayi, Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trichomonas vaginalis, Aedes aegypti or any combination thereof.

[0138] In certain embodiments, the third antigen may comprise a third eukaryotic antigen. In certain embodiments, the third eukaryotic antigen may be derived from a eukaryotic pathogen. In certain Petition 870250095390, dated 10 / 19 / 2025, page 43 / 166 40 / 115 modalities, the third eukaryotic antigen may comprise any antigen derived from a third eukaryotic pathogen.

[0139] In certain embodiments, the third viral antigen may comprise a third coronavirus antigen. In certain embodiments, the third coronavirus antigen may comprise an antigen of a Coronaviridae virus. In certain embodiments, the third coronavirus antigen may comprise a MERS-CoV antigen, a SARS-CoV-1 antigen, a SARS-CoV-2 antigen (e.g., but not limited to Wuhan coronavirus antigens, BA.1 coronavirus antigens, BA.2 coronavirus antigens, or B.1.351 coronavirus antigens), an HCoV-HKU1 antigen, an HCoV-OC43 antigen, a BtCoV-RaTG13 antigen, a BtSL-CoV-WIV1 antigen, an HKU4-CoV antigen, an HKU5-CoV antigen, a PDF-2108 CoV antigen, an SHC014-CoV antigen, a BtSCoV-RsSHC014 antigen, a BtSCoV-Rs3367 antigen, a BANAL-52 antigen, a BANAL236 antigen, a Pangolin-CoV GX / P2V antigen, a bat coronavirus CDPHE15 antigen, a bat coronavirus HKU10 antigen,a Rhinolophus ferrumequinum alphacoronavirus HuB-2013 antigen, a human coronavirus antigen 229E, a mouse coronavirus Lucheng Rn antigen, a monkey coronavirus 1 antigen, a ferret coronavirus 1 antigen, a mouse coronavirus 1 antigen, a mouse coronavirus antigen Miniopterus bat HKU8 coronavirus antigen, Myotis ricketti alphacoronavirus antigen Sax-2011, Nyctalus velutinus SC-2013 alphacoronavirus antigen, Nyctalus velutinus coronavirus 3398 antigen, Pipistrellus kuhlivirus antigen pig, a Scotophilus bat coronavirus 512 antigen, a Rhinolophus bat HKU2 coronavirus antigen, a human NL63 coronavirus antigen, a NL63-related bat coronavirus strain BtKYNL63-9b antigen, a Sore coronavirus T14 antigen araneus, a Suncus murine coronavirus X74 antigen, an Alphacoronavirus 1 antigen, a canine coronavirus antigen, a feline coronavirus antigen,a human CCoV-HuPn-2018 antigen, a swine transmissible gastroenteritis coronavirus antigen, a porcine acute diarrheal syndrome coronavirus (SADS-CoV) antigen, an HCoV-NL63 antigen, an antigen of the NL63-related bat coronavirus strain BtKYNL63-9b, a Petition 870250095390, dated 10 / 19 / 2025, page 44 / 166 / 115: HCoV-229E antigen, a Khosta2 sarbecovirus antigen, a Kenyan bat coronavirus BtKY72 antigen, a bat SARS coronavirus HKU3 antigen, or any combination thereof. In certain embodiments, the third viral antigen may comprise a sequence selected from SEQ ID NOS: 12 to 24 or a nucleic acid selected from SEQ ID NOS: 25 to 67 that encodes the antigen. In certain embodiments, the third viral antigen may comprise an antigen derived from a Coronaviridae spike protein, S1 protein, receptor-binding domain (RBD), and / or any fragment thereof.In certain embodiments, the antigen sequence may have at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with a sequence selected from SEQ ID NOs: 12 to 24 or the nucleic acid encoding the fusion polypeptide selected from SEQ ID NOs: 25-67.

[0140] In certain embodiments, the third coronavirus antigen may comprise a spike (S) protein or a fragment thereof. As used herein, a coronavirus spike (S) protein may comprise a spike protein or a fragment thereof from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. In certain embodiments, the spike protein may comprise any Coronaviridae spike protein or a fragment thereof, a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae spike protein. In certain embodiments, the spike (S) protein, or a fragment thereof, may be a receptor-binding domain (RBD) from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof.In certain embodiments, the RBD may comprise any Coronaviridae RBD or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae RBD. In certain embodiments, the spike (S) protein, or a fragment thereof, may be an S1 protein from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. Petition 870250095390, dated 10 / 19 / 2025, page 45 / 166 42 / 115 In certain embodiments, the spike protein may comprise any Coronaviridae S1 protein or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae S1 protein.

[0141] In certain embodiments, the fusion polypeptide may comprise a plurality of antigens (5), wherein the plurality of antigens may comprise vertebrate pathogens comprising prokaryotic antigens, viral antigens, fungal antigens or any combination thereof.

[0142] In certain embodiments, the plurality of viral pathogen antigens may include: adeno-associated virus, Aichi virus, Australian bat lyssavirus, Banna virus, Barmah forest virus, BK polyomavirus, Bunyamwera virus, La Crosse Bunyavirus, snow hare virus (Bunyavirus), Cercopithecine herpesvirus, Chandipura virus, Chikungunya virus, Cosavirus A, Cowpox virus, Coxsackievirus, Crimean-Congo hemorrhagic fever virus, dengue virus, Dhori virus, Dugbe virus, Duvenhage virus, eastern chimpanzee foamy virus, eastern equine encephalitis virus, Ebola virus, Echovirus, encephalomyocarditis virus, Epstein-Barr virus, European bat lyssavirus, GBC virus / hepatitis G virus, Hantaan virus, Hendra virus, hepatitis A virus, hepatitis B virus, hepatitis C virus C, Hepatitis Delta virus, Hepatitis E virus, Horsepox virus, Human adenovirus, Human astrovirus, Human coronavirus, Human cytomegalovirus, Human Enterovirus 68,70Human Herpesvirus 1, Human Herpesvirus 2, Human Herpesvirus 6, Human Herpesvirus 7, Human Herpesvirus 8, Human Immunodeficiency Virus, Human Papillomavirus 1, Human Papillomavirus 16, 18, Human Papillomavirus 2, Human Parainfluenza, Human Parvovirus B19, Human Respiratory Syncytial Virus, Human Rhinovirus, Human SARS Coronavirus, Human T-lymphotropic Virus, Human Torovirus, Influenza A Virus, Influenza B Virus, Influenza C Virus, Isfahan Virus, Japanese Encephalitis Virus, JC Polyomavirus, Junin Arenavirus, KI Polyomavirus, Lagos Bat Virus, Lake Victoria Marburgvirus, Langat Virus, Lassa Virus, Louping Disease Virus, Lymphocytic Choriomeningitis Virus. Machupo virus, mammalian orthorubulavirus 5 (simian virus 5), Mayaro virus, measles virus, Merkel cell polyomavirus, MERS coronavirus, virus, Petition 870250095390, dated 10 / 19 / 2025, page 46 / 166 43 / 115 Mokola virus, Molluscum contagiosum virus, monkeypox virus, mumps virus, Murray Valley encephalitis virus, New York virus, Nipah virus, Norwalk virus, O'nyong-nyong virus, Orf virus, Oropouche virus, Pichinde virus, Poliovirus, Punta Toro sandfly virus, Puumala virus, rabies virus, Rift Valley fever virus, Rosavirus A, Ross River virus, Rotavirus A, Rotavirus B, Rotavirus C, rubella virus, Sagiyama virus, Salivirus A, Naples sandfly virus (Toscana virus), Sicilian sandfly virus, Sapporo virus, SARS coronavirus, SARS-CoV-2 coronavirus, Semliki Forest virus, Seoul virus, simian foamy virus, Sindbis virus, Southampton virus, St. John's encephalitis virus.Louis, tick-borne powassan virus, Torque teno virus, Uukuniemi virus, Vaccinia virus, Varicella-zoster virus, smallpox virus, Venezuelan equine encephalitis virus, vesicular stomatitis virus, West Nile virus, western equine encephalitis virus, WU polyomavirus, Yaba monkey tumor virus, Yaba-like disease virus, yellow fever virus, Zika virus, Khosta2 sarbecovirus, bat SARS-like coronavirus WIV1, Kenya bat coronavirus BtKY72, pangolin coronavirus Pang17, bat SARS coronavirus HKU3, SARS Urbani coronavirus, bat coronavirus RaTG13, Wuhan coronavirus, BA.1 coronavirus, BA.2 coronavirus, B.1.351 coronavirus, any serotype thereof, any serotype thereof or any variant thereof or any combination thereof.

[0143] In certain embodiments, the plurality of antigens may comprise a plurality of viral antigens. In certain embodiments, the plurality of viral antigens may be derived from a viral pathogen. In certain embodiments, the plurality of viral antigens may comprise any antigen derived from the plurality of antigens of viral pathogens.

[0144] In certain embodiments, the plurality of prokaryotic pathogens may comprise: Actinomyces israelii, Bacillus anthracis, Bacteroides fragilis, Bordetella pertussis, Borrelia, Brucella, Campylobacter jejuni, Chlamydia, Chlamydophila psittaci, Clostridium, Corynebacterium diphtheriae, Ehrlichia, Enterococcus, Escherichia, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira, Listeria monocytogenes, Mycobacterium, Mycoplasma pneumoniae, Petition 870250095390, dated 10 / 19 / 2025, p. 47 / 166 44 / 115 Neisseria, Pseudomonas aeruginosa, Nocardia asteroides, Rickettsia rickettsii, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema pallidum, Vibrio cholerae, Yersinia pestis, or any combination thereof.

[0145] In certain embodiments, the plurality of antigens may comprise a plurality of prokaryotic antigens. In certain embodiments, the plurality of prokaryotic antigens may be derived from a prokaryotic pathogen. In certain embodiments, the plurality of prokaryotic antigens may comprise any known antigen derived from the plurality of prokaryotic pathogens.

[0146] In certain embodiments, the plurality of eukaryotic pathogens may include: Trypanosoma brucei, Entamoeba histolytica, Babesia bovis, Babesia divergens, Candida albicans, Trypanosoma cruzi, Giardia lamblia, Acanthamoeba culbertsoni, Necator americanus, Leishmania major, Bruga malayi, Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trichomonas vaginalis, Aedes aegypti or any combination thereof.

[0147] In certain embodiments, the plurality of antigens may comprise a plurality of eukaryotic antigens. In certain embodiments, the plurality of eukaryotic antigens may be derived from a plurality of eukaryotic pathogens. In certain embodiments, the plurality of eukaryotic antigens may comprise any antigen derived from the plurality of eukaryotic antigens.

[0148] In certain embodiments, the plurality of viral antigens may comprise a plurality of coronavirus antigens. In certain embodiments, the plurality of coronavirus antigens may comprise antigens of a Coronaviridae virus. In certain embodiments, the plurality of coronavirus antigens may comprise antigens of a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. In certain embodiments, the plurality of coronavirus antigens may comprise MERSCoV antigens, SARS-CoV-1 antigens, SARS-CoV-2 antigens (for example, but not limited to Wuhan coronavirus antigens, BA.1 coronavirus antigens, BA.2 coronavirus antigens, or B.1.351 coronavirus antigens), HCoV-HKU1 antigens, HCoV-OC43 antigens, BtCoV-RaTG13 antigens, Bt SL-CoV-WIV1 antigens, HKU4-CoV antigens, HKU5-CoV antigens, Petition 870250095390, dated 10 / 19 / 2025, page 48 / 166 45 / 115 antigens PDF-2108 CoV, antigens SHC014-CoV, antigens BtSCoVRsSHC014, antigens BtSCoV-Rs3367, antigens BANAL-52, antigens BANAL-236, antigens Pangolin-CoV GX / P2V, coronavirus antigens CDPHE15 of morsel, coronavirus HKU10 antigens of morsel, an alphacoronavirus HuB-2013 antigen of Rhinolophus ferrumequinum, human coronavirus antigens 229E, mouse coronavirus antigens Lucheng Rn, coronavirus antigens 1 do mink, coronavirus antigens of furan, coronavirus 1 antigens of Miniopterus carcass, coronavirus HKU8 antigens of Miniopterus carcass, alphacoronavirus Sax2011 antigens of Myotis ricketti, alphacoronavirus SC-2013 antigens of Nyctalus velutinus, coronavirus 3398 antigens of Pipistrellus kuhlii, swine epidemic diarrhea virus antigens, coronavirus 512 antigens of Scotophilus species, coronavirus HKU2 antigens of Rhinolophus species, human coronavirus NL63 antigens,Antigens of the NL63-related bat coronavirus strain BtKYNL63-9b, Sorex araneus coronavirus T14 antigens, Suncus murinus coronavirus X74 antigens, alphacoronavirus 1 antigens, canine coronavirus antigens, feline coronavirus antigens, human CCoV-HuPn-2018 antigens, porcine transmissible gastroenteritis coronavirus antigens, porcine acute diarrheal syndrome coronavirus (SADS-CoV) antigens, HCoV-NL63 antigens, NL63-related bat coronavirus strain BtKYNL63-9b antigens, HCoV-229E antigens, Khosta2 sarbecovirus antigen, Kenya bat coronavirus BtKY72 antigens, bat SARS coronavirus HKU3 antigens, or any combination thereof. In certain embodiments, the plurality of viral antigens may comprise a sequence selected from SEQ ID NOs: 12 to 24 or a nucleic acid selected from SEQ ID NOs: 25 to 67 that encodes the antigen. In certain embodiments,The plurality of viral antigens may comprise an antigen derived from a Coronaviridae spike protein, S1 protein, receptor-binding domain (RBD), and / or any fragment thereof. In certain embodiments, the antigen sequence may have at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least... Petition 870250095390, dated 10 / 19 / 2025, page 49 / 166 46 / 115 98% identity, at least 99% identity with a sequence selected from SEQ ID Nos: 12 to 24 or the nucleic acid encoding the fusion polypeptide selected from SEQ ID Nos: 25-67.

[0149] In certain embodiments, the plurality of coronavirus antigens may comprise a spike (S) protein, S1 protein, receptor-binding domain, or fragment thereof. As used herein, a coronavirus spike (S) protein may comprise a spike protein or fragment thereof from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. In certain embodiments, the spike protein may comprise any Coronaviridae spike protein or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae spike protein. In certain embodiments, the spike (S) protein, or fragment thereof, may be a receptor-binding domain (RBD) from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof.In certain embodiments, the RBD may comprise any Coronaviridae RBD or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae RBD. In certain embodiments, the spike (S) protein, or a fragment thereof, may be an S1 protein from a Betacoronavirus, a Gammacoronavirus, an Alphacoronavirus, a Deltacoronavirus, or any combination thereof. In certain embodiments, the spike protein may comprise any Coronaviridae S1 protein or a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to any Coronaviridae S1 protein.

[0150] In certain embodiments, the plurality of antigens may comprise two or more antigens, such as 2 antigens, 3 antigens, 4 antigens, 5 antigens, 6 antigens, 7 antigens, 8 antigens, 9 antigens, or 10 antigens. In certain embodiments, the plurality of antigens may comprise at least 2 antigens. In certain embodiments, the plurality of antigens may comprise from 2 to 4 antigens.

[0151] In certain modalities, the terms “first antigen” and “third antigen” may refer to the number of antigens in the fusion construct, of Petition 870250095390, dated 10 / 19 / 2025, page 50 / 166 47 / 115 such that the “third” antigen is one of the three antigens present in the fusion polypeptide, such as three viral antigens. In certain embodiments, the terms “first” and “third” may encompass a position of the antigen in the fusion polypeptide, such that the “third” antigen is in a third position, for example, preceding the first antigen, but it may only be the first or second of said antigen in the fusion polypeptide.

[0152] In certain embodiments, the fusion polypeptide may comprise a selected sequence of: SEQ ID Nos: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 or a nucleic acid encoding the sequence thereof. In certain embodiments, the fusion polypeptide may consist of a selected sequence of: SEQ ID Nos: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 or a nucleic acid encoding the sequence thereof. In certain embodiments, the fusion polypeptide may comprise a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with the fusion polypeptide of any of the SEQ ID Nos: 1-11.

[0153] As used herein, an “immunogenic” composition, protein, polypeptide, or peptide may be a composition or molecule that includes one or more epitopes and can modulate an immune response. These peptides can be identified using any number of epitope mapping techniques, well known in the art. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology (2018) (Johan Rockberg and Johan Nilvebrant, Eds.) Springer, New York. For example, linear epitopes can be determined by, for example, software programs (see, for example, Saha et al., Structure, Function, and Bioinformatics (2006) 65:40-48); or by the simultaneous synthesis of large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still bound to the supports.Similarly, conformational epitopes are easily identified by determining the spatial conformation of amino acids, for example, by X-ray crystallography and resonance. Petition 870250095390, dated 10 / 19 / 2025, page 51 / 166 48 / 115 two-dimensional nuclear magnetic field. See, for example, Epitope Mapping Protocols, supra. Protein antigenic regions can be identified using standard antigenicity and hydropathy plots, such as those calculated using, for example, the Omiga software program available from the Oxford Molecular Group. This computer program employs the Hopp / Woods method, Hopp et al., Proc. Natl. Acad. Sci USA (1981) 78:3824-3828 to determine antigenicity profiles, and the Kyte-Doolittle technique, Kyte et al., Mol. Biol. (1982) 157:105-132 for hydropathy plots.

[0154] Immunogenic molecules, for the purposes of the present invention, will generally have at least about 5 amino acids in length, as well as at least about 10 to about 15 or more amino acids in length. There is no critical upper limit for the length of the molecule, which may comprise the total length of the protein sequence, or even a fusion protein comprising two or more epitopes, proteins, antigens, etc.

[0155] As used herein, the term “epitope” may refer to a site on an antigen that is recognized by a T cell receptor, a B cell, and / or an antibody. Several different epitopes may be carried by a single antigenic molecule. The term “epitope” also includes modified amino acid sequences that stimulate whole-body responses. The epitope may be generated from knowledge of the amino acid and corresponding DNA sequences of the polypeptide, as well as the nature of specific amino acids, such as size, charge, etc., and the codon table, without undue experimentation, as would be known, for example, by Ivan Roitt, Essential Immunology, Janis Kuby, Immunology.

[0156] An “immune response” to an antigen or composition is the development in a subject of a humoral and / or cellular immune response to an antigen present in the composition of interest. As used herein, a “humoral immune response” may refer to an immune response mediated by antibody molecules, while a “cellular immune response” is one mediated by T lymphocytes and / or other white blood cells. An important aspect of cellular immunity involves a specific response to the antigen by cytotoxic T cells (“CTLs”). CTLs have specificity for peptide antigens that are presented in association with proteins encoded by Petition 870250095390, dated 10 / 19 / 2025, page 52 / 166 49 / 115 major histocompatibility complex (MHC) and expressed on cell surfaces. CTLs help induce and promote the destruction of intracellular microbes or the lysis of cells infected by such microbes. Another aspect of cellular immunity involves a specific antigen response by helper T cells. Helper T cells can help stimulate the function and focus the activity of non-specific effector cells against cells displaying peptide antigens in association with MHC molecules on their surface. A “cellular immune response” can also refer to the production of cytokines, such as interferons, chemokines, and other similar molecules, produced by activated T cells and / or other white blood cells, including those derived from CD4+ and CD8+ T cells. In certain modalities, pathogen reduction may comprise the reduction of the pathogen by a humoral and / or cellular immune response to the antigen comprised in a fusion polypeptide in a subject.

[0157] Thus, an immune response, as used herein, may be one that stimulates the production of antibodies. The antigen of interest may also induce the production of CTLs. Therefore, an immune response may include one or more of the following effects: the production of antibodies by B cells; and / or the activation of suppressor T cells and / or memory / effector T cells specifically directed to one or more antigens present in the fusion polypeptide, composition, or vaccine of interest. These responses may serve to neutralize infectivity and / or mediate antibody-dependent cellular cytotoxicity (ADCC) or antibody-complement to provide protection to an immunized host. Such responses may be determined using standard immunoassays and neutralization assays, well known in the art.

[0158] The innate immune system of mammals also recognizes and responds to the molecular characteristics of pathogenic organisms through the activation of Toll-like receptors and similar receptor molecules on immune cells. Following activation of the innate immune system, various non-adaptive immune response cells are activated to, for example, produce various cytokines, lymphokines, and chemokines. Cells activated by an innate immune response include immature and mature dendritic cells of the monocyte and plasmacytoid lineage (MDC, PDC), as well as gamma, delta, and alpha T cells. Petition 870250095390, dated 10 / 19 / 2025, page 53 / 166 50 / 115 and beta and B cells and the like. Thus, the present invention also contemplates an immune response in which the immune response involves an innate and adaptive response.

[0159] In certain embodiments, an immunogenic composition is provided herein which may comprise a fusion polypeptide as described herein and a pharmaceutically acceptable salt, carrier or adjuvant. In certain embodiments, the pharmaceutically acceptable salt, carrier or adjuvant may comprise an oil-in-water emulsion adjuvant. In certain embodiments, the pharmaceutically acceptable salt, carrier or adjuvant may comprise a squalene-in-water emulsion adjuvant. In certain embodiments, the pharmaceutically acceptable salt, carrier or adjuvant may comprise Sepivac SWE™ adjuvant.

[0160] An “immunogenic composition”, as used herein, may be a composition comprising an immunogenic molecule, wherein administration of the composition to a subject results in the development in the subject of a humoral and / or cellular immune response to the molecule(s) of interest.

[0161] In certain embodiments, the use of a fusion polypeptide or immunogenic composition as described herein is provided in the manufacture of a medicament for the treatment or prevention of a pathogenic infection in a subject in need thereof.

[0162] In certain embodiments, the use of a fusion polypeptide or the immunogenic composition described herein is provided for the treatment or prevention of a pathogenic infection in a subject who requires it.

[0163] In certain embodiments, a method of treating or preventing a pathogenic infection is provided, comprising administering an effective amount of a fusion polypeptide or immunogenic compound, as described herein, to a subject in need thereof. In certain embodiments, the effective amount is an amount sufficient to treat and / or prevent the pathogenic infection.

[0164] In certain embodiments, pathogenic infection may comprise a viral infection of a viral pathogen, a prokaryotic infection of a prokaryotic pathogen, or a eukaryotic infection of a eukaryotic pathogen. Petition 870250095390, dated 10 / 19 / 2025, p. 54 / 166 51 / 115

[0165] In certain modalities, viral infection may comprise an adeno-associated virus infection, Aichi virus, Australian bat lyssavirus, Banna virus, Barmah forest virus, BK polyomavirus, Bunyamwera virus, La Crosse Bunyavirus, snow hare virus (Bunyavirus), Cercopithecine herpesvirus, Chandipura virus, Chikungunya virus, Cosavirus A, cowpox virus, Coxsackie virus, Crimean-Congo hemorrhagic fever virus, dengue virus, Dhori virus, Dugbe virus, Duvenhage virus, eastern chimpanzee ape foamy virus, eastern equine encephalitis virus, Ebola virus, EcHovirus, encephalomyocarditis virus, Epstein-Barr virus, European bat lyssavirus, GBC virus / hepatitis G virus, Hantaan virus, Hendra virus, hepatitis A virus, hepatitis C virus B, hepatitis C virus, hepatitis delta virus, hepatitis E virus, horsepox virus, human adenovirus, human astrovirus, human coronavirus, human cytomegalovirus, human enterovirus 68,70Human herpesvirus 1, Human herpesvirus 2, Human herpesvirus 6, Human herpesvirus 7, Human herpesvirus 8, Human immunodeficiency virus, Human papillomavirus 1, Human papillomavirus 16, 18, Human papillomavirus 2, Human parainfluenza, Human parvovirus B19, Human respiratory syncytial virus, Human rhinovirus, Human SARS coronavirus, Human T-lymphotropic virus, Human torovirus, Influenza A virus, Influenza B virus, Influenza C virus, Isfahan virus, Japanese encephalitis virus, JC polyomavirus, Junin arenavirus, KI polyomavirus, Lagos bat virus, Lake Victoria Marburgvirus, Langat virus, Lassa virus, Louping disease virus, Lymphocytic choriomeningitis virus, Machupo virus, Mammalian orthorubulavirus 5 (simian virus 5), Mayaro virus, Measles virus, Merkel cell polyomavirus, MERS coronavirus, Mokola virus, Molluscum contagiosum virus, monkeypox virus, mumps virus, Murray Valley encephalitis virus, New York virus,Nipah virus, Norwalk virus, O'nyong-nyong virus, Orf virus, Oropouche virus, Pichinde virus, Poliovirus, Punta Toro sandfly, Puumala virus, rabies virus, Rift Valley fever virus, Rosavirus A, Ross River virus, Rotavirus A, Rotavirus B, Rotavirus C, rubella virus, Sagiyama virus, Salivirus A, Naples sandfly (Toscana virus), Sicilian sandfly, Sapporo virus, SARS coronavirus, SARS-CoV-2 coronavirus, Semliki Forest virus, Seoul virus, foamy virus. Petition 870250095390, dated 10 / 19 / 2025, page 55 / 166 / 115 simian, Sindbis virus, Southampton virus, St. John's encephalitis virus, torque teno virus, Uukuniemi virus, vaccinia virus, varicella-zoster virus, smallpox virus, Venezuelan equine encephalitis virus, vesicular stomatitis virus, West Nile virus, western equine encephalitis virus, WU polyomavirus, Yaba monkey tumor virus, Yaba-like disease virus, yellow fever virus, Zika virus, any serotype thereof, any variant thereof, or any combination thereof.

[0166] In certain embodiments, the prokaryotic infection may comprise Actinomyces israelii, Bacillus anthracis, Bacteroides fragilis, Bordetella pertussis, Borrelia, Brucella, Campylobacter jejuni, Chlamydia, Chlamydophila psittaci, Clostridium, Corynebacterium diphtheriae, Ehrlichia, Enterococcus, Escherichia, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Legionella pneumophila, Leptospira, Listeria monocytogenes, Mycobacterium, Mycoplasma pneumoniae, Neisseria, Pseudomonas aeruginosa, Nocardia asteroides, Rickettsia rickettsii, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema pallidum, Vibrio cholerae, Yersinia pestis or any combination thereof.

[0167] In certain forms, eukaryotic infection may include Trypanosoma brucei, Entamoeba histolytica, Babesia bovis, Babesia divergens, Candida albicans, Trypanosoma cruzi, Giardia lamblia, Acanthamoeba culbertsoni, Necator americanus, Leishmania major, Bruga malayi, Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trichomonas vaginalis, Aedes aegypti, or any combination thereof.

[0168] In some embodiments, the viral infection can comprise a coronavirus. In some embodiments, the coronavirus may comprise a Coronaviridae virus. In some embodiments, the coronavirus can comprise MERS-CoV, SARS-CoV-1, SARS-CoV-2, HCoV-HKU1, HCoV-OC43, BtCoVRaTG13, Bt SL-CoV-WIV1, HKU4-CoV, HKU5-CoV, PDF-2008, CoVHCV, CoV401, BtSCoV-RsSHC014, BtSCoV-Rs3367, BANAL-52, BANAL-236, PangolinCoV GX / P2V, bat coronavirus CDPHE15, bat coronavirus HKLI10, Rhinolophus ferrum HuB-2013 alphacoronavirus, human coronavirus E mouse coronavirus Lucheng Rn, mink coronavirus 1, ferret coronavirus, bat coronavirus 1 Miniopterus, bat coronavirus HKLI8 Miniopterus, alphacoronavirus Sax-2011 Petition 870250095390, of 19 / 10 / 2025, p. 56 / 166 53 / 115 Myotis ricketti, Nyctalus velutinus alphacoronavirus SC-2013, Pipistrellus kuhlii coronavirus 3398, swine epidemic diarrhea virus, Scotophilus morsel coronavirus 512, Rhinolophus morsel HKLI2 coronavirus, human coronavirus NL63, strain BtKYNL63-9b of mortality coronavirus related to NL63, Sorex araneus coronavirus T14, Suncus murinus coronavirus X74, Alphacoronavirus 1, canine coronavirus, feline coronavirus, CCoV-HuPn- 2018 human, swine transmissible gastroenteritis coronavirus, da swine acute diarrheal syndrome (SADS-CoV), HCoV-NL63, BtKYNL63-9b strain of morcellation coronavirus related to NL63, HCoV229E, Khosta2 sarbecovirus, SARS-like coronavirus WIV1, morcellation coronavirus BtKY72 of Kenya, coronavirus morsel SHC014, pangolim coronavirus Pang17, SARS morsel HKLI3 coronavirus, SARS Urbani coronavirus, morsel RaTG13 coronavirus, Wuhan coronavirus, coronavirus BA.1, coronavirus BA.2, coronavirus B.1.351 or any combination thereof.

[0169] In certain embodiments, the fusion polypeptide or immunogenic composition is administered or must be administered one or more times, such as, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times.

[0170] In certain embodiments, the fusion polypeptide or immunogenic composition can neutralize two or more different pathogens, two or more different antigens, or both, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 different pathogens or different antigens. In certain embodiments, the two or more different pathogens may comprise two or more protein variants derived from the same parental pathogen, such as an omicron variant of SARS-CoV-2, a delta variant of SARS-CoV-2, and / or a beta variant of SARS-CoV-2.

[0171] In certain embodiments, the fusion polypeptide or immunogenic composition may reduce the amount of pathogen in the subject. In certain embodiments, the reduction in the amount of pathogen in a subject may comprise a reduction such that the subject is treated or prevented from experiencing symptoms associated with the pathogen. In certain embodiments, the reduction in the amount of pathogen in a subject may comprise a reduction such that the subject has diminished or improved symptoms associated with the pathogen. In certain embodiments, the reduction in the amount of pathogen in Petition 870250095390, dated 10 / 19 / 2025, page 57 / 166 / 115 a subject may understand a complete removal of the pathogen from the subject or the complete prevention of infection in the subject.

[0172] In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen, and a bat SARS-like WIV1 coronavirus antigen. In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a BA.2 coronavirus antigen, a Kenya bat BtKY72 coronavirus antigen, and a BtSCoV-RsSHC014 antigen. In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a Wuhan coronavirus antigen, a Pang17 pangolin coronavirus antigen, and a SARS-like bat WIV1 coronavirus antigen. In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen, a BtSCoV-RsSHC014 antigen, and a SARS-like bat WIV1 coronavirus antigen.In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a BA.2 coronavirus antigen, a bat SARS HKU3 coronavirus antigen, a Kenya bat BtKY72 coronavirus antigen, and a bat SARS-like WIV1 coronavirus antigen. In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen, a BtSCoV-RsSHC014 antigen, and a SARS Urbani coronavirus antigen. In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a Wuhan coronavirus antigen, a bat RaTG13 coronavirus antigen, a Kenya bat BtKY72 coronavirus antigen, and a SARS-like WIV1 bat coronavirus antigen. In certain embodiments, the fusion or immunogenic composition may comprise: a Wuhan coronavirus antigen and a BA.1 coronavirus antigen.In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a Wuhan coronavirus antigen and a BA.2 coronavirus antigen. In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a Wuhan coronavirus antigen and a B.1.617.2 coronavirus antigen. Petition 870250095390, dated 10 / 19 / 2025, page 58 / 166 55 / 115 In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a B.1.351 coronavirus antigen, a Wuhan coronavirus antigen, and a BA.2 coronavirus antigen. In certain embodiments, the fusion polypeptide or immunogenic composition may comprise: a B.1.351 coronavirus antigen, a Wuhan coronavirus antigen, and a BA.1 coronavirus antigen. In certain embodiments, the fusion polypeptide or composition may comprise any combination of two or more of the following: a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen, a bat SARS-like WIV1 coronavirus antigen, a BA.2 coronavirus antigen, a Kenya bat BtKY72 coronavirus antigen, a BtSCoV-RsSHC014 antigen, a pangolin Pang17 coronavirus antigen, a bat SARS HKU3 coronavirus antigen, a SARS Urbani coronavirus antigen, a bat RaTG13 coronavirus antigen, and a B.1.617.2 coronavirus antigen.In certain embodiments, the fusion polypeptide or composite may comprise any combination of two or more sequences selected from 12 to 24 or a nucleic acid selected from SEQ ID NOs: 25 to 67 that encodes the two or more sequences. In certain embodiments, the antigen sequence may have at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with a sequence selected from SEQ ID NOs: 12 to 24 or the nucleic acid encoding the fusion polypeptide selected from SEQ ID NOs: 25-67.

[0173] In certain embodiments, a nucleic acid encoding a fusion polypeptide as described herein is provided. In certain embodiments, the nucleic acid encoding the fusion polypeptide may be selected from SEQ ID NOs: 25 to 67.

[0174] In certain embodiments, a transformed cell is provided with a nucleic acid described herein or expressing a fusion polypeptide as described herein. A person skilled in the art, in light of the teachings contained herein, would be able to select an appropriate method, such as a lipid-based transfection reagent, to transform the cell with the nucleic acid. Petition 870250095390, dated 10 / 19 / 2025, page 59 / 166 56 / 115 nucleic acid. In certain embodiments, the cell may comprise a mammalian cell, a yeast cell, a plant cell, a bacterial cell, or an insect / arthropod cell. The person skilled in the art, in the light of the teachings contained herein, would be able to select an appropriate cell for a particular application. In certain embodiments, the cell comprises a Chinese hamster ovary cell (CHO).

[0175] As used herein, a “subunit vaccine” may refer to a vaccine composition that includes one or more selected antigens, but not all antigens, derived from or homologous to an antigen of a pathogen of interest. Such a composition may be substantially free of intact pathogenic cells or pathogenic particles, or of the lysate of such cells or particles. Thus, a “subunit vaccine” may be prepared from at least partially purified (preferably substantially purified) immunogenic molecules of the pathogen, or analogues thereof. A person skilled in the art, in light of the teachings contained herein, would be able to select a method of obtaining an antigen included in the subunit vaccine, such as standard purification techniques, recombinant production, or synthetic production.

[0176] A “coding sequence” or a sequence that “encodes” a selected polypeptide is a nucleic acid molecule that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory sequences (or “control elements”). The boundaries of the coding sequence may be determined by a start codon at the 5' (amino) end and a translation stop codon at the 3' (carboxy) end. A coding sequence may include, but is not limited to, cDNA from viral, prokaryotic, or eukaryotic mRNA, genomic DNA sequences from viral or prokaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence may be located 3' relative to the coding sequence.

[0177] As used herein, “different pathogen” may comprise the same pathogen, such as a coronavirus, but the “different pathogen” may comprise different mutations or variants in the genome of the different pathogen. In certain embodiments, the different pathogen may Petition 870250095390, dated 10 / 19 / 2025, pp. 60 / 166 57 / 115 comprise a different protein from the same pathogen, such as, for example, a spike protein of SARS-CoV-2 and a nucleocapsid protein of SARS-CoV-2. In certain embodiments, the different pathogen may comprise any pathogen that is a different organism, such as, for example, a Coronaviridae and an Orthomyxoviridae. In certain embodiments, the different pathogen may comprise any pathogen that is a different variant, such as, for example, an omicron variant of SARS-CoV-2 and a delta variant of SARS-CoV-2. In certain embodiments, the different pathogen may comprise differences in one or more of the following: phyla, organisms, genera, lineages, species, variants, serotypes, and strains.

[0178] As used herein, the term “variant” may comprise the ancestral or parental pathogen in which a genome of the ancestral or parental pathogen has been modified, such as by one or more base pair changes in the genome, one or more base pair deletions in the genome, and / or one or more base pair additions in the genome compared to the genome of the ancestral or parental pathogen. In certain embodiments, the properties of the variant ancestral pathogen or variant parental pathogen may be modified when compared to the ancestral or parental pathogen. In certain embodiments, the variant may comprise a modification of the genome of the ancestral or parental pathogen that increases pathogen transmission, worsens symptoms associated with infection by the pathogen, and / or impairs vaccine-induced immunity. In certain embodiments, the “variant” may be a “variant of concern”.As used herein, a “variant of concern” may be any variant in which a genomic modification comprising the variant may modify the properties of the variant compared to the ancestral or parental pathogen, or be predicted to modify the properties of the variant compared to the ancestral or parental pathogen, such that the variant of concern may be a public health risk or have the potential to pose a public health risk, such as a hypothetical alteration in the properties of the pathogen. In certain embodiments, the “variant” or “variant of concern” may comprise a serotype different from the ancestral or parental pathogen.

[0179] The following examples are provided for illustrative purposes and are intended for persons skilled in the art. These examples are provided Petition 870250095390, dated 10 / 19 / 2025, page 61 / 166 58 / 115 to demonstrate certain modalities as described herein and should not be seen as limiting in any way. Examples Example 1: Expression and purification of fusion polypeptides

[0180] Fusion proteins were expressed by transient transfection in Expi-CHO cells, according to the manufacturer's instructions. In summary, cells were transfected with 0.6 pg / 1 mL of plasmid DNA and subsequently cultured for 3 to 8 days until protein production reached maximum levels or cell viability began to decline. The supernatant containing the proteins was harvested and then clarified by centrifugation at 4000 xg for 30 min at 4°C, addition of 300 nM NaCl and 0.05% Tween 80, and a final filtration through a 0.2 µm filter. The clarified supernatant was concentrated, diluted 1:1 in PBS pH 8, and then loaded onto Repligen NGL Covid-19 Spike protein AR 2.0 resin. The column volume and residence times were adjusted based on the expected protein in the sample and the number of receptor-binding domains (RBDs) present in the construct.The columns were washed with 10 column volumes (CV) of phosphate-buffered saline (PBS) pH 8 before elution into 8 CV of 100 mM sodium acetate pH 5.0 + 1 M arginine. Fractions containing S1 protein constructs were buffer-exchanged in PBS and sterile filtered before formulation. Example 2: Administration of immunogenic compositions comprising fusion polypeptides.

[0181] Male hamsters aged six to eight weeks were vaccinated twice intramuscularly (IM), 28 days apart, with COVAC-2, an unfused S1 subunit antigen (WuhanS1), fusion polypeptide antigen 4304 (WuhanS1-oRBD), or fusion polypeptide antigen 4296 (WuhanS1-dRBD), all formulated with Sepivac SWE™ adjuvant. Three weeks after the second vaccination, the animals were challenged intranasally (IN) with the Beta, Delta, or Omicron variant of SARS-CoV-2. To compare protective immunity between fusion (bound) and unbound antigens, hamsters were vaccinated twice intramuscularly, 28 days apart, with fusion polypeptide antigen 4372 or an unbound triple antigen 4372, both formulated with the Petition 870250095390, dated 10 / 19 / 2025, page 62 / 166 59 / 115 adjuvant Sepivac SWE™. Three weeks after the second vaccination, the animals were challenged IN with the Delta variant of SARS-CoV-2. The animals' weight and clinical signs were monitored throughout the challenge. At 5 and 10 days post-challenge (dpc), half of the animals in each group were euthanized, and nasal washes and lung samples were collected for virological and pathological analysis. Sera were collected for ELISA and viral neutralization assay before each immunization and challenge.

[0182] In contrast to COVAC-2, both S1Wu-dRBD and S1Wu-oRBD induced high titers of virus-neutralizing antibodies in immunized animals prior to challenge (Figure 5), which significantly prevented weight loss (Figure 6) and infectious virus replication in the upper respiratory tract (Figure 7) against all variants of concern (VOCs) tested.

[0183] Syrian hamsters vaccinated with COVAC-2 lost weight when challenged with Beta and Delta VOCs; however, the weight loss was slightly less when compared to unvaccinated animals (Figure 6). Both COVAC-2 vaccinated animals and sham animals gained weight starting 7 days after infection with the Omicron VOC (Figure 6). 4,304 vaccinated hamsters lost less weight compared to sham vaccinated animals in the Delta and Omicron VOC challenge (Figure 6). 4,296 vaccinated hamsters lost less weight compared to sham vaccinated animals in the Delta and Omicron VOC challenge (Figure 6).

[0184] COVAC-2 did not prevent nasal shedding of SARS-CoV-2 when challenged with Beta, Delta, and Omicron VOCs, except for reduced shedding on day 5 after challenge with Delta VOCs (Figure 7). 4,304 vaccinated animals showed reduced nasal shedding of the virus as early as 3 days after challenge with Beta, Delta, and Omicron VOCs (Figure 7). 4,296 vaccinated animals showed reduced nasal shedding of the virus as early as 3 days after challenge with Beta and Omicron VOCs (Figure 7).

[0185] In contrast to the control group, both the bound (betaRBD-WhS1-omiRBD) and unbound fusion antigens induced high titers of S1 virus neutralizing antibodies in animals immunized prior to challenge (Figure 9A). Furthermore, in contrast to the control and the unbound triple antigen, the betaRBD-WhS1-omiRBD fusion induced high antibody titers. Petition 870250095390, dated 10 / 19 / 2025, page 63 / 166 60 / 115 specific neutralizers for the Delta virus (Figure 9B), in the absence of exposure to a Delta-specific antigen, which significantly prevented weight loss in response to a challenge with the Delta variant (Figure 9C). The fusion polypeptide vaccine (linked) provided protection against heterologous strains not included in the vaccine, while the unlinked version of the vaccine did not. Example 3: Candidate antigen model strategy for pan-sarbecovirus

[0186] For the informatics pipeline approach, two hundred sarbecovirus spike protein sequences were acquired from GISAID and Nextstrain. Phylogenetic trees were constructed to identify relatedness between viruses within each lineage and between lineages using an evolutionary history approach employing the Maximum Likelihood method and the JTT matrix-based model. Heuristic searches were used for the trees obtained automatically by applying the Neighbor-Join and BioNJ algorithms to a paired distance matrix estimated using the JTT model, and the topology with the highest log likelihood value was selected. Evolutionary analyses were conducted on MEGA11. Rationally chosen sequences representing important nodes of each lineage in the tree at distances to cover specific clades were used for the candidate vaccine designs.One representative from each of the sarbecovirus clades was chosen to be included in the antigen, and approximately 10 candidates were designed based on this approach (Figure 11).

[0187] Before candidate proteins progressed to lead candidate selection, each candidate was screened for B-cell and T-cell epitopes within the chosen “engine” and “car” sequences. The diversity and similarity of each chosen component sequence in the candidates was determined. Candidates were removed from the competition if the identified component sequences were not immunogenic or did not have ideal diversity to induce broadly protective responses. B-cell epitopes were predicted using Discotope and Bepipred-2.0, while T-cell epitopes were predicted using NetMHCpan EL 4.1 for MHC-1 molecules and NetMHC11 2.3 server for MHC-11 molecules. Diversity plots were created using EMBOSS plotcon to measure variability within a given peptide length in Petition 870250095390, dated 10 / 19 / 2025, pp. 64 / 166 61 / 115 comparison with other antigens within each candidate. A BLOSUM90 scoring matrix was used to identify similar and identical sequences. Candidates that had a score reflecting a very high or very low level of similarity between the different components within the same antigen were removed, as it was hypothesized that these candidates would not be effective in eliciting a cross-reaction response. The results of individual epitopes were compared in RStudio using the tidyverse package (version 1.3.0) to identify epitopes shared between viruses.

[0188] In the end, 7 candidates were constructed (Figure 11) and used to test their ability to be expressed and purified. Example 4: Evaluation of candidates in mice

[0189] Studies were conducted in mice to evaluate the immunogenicity of all purified fusion polypeptide candidates (Figure 12a). Animals received 5 µg of vaccine comprising a fusion polypeptide on Days 0 and 21 and were sacrificed on Day 42. A bivalent comparator vaccine (BA4 / 5) from Pfizer was included in all assays. Serum binding ELISA (Figure 12b) and ELISPOT IFNγ / IL-5 (Figure 13) were completed. As 4503 may be present primarily as a dimer, it was evaluated with and without Tween 80.

[0190] Serum binding ELISA (Figure 12b) shows that the candidate antigens induce better binding antibodies (B cell response) against the coronavirus panel (against their respective Receptor Binding Domains (RBDs)) than the placebo group (blue stars above the values) and that many also produce better binding antibodies than Pfizer's bivalent mRNA vaccine (red stars below the values). Regardless of the number or positioning of the antigens in the fusion polypeptide, the level of binding antibodies to SARS-CoV-2 S1 Wuhan (Wh) is similar (top row of Figure 12b). Furthermore, all candidate antigens demonstrated inducing significant binding antibodies to viruses that are not represented in the candidate antigen. For example, candidate 4500, which contains Pang 17 and WIV1 antigens, was able to induce significant antibodies against Khosta2, RsSHC014, Urbani, and RatG13. Petition 870250095390, dated 10 / 19 / 2025, pp. 65 / 166 / 115

[0191] ELISPOT IFNg / IL-5 (Figure 13) shows that fusion polypeptides comprising the candidate antigens are also able to induce a better T cell response (IFNg and IL-5) than Pfizer's bivalent mRNA vaccine. Example 5: Evaluating Candidates in Hamsters

[0192] Trials were conducted to evaluate vaccine candidates comprising fusion polypeptides, as described herein (Figure 14), with each trial containing a PBS control group and a Pfizer bivalent vaccine group (BA4 / 5; 5 ug / dose), in addition to the groups described in Figures 15 and 16. Hamsters were vaccinated on Day 0 and Day 28 with the respective antigens combined with SWE adjuvant. Hamsters were intranasally challenged on Day 48 with the Delta variant of SARS-CoV-2 (1x10⁵TCID₅₀). Serum was collected for ELISA and viral neutralization assays on Days 0, 28, and 48. Nasal wash samples were collected on Days 1, 3, 5, 7, and 10 post-challenge. Animals were sacrificed on Days 5 and 10 post-challenge for respiratory tissue collection. Since 4503 can be present primarily as a dimer, it was evaluated with and without Tween 80.

[0193] The hamsters' daily weight was recorded and daily weight changes were calculated as a percentage of pre-challenge weight (Figure 15). These data demonstrate that fusion polypeptides comprising candidate antigens, as described herein, were able to protect hamsters from weight loss after being challenged (infected) with the concerning SARS-CoV-2 Delta variant. Some candidates provided better protection than others, but this infection can be considered a heterologous infection because none of the vaccine candidates had a SARS-CoV-2 Delta component, indicating broad protection.

[0194] The ELISA (Figure 16) shows that the candidate antigens induce better binding antibodies (B cell response) against the coronavirus panel (against their respective Receptor Binding Domains (RBDs)) than the placebo group (blue stars above the values) and that many also produce better binding antibodies than the Pfizer bivalent mRNA vaccine (red stars below the values). Regardless of the number or positioning of antigens in the fusion polypeptide, the level of binding antibodies SARS-2 S1 Wuhan Petition 870250095390, dated 10 / 19 / 2025, pp. 66 / 166 63 / 115 (Wh) is similar (top line of Figure 16). Furthermore, candidate 4503 produced more binding antibodies against the concerning XBB 1.5 variant of SARS-CoV-2 (an Omicron sublineage) than the Pfizer bivalent control vaccine. This is significant because the Pfizer vaccine contains BA4 / 5, which is also an Omicron sublineage. Table 1: Amino acid sequences of fusion polypeptides and exemplary antigens, as described herein. Sequence Identifier 4296_WHS1_ DeltaRBD (SEQ ID NO: 1) MFVFLVLLPLVSSQCVNLTTRQLPPAYTNSFTRGVYYPDKVFRSSV LHSTQDLFPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGV YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKN LREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRF QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRWVVLSFELL HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQ FGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY QDVNCTEVPVAIHADQLTTPWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTNSPRGSGSGSGRVQPTESIVRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYG VSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYKLPDD FTGCVIAWNSNNLDSKVGGNYRYRLFRKSNLKPFERDISTEIYQA GSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVLSFELLHA PATVCGPKKSTN LVKN KCVN FNFNG4304_WHS1_ OmicronRBD (SEQ ID NO: 2) MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSV LHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGV YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKN LREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRF Petition 870250095390, dated 10 / 19 / 2025, page 67 / 166 / 115 QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQ FGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY QDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPRGSGSGSGRVQPTESIVRFPNITNL CPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYG VSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQA GNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAP ATVCG PKKSTN LVKN KCVN FNFNG 4371_BetaRB D_WHS1_Del taRBD (SEQ ID NO: 3) MFVFLVLLPLVSSRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAW NRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVG GNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQ SYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFGSGSGSGMQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVL HSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGV YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKN LREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRF QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQ FGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY QDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPRGSGSGSGRVQPTESIVRFPNITNL CPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYG Petition 870250095390, dated 10 / 19 / 2025, pp. 68 / 166 65 / 115 VSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQA GSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHA PATVCGPKKSTN LVKN KCVN FNFNG 4372_BetaRBD_WHS1_Om icronRBD (SEQ ID NO: 4) MFVFLVLLPLVSSRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAW NRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF VIRGDEVRQIAPGQTGNIADYNNYKLPDDFTGCVIAWNSNNLDSKVG GNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQ SYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCV NFGSGSGSGMQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVL HSTQDLFPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFGLV YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKN LREFVFKNIDGYFKIYSHTPINLVRDLPQGFSALEPLVDLPIGINITRF QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQ FGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY QDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPRGSGSGSGRVQPTESIVRFPNITNL CPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYG VSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQA GNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAP ATVCG PKKSTN LVKN KCVN FNFNG 4495_[S1_O micron_BtKY7 2_RsSCHC01 4] (SEQ ID NO: 5) MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHS TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEK SNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYH KNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLRE FVFKNIDGYFKIYSKHTPINLGRDLPQGFSALEPLVDLPIGINITRFQTL LALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD Petição 870250095390, de 19 / 10 / 2025, pág. 69 / 166 66 / 115 AVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNL CPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYG VSPTKLN DLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNKLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQA GNKPCNGVAGFNCYFPLRSYGFRPTYGVGHQPYRVVVLSFELLHA PATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFG RDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQG VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSY ECDIPIGAGICGSGSGSRVSPSTEVVRFPNITNLCPFGQVFNASNFP SVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSS VYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNS VDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCY EPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTELVKN KCVNFGSGSGSRVAPSKEVVRFPNITNLCPFGEVFNATTFPSVYAW ERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSF VVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTS GNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPL RPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCV NF 4498_[S1_O micron_HKU3 _BTKY72 (SEQ ID NO: 6) MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEK SNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYH KNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLRE FVFKNIDGYFKIYSKHTPINLGRDLPQGFSALEPLVDLPIGINITRFQTL LALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD AVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNL CPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYG VSPTKLN DLCFTNVYADSFVI RGNEVSQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNKLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQA GNKPCNGVAGFNCYFPLRSYGFRPTYGVGHQPYRVVVLSFELLHA PATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFG RDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQG VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSY ECDIPIGAGICGSGSGSRVSPSTEVVRFPNITNLCPFGQVFNASNFP SVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSS VYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNS Petition 870250095390, dated 10 / 19 / 2025, page 70 / 166 67 / 115 VDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCY EPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTELVKN KCVNFGSGSGSRVAPSKEVVRFPNITNLCPFGEVFNATTFPSVYAW ERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSF VVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTS GNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPL RPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCV NF 4499_[WHS1 MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSV _KHOSTA2R LHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS BD_WIVIRBD TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGV ] (SEQ ID NO: YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKN 7) LREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRF QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY QDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPRGSGSGSRVSPSLDVVRFPNMTNI CPFDQVFNKTQFPSVYAWERVRISDCVSDYTVLYNSSAFSTFKCY GVSPTKLNDLCFSGVYADYFVVKGDHVHQIAPGQTGVIADYNYKLP SEFVGCILAWNTRTIDSKRGFYYRLFRHGNIRPYERDTSNVPYNAAG GTCNQPGTHNCYEPLQDYGFTSTSGVGYQPFRVVVLSFELLNAPAT VCGPKQSTDLVKNKCVNFGSGSGSRVAPSKEVVRFPNITNLCPFGE VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKL NDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFTGCV LAWNTRNIDATQTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKP CTPPAFNCYWPLNDYGFYITNGIGYQPYRVVVLSFELLNAPATVCGP KLSTDLIKNQCVNF 4500_[WHS1 MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSV _Pang17RBD LHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS Petition 870250095390, dated 10 / 19 / 2025, page 71 / 166 68 / 115 _WIV1RBD] (SEQ ID NO: 8) TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGV YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKN LREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRF QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQ FGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY QDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPRGSGSGSRVQPTISIVRFPNITNLC PFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGV SPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDF TGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAG STPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTTLVKDKCVNFGSGSGSRVAPSKEVVRFPNITNLCPFG EVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATK LNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFTGCVLAWNTRNIDATQTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGK PCTPPAFNCYWPLNDYGFYITNGIGYQPYRVVVLSFELLNAPATVCG PKLSTDLIKNQCVNF 4501_[WHS1 _Khosta2RBD RsSHC014R BD_WIV1RB D] (SEQ ID NO: 9) MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSV LHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGV YYHKNNKSWMESEFRVYSSANNCTTFEYVSQPFLMDLEGKQGNFKN LREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRF QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQ FGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY Petition 870250095390, dated 10 / 19 / 2025, page 72 / 166 69 / 115 QDVNCTEVPVAIHADQLTTPWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPRGSGSSRVSPSLDVVRFPNMTNI CPFDQVFNKTQFPSVYAWERVRISDCVSDYTVLYNSSASFTFKCY GVSPTKLNDLCFSGVYADYFVVKGDHVHQIAPGQTGVIADYNYKLP SEFVGCILAWNTRTIDSKRGFYYRLFRHGNIRPYERDTSNVPYNAAG GTCNQPGTHNCYEPLQDYGFTSTSGVGYQFPRVVVLSFELLNAPAT VCGPKQSTDLVKNKCVNFGGSGSGSRVAPSKEVVRFPNITNLCPFGE VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKL NDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCV LAWNTNSKDSSTSGNYLYRWVRRSKLNPYERDLSNDIYSSPGGQ SCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVC GPKLSTDLIKNQCVNFGSGSGSRVAPSKEVRFPNITNLCPFGEVFN ATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDL CFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFTGCVLAW NTRNIDATQTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTP PAFNCYWPLNDYGFYITNGIGYQPYRVVVLSFELLNAPATVCGPKLS TDLIKNQCVNF 4502_[WHS1 MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSV _KHOSTA2R LHSTQDLFPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS BD_RSCH01 TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGV 4RBD_URBAYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKN NIRBD] (SEQ LREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRF ID NO: 10) QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQ FGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY QDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPRGSGSGSRVSPSLDVVRFPNMTNI CPFDQVFNKTQFPSVYAWERVRISDCVSDYTVLYNSSASFSTFKCY GVSPTKLNDLCFSGVYADYFVVKGDHVHQIAPGQTGVIADYNYKLP SEFVGCILAWNTRTIDSKRGFYYRLFRHGNIRPYERDTSNVPYNAAG GTCNQPGTHNCYEPLQDYGFTSTSGVGYQPFRVVVLSFELLNAPAT Petição 870250095390, de 19 / 10 / 2025, pág. 73 / 166 70 / 115 VCGPKQSTDLVKNKCVNFGSGSGSRVAPSKEVVRFPNITNLCPFGE VFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKL NDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCV LAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQ SCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVC GPKLSTDLIKNQCVNFGSGSGSRVVPSGDVVRFPNITNLCPFGEVF NATKFPSVYAWERKKISNCVADYSVLYNSTFFSTFKCYGVSATKLND LCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLA WNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCT PPALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATVCGPKL STDLIKNQCVNF 4503_[Wuhan MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSV S1_RATG13R LHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS BD_BTKY72R TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGV BD_WIV1RB YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKN D] (SEQ ID LREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRF NO: 11) QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQ FGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY QDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPRGSGSGSRVQPTDSIVRFPNITNLC PFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGV SPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFT GCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGS KPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPAT VCGPKKSTNLVKNKCVNFGSGSGSRVSPSTEVVRFPNITNLCPFGQ VFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPT KLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGC VLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTC SSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGP KKSTELVKNKCVNFGSGSGSRVAPSKEVVRFPNITNLCPFGEVFNA Petição 870250095390, de 19 / 10 / 2025, pág. 74 / 166 71 / 115 TTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLC FSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFTGCVLAWN TRNIDATQTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPA FNCYWPLNDYGFYITNGIGYQPYRVVVLSFELLNAPATVCGPKLSTD LIKNQCVNF 4495_4498_B A2S1 (SEQ ID NO: 12) MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHS TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEK SNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYH KNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLRE FVFKNIDGYFKIYSKHTPINLGRDLPQGFSALEPLVDLPIGINITRFQTL LALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITD AVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNL CPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYG VSPTKLN DLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNKLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQA GNKPCNGVAGFNCYFPLRSYGFRPTYGVGHQPYRVVVLSFELLHA PATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFG RDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQG VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSY ECDIPIGAGIC 4296_4304_4 371_4372_44 99_4500_450 1_4502_4503 _WuhanS1 (SEQ ID NO: 13)MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSV LHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFAS TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGV YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKN LREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRF QTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTI TDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKC YGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIY QAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQ FGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLY QDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNN SYECDIPIGAGICASYQTQTNSPR Petition 870250095390, dated 10 / 19 / 2025, page 75 / 166 / 115 4495_4498_4 503_BTKY72 (SEQ ID NO: 14) RVSPSTEVVRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADY AVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIA PAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHG KIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQ PYRVVVLSFELLNAPATVCGPKKSTELVKNKCVNF 4495_4501_4 502_RsShC0 14 (SEQ ID NO: 15) RVAPSKEVVRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADY SVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVR RSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVG HQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNF 4498_HKU3 (SEQ ID NO: 16) RVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADY TVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPG ETGVIADYNYKLPDDFTGCVIAWNTAKHDTGNYYYRSHRKTKLKPFE RDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATV CGPKLSTELVKNQCVNF 4498_4499_4 500_4501_45 03_WIV1 (SEQ ID NO: 17) RVAPSKEVVRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADY SVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP GQTGVIADYNYKLPDDFTGCVLAWNTRNIDATQTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFYITNGIGYQ PYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNF 4499_4501_4 502_Khosta2 (SEQ ID NO: 18) RVSPSLDVVRFPNMTNICPFDQVFNKTQFPSVYAWERVRISDCVSD YTVLYNSSASFSTFKCYGVSPTKLNDLCFSGVYADYFVVKGDHVHQI APGQTGVIADYNYKLPSEFVGCILAWNTRTIDSKRGFYYRLFRHGNI RPYERDTSNVPYNAAGGTCNQPGTHNCYEPLQDYGFTSTSGVGYQ PFRVVVLSFELLNAPATVCGPKQSTDLVKNKCVNF 4500_Pang17 (SEQ ID NO: 19) RVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYS VLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPG QTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKS KLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNY QPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNF 4502_Urbani RVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADY Petição 870250095390, de 19 / 10 / 2025, pág. 76 / 166 73 / 115 (SEQ ID NO: SVLYNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAP 20) GQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRH GKLRPFERDISNVPFSPDGKPCTPPALNCYWPLNDYGFYII IGIGY QPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNF 4503_RatG13 RVQPTDSIVRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADY SVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAP (SEQ ID NO: 21) GQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKA NLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGH QPYRVVVLSFELLNAPATVCGPKKSTNLVKNKCVNF OmicronRBD RVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADY SVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP (SEQ ID NO: 22) GQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRK SNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVG HQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNG BetaRBD MFVFLVLLPLVSSRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAW NRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF (SEQ ID NO: 23) VIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVG GNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQ SYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCV NF DeltaRBDRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADY SVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAP (SEQ ID NO: 24) GQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRK SNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVG YQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNG Petition 870250095390, dated 10 / 19 / 2025, page 77 / 166 / 115 Table 2: Exemplary nucleic acid sequences encoding fusion polypeptides and antigens as described herein. Identifica - dor 4296_WHS 1_DeltaRB D (SEQ ID NO: 25) ATGTTCGTGTTTCTGGTGCTGCTGCCTCTGGTGTCCAGCCAGTGT GTGAACCTGACCACCAGAACACAGCTGCCTCCAGCCTACACCAAC AGCTTTACCAGAGGCGTGTACTACCCCGACAAGGTGTTCAGATCC AGCGTGCTGCACTCTACCCAGGACCTGTTCCTGCCTTTCTTCAGC AACGTGACCTGGTTCCACGCCATCCACGTGTCCGGCACCAATGG CACCAAGAGATTCGACAACCCCGTGCTGCCCTTCAACGACGGGG TGTACTTTGCCAGCACCGAGAAGTCCAACATCATCAGAGGCTGGA TCTTCGGCACCACACTGGACAGCAAGACCCAGAGCCTGCTGATC GTGAACAACGCCACCAACGTGGTCATCAAAGTGTGCGAGTTCCAG TTCTGCAACGACCCCTTCCTGGGCGTCTACTACCACAAGAACAAC AAGAGCTGGATGGAAAGCGAGTTCCGGGTGTACAGCAGCGCCAA CAACTGCACCTTCGAGTACGTGTCCCAGCCTTTCCTGATGGACCT GGAAGGCAAGCAGGGCAACTTCAAGAACCTGCGCGAGTTCGTGT TCAAGAACATCGACGGCTACTTCAAGATCTACAGCAAGCACACCC CTATCAACCTCGTGCGGGATCTGCCTCAGGGCTTCTCTGCTCTGG AACCCCTGGTGGATCTGCCCATCGGCATCAACATCACCCGGTTTC AGACACTGCTGGCCCTGCACAGAAGCTACCTGACACCTGGCGAT AGCAGCAGCGGATGGACAGCTGGTGCCGCCGCTTACTATGTGGG CTACCTGCAGCCTAGAACCTTCCTGCTGAAGTACAACGAGAACGG CACCATCACCGACGCCGTGGATTGTGCCCTTGATCCTCTGAGCGAGACAAAGTGCACCCTGAAGTCCTTCACCGTGGAAAAGGGCATCTA CCAGACCAGCAACTTCCGGGTGCAGCCCACCGAATCCATCGTGC GGTTCCCCAATATCACCAATCTGTGCCCCTTCGGCGAGGTGTTCA ATGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAAGCGG ATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACTCCGCC AGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCCTACCAAGCTG AACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTTCGTGATC CGGGGAGATGAAGTGCGGCAGATTGCCCCTGGACAGACAGGCAA GATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACCGGCT GTGTGATTGCCTGGAACAGCAACAACCTGGACTCCAAAGTCGGC GGCAACTACAATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTG Petição 870250095390, de 19 / 10 / 2025, pág. 78 / 166 75 / 115 AAGCCCTTCGAGCGGGACATCTCCACCGAGATCTATCAGGCCGG CAGCACCCCTTGTAACGGCGTGGAAGGCTTCAACTGCTACTTCCC ACTGCAGTCCTACGGCTTCAGCCCACAAATGGCGTGGGCTATCA GCCCTACAGAGTGGTGGTGCTGAGCTTCGAACTGCTGCATGCCC CTGCCACAGTGTGCGGCCCTAAGAAAAGCACCAATCTCGTGAAGA ACAAATGCGTGAACTTCCAACTCAACGGCCTGACCGGCACCGGCC GTGCTGACAGAGAGCAACAAGAAGTTCCTGCCATTCCAGCAGTTT GGCCGGGATATCGCCGATACCACAGACGCCGTTAGAGATCCCA GACACTGGAAATCCTGGACATCACCCCTTGCAGCTTCGGCGGAG TGTCTGTGATCACCCCTGGCACCAACACCAGCAATCAGGTGGCA GTGCTGTACCAGGACGTGAAACTGTACCGAAGTGCCCGTGGCCAT TCACGCCGATCAGCTGACCTACATGGCGGGTGACTCCACCG GCAGCAATGTGTTTCAGACCAGAGCGGCTGTCTGATCGGAGCC GAGCACGTGAACAATAGCTACGAGTGCGACATCCCCATCGGCGC TGGCATCTGTGCCAGCTACCAGACCAGACAAACACCCCCAGAG GATCCGGCAGTGGGTCAGGAAGGGTTCAGCCCACAGAGTCCATA GTACGGTTCCCTAATATTACCAACCTGTGTCCGTTCGGTGAAGTC TTCAATGCCACAAGATTGCCACGCTTTTATGCCTGGAACCGAAAG AGAATTAGTAATTGGTTGCGGATTATTCTGTCCTTTACAATAGTG CAAGCTTCTCCACCTTCAAGTGTTACGGGGTTTCCCCGACGAAAC TCAACGACCTTTTG llll ACAAATGTGTATGCAGATTCATTTGTTATCCGAGGAGATGAGGTACGGCAAATAGCCCCCGGACAAACAGGAAA GATAGCCGATTACAACTATAAACTGCCTGATGACTTCACTGGGTG CGTCATCGCATGGAATAGCAACAACCTTGATTCCAAAGTAGGGGG CAATTATAATTACCGCTATCGAC llll CCGCAACCAACTCAACTCAAACT CCCTTCGAGCGCGATATCAGCACGGAAATTTACCAAGCGGGCAG CAAACCATGCAACGGAGTCGAAGGATTTAATTTGTTACTTCCCGTT GGCAATCCTATGGCTTTCAACCAACCAACGGTGTTGGTTACCAACC TTATAGAGTTGTCGTTCTCAG Illi GAGCTCCTCCATGCCCCGGCGA CACCGTATGCGGCCCAAAGAAATCAACAAACCTCGTTAAGAACAA ATGTGTCAACTTTAATTTCAATGGGTAG 4304_WHS1 _OmicronRB D (SEQ ID NO: 26) atgttcgtgtctctggtgctgctgcctggtgtccagccagtgt gtgaacctgaccacccaccgccac agctttaccagaggcgtgtaccccgacaaggtgttcagatcc agcgtgctgcactctacccaggacctgttcctgcctttcttcagc aacgtgacctggttccacgccatccacgtgtccggcaccaatgg Petition 870250095390, of 19 / 10 / 2025, p. 79 / 166 76 / 115 CACCAAGAGATTCGACAACCCCGTGCTGCCCTTCAACGACGGGG TGTACTTTGCCAGCACCGAGAAGTCCAACATCATCAGAGGCTGGA TCTTCGGCACCACACTGGACAGCAAGACCCAGAGCCTGCTGATC GTGAACAACGCCACCAACGTGGTCATCAAAGTGTGCGAGTTCCAG TTCTGCAACGACCCCTTCCTGGGCGTCTACTACCACAAGAACAAC AAGAGCTGGATGGAAAGCGAGTTCCGGGTGTACAGCAGCGCCAA CAACTGCACCTTCGAGTACGTGTCCCAGCCTTTCCTGATGGACCT GGAAGGCAAGCAGGGCAACTTCAAGAACCTGCGCGAGTTCGTGT TCAAGAACATCGACGGCTACTTCAAGATCTACAGCAAGCACACCC CTATCAACCTCGTGCGGGATCTGCCTCAGGGCTTCTCTGCTCTGG AACCCCTGGTGGATCTGCCCATCGGCATCAACATCACCCGGTTTC AGACACTGCTGGCCCTGCACAGAAGCTACCTGACACCTGGCGAT AGCAGCAGCGGATGGACAGCTGGTGCCGCCGCTTACTATGTGGG CTACCTGCAGCCTAGAACCTTCCTGCTGAAGTACAACGAGAACGG CACCATCACCGACGCCGTGGATTGTGCCCTTGATCCTCTGAGCGA GACAAAGTGCACCCTGAAGTCCTTCACCGTGGAAAAGGGCATCTA CCAGACCAGCAACTTCCGGGTGCAGCCCACCGAATCCATCGTGC GGTTCCCCAATATCACCAATCTGTGCCCCTTCGGCGAGGTGTTCA ATGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAAGCGG ATCAGCAATTGCGTGGCCGACTACTCCGTGCTGTACAACTCCGCC AGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCCTACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCCGACAGCTTCGTGATC CGGGGAGATGAAGTGCGGCAGATTGCCCCTGGACAGACAGGCAA GATCGCCGACTACAACTACAAGCTGCCCGACGACTTCACCGGCT GTGTGATTGCCTGGAACAGCAACAACCTGGACTCCAAAGTCGGC GGCAACTACAATTACCTGTACCGGCTGTTCCGGAAGTCCAATCTG AAGCCCTTCGAGCGGGACATCTCCACCGAGATCTATCAGGCCGG CAGCACCCCTTGTAACGGCGTGGAAGGCTTCAACTGCTACTTCCC ACTGCAGTCCTACGGCTTTCAGCCCACAAATGGCGTGGGCTATCA GCCCTACAGAGTGGTGGTGCTGAGCTTCGAACTGCTGCATGCCC CTGCCACAGTGTGCGGCCCTAAGAAAAGCACCAATCTCGTGAAGA ACAAATGCGTGAACTTCAACTTCAACGGCCTGACCGGCACCGGC GTGCTGACAGAGAGCAACAAGAAGTTCCTGCCATTCCAGCAGTTT GGCCGGGATATCGCCGATACCACAGACGCCGTTAGAGATCCCCA GACACTGGAAATCCTGGACATCACCCCTTGCAGCTTCGGCGGAG TGTCTGTGATCACCCCTGGCACCAACACCAGCAATCAGGTGGCA GTGCTGTACCAGGACGTGAACTGTACCGAAGTGCCCGTGGCCAT Petição 870250095390, de 19 / 10 / 2025, pág. 80 / 166 77 / 115 TCACGCCCGATCAGCTGACACCTACATGGCGGGTGTCTCGATCGGAGCC GAGCACGTGAACAATAGCTACGAGTGCGACATCCCCCATCGGCGC TGGCATCTGTGCCAGCTACCGAGACACACAAACAGCCCCAGAG GATCCGGCAGTGGGTCAGGACGAGTCCAACCAACAGAGTCAATC GTAAGATTCCCCCAATATCACCAACCTCTGCCCCTTTGACGAAGTTTT TCAACGCTACCAGATTTGCAAGTGTGTACGCCTGGAATAGGAAGC GGATCAGTAACTGCGTCGCCGACTACTCTGTACTTAACCTCG CGCCCTTTCTTACATTCAAGTGCTATGGCGTCTCCCCACGAAAC TTAATGACCTCTGTTTCACGAACGTCTACGCCGATTCCTTTGGT AAGAGGGGATGAGGTAAGACAAATAGCACTGGTCAGACAGGCA ACATAGCAGACTATAACTATAAGTTGCCCGACGACTTTACAGGAT GTGTAATTGCTTGGAACAGTAACAAGCTGGATTCAAAGGTTTCCG GCAATTATAACTACCTGTACAGACTGTTCAGAAAAAGTAATCTCAA ACCCTTCGAGAGAGACATTTCAACCGAAATCTATCAGGCCGGGAA CAAACCATGCAACGGCGTCGCTGGATTCAACTGTTACTTCCCCCCT CCGATCATACTCCTTTAGGCCCACATATGGAGTGGGTCATCAACC TTACCGAGTTGTTGTCCTGTCTTTCGAGCTCTTGCACGCGCCGGC AACTGTGTGTGGACCTAAAAAAGTACGAACTTGGTGAAGAATAA GTGTGTAAACTTTTAACTTTAATGGTTAG 4371_BetaR BD_WHS1_ DeltaRBD (SEQ ID NO: 27) ATGTTCGTGTTTCTGGTGCTGCTGCCTCTGGTGTCCAGCCGGGTGCAGCCCACCGAATCCATCGTGCGGTTCCCCAATATCACCAATCTG TGCCCCTTCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTG TACGCCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTA TAGTGTACTGTATAACTCAGCATCC IIIICCACGTTTAAGTGCTAC GGGGTCAGTCCTACAAAGTTGAATGACTTGTGCTTTACAAACGTAT ATGCTGATTCCTTTGTCATACGAGGCGATGAGGTCAGACAGATTG CTCCGGGACAAAACCGGAAATATTGCCGACTACAACTACAAACTTC CCGACGAII IIACTGGGTGTGTAATTGCCTGGAACGAACTATC TTGACTCAAAAGTGGGGGGAAATTACATTACCTTTAGACTCTT CCGCAAGAGCAAICCAAGCC IIII GAACGCGATATCTACCGA AATATACCAGGCCGGTTCTACTCCATGCAATGGAGTTAAGGGATT TAATTGTTACTTTCCTCTCCAATCCTTATGGGGACCAGCCAGCCATTA GGAGTCGGTTATCAGCCATATCGAGTCGTTGTGCTCAGCTTCGAA CTGCTTCATGCCCCAGCTACTGTTTGGGCCGAAAGTCCACT AATCTCGTGAAGAATAAGTGCGTAAACTTTGGCAGTGGGTCAGGA Petition 870250095390, of 19 / 10 / 2025, p. 81 / 166 78 / 115 TCCGGAATGCAGTGTGTGAACCTGACCACCAGAACACAGCTGCCT CCAGCCTACACCAACAGCTTTACCAGAGGCGTGTACTACCCCGAC AAGGTGTTCAGATCCAGCGTGCTGCACTCTACCCAGGACCTGTTC CTGCCTTTCTTCAGCAACGTGACCTGGTTCCACGCCATCCACGTG TCCGGCACCAATGGCACCAAGAGATTCGACAACCCCGTGCTGCC CTTCAACGACGGGGTGTACTTTGCCAGCACCGAGAAGTCCAACAT CATCAGAGGCTGGATCTTCGGCACCACACTGGACAGCAAGACCC AGAGCCTGCTGATCGTGAACAACGCCACCAACGTGGTCATCAAAG TGTGCGAGTTCCAGTTCTGCAACGACCCCTTCCTGGGCGTCTACT ACCACAAGAACAACAAGAGCTGGATGGAAAGCGAGTTCCGGGTG TACAGCAGCGCCAACAACTGCACCTTCGAGTACGTGTCCCAGCCT TTCCTGATGGACCTGGAAGGCAAGCAGGGCAACTTCAAGAACCT GCGCGAGTTCGTGTTCAAGAACATCGACGGCTACTTCAAGATCTA CAGCAAGCACACCCCTATCAACCTCGTGCGGGATCTGCCTCAGG GCTTCTCTGCTCTGGAACCCCTGGTGGATCTGCCCATCGGCATCA ACATCACCCGGTTTCAGACACTGCTGGCCCTGCACAGAAGCTACC TGACACCTGGCGATAGCAGCAGCGGATGGACAGCTGGTGCCGCC GCTTACTATGTGGGCTACCTGCAGCCTAGAACCTTCCTGCTGAAG TACAACGAGAACGGCACCATCACCGACGCCGTGGATTGTGCCCT TGATCCTCTGAGCGAGACAAAGTGCACCCTGAAGTCCTTCACCGT GGAAAAGGGCATCTACCAGACCAGCAACTTCCGGGTGCAGCCCACCGAATCCATCGTGCGGTTCCCCAATATCACCAATCTGTGCCCCT TCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTGTACGCCT GGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACTCCGTG CTGTACAACTCCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTG TCCCCTACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCC GACAGCTTCGTGATCCGGGGAGATGAAGTGCGGCAGATTGCCCC TGGACAGACAGGCAAGATCGCCGACTACAACTACAAGCTGCCCG ACGACTTCACCGGCTGTGTGATTGCCTGGAACAGCAACAACCTGG ACTCCAAAGTCGGCGGCAACTACAATTACCTGTACCGGCTGTTCC GGAAGTCCAATCTGAAGCCCTTCGAGCGGGACATCTCCACCGAG ATCTATCAGGCCGGCAGCACCCCTTGTAACGGCGTGGAAGGCTT CAACTGCTACTTCCCACTGCAGTCCTACGGCTTTCAGCCCACAAA TGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTTCG AACTGCTGCATGCCCCTGCCACAGTGTGCGGCCCTAAGAAAAGC ACCAATCTCGTGAAGAACAAATGCGTGAACTTCAACTTCAACGGC CTGACCGGCACCGGCGTGCTGACAGAGAGCAACAAGAAGTTCCT Petição 870250095390, de 19 / 10 / 2025, pág. 82 / 166 79 / 115 GCCATTCCAGCAGTTTGGCCGGGATATCGCCGATACCACAGACG CCGTTAGAGATCCCCAGACACTGGAAATCCTGGACATCACCCCTT GCAGCTTCGGCGGAGTGTCTGTGATCACCCCTGGCACCAACACC AGCAATCAGGTGGCAGTGCTGTACCAGGACGTGAACTGTACCGA AGTGCCCGTGGCCATTCACGCCGATCAGCTGACACCTACATGGC GGGTGTACTCCACCGGCAGCAATGTGTTTCAGACCAGAGCCGGC TGTCTGATCGGAGCCGAGCACGTGAACAATAGCTACGAGTGCGA CATCCCCATCGGCGCTGGCATCTGTGCCAGCTACCAGACACAGA CAAACAGCCCCAGAGGATCCGGCAGTGGGTCAGGAAGGGTTCAG CCCACAGAGTCCATAGTACGGTTCCCTAATATTACCAACCTGTGT CCGTTCGGTGAAGTCTTCAATGCCACAAGATTCGCCAGCGTTTAT GCCTGGAACCGAAAGAGAATTAGTAATTGTGTTGCGGATTATTCT GTCCTTTACAATAGTGCAAGCTTCTCCACCTTCAAGTGTTACGGG GTTTCCCCGACGAAACTCAACGACCTTTGIIIIACAAATGTGTATG CAGATTCATTTGTTATCCGAGGAGATGAGGTACGGCAAATAGCCC CCGGACAAACAGGAAAGATAGCCGATTACAACTATAAACTGCCTG ATGACTTCACTGGGTGCGTCATCGCATGGAATAGCAACAACCTTG ATTCCAAAGTAGGGGGCAATTATAATTACCGCTATCGAC IIII CCG CAAGTCCAACCTCAAACCCTTCGAGCGCGATATCAGCACGGAAAT TTACCAAGCGGGCAGCAAACCATGCAACGGAGTCGAAGGATTTAA TTGTTACTTCCCGTTGCAATCCTATGGCTTTCAACCAACCAACGGT GTTGGTTACCAACCTTATAGAGTTGTCGTTCTCAGIIII GAGCICC TCCATGCCCCGGCCACCGTATGCGGCCCAAAGAAATCAACAAAC CTCGTTAAGAACAAATGTGTCAACTTTAATTTCAATGGGTAG 4372_BetaR BD_WHS1_ OmicronRBD (SEQ ID NO: 28) ATGTTCGTGTTTCTGGTGCTGCTGCTGGTGGCCGCC CAGCCCACCGAATCCATCGTGCGGTTCCCCAATATCACCAATCTG TGCCCCTTCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTG TACGCCTGGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTA TAGTGTACTGTATAACTCAGCATCC IIII CCACGTTTAAGTGCTAC GGGGTCAGTCCTACAAAGTTGAATGACTGTGCTTTACAAACGTAT ATGCTGATTCCTTTGTCATACGAGGCGATGAGGTCAGACAGATTG CTCCGGGACAAAACCGGAAATATTGCCGACTACAACTACAAACTTC CCGACGAII IIACTGGGTGTGTAATTGCCTGGAACAGTATCAGTA TTGACTCAAAAGTGGGGGGAAATTACAATTACCTTTATAGACTCTT CCGCAAGAGCAAICICAAGCC IIII GAACGCGATATCTACCGA AATATACCAGGCCGGTTCTACTCCATGCAATGGAGTTAAGGGATT Petition 870250095390, of 19 / 10 / 2025, p. 83 / 166 80 / 115 TAATTGTTACTTTCCTCTCCAATCTTATGGGTTCCAGCCAACTTAT GGAGTCGGTTATCAGCCATATCGAGTCGTTGTGCTCAGCTTCGAA CTGCTTCATGCCCCAGCTACTGTTTGTGGGCCGAAAAAGTCCACT AATCTCGTGAAGAATAAGTGCGTAAACTTTGGCAGTGGGTCAGGA TCCGGAATGCAGTGTGTGAACCTGACCACCAGAACACAGCTGCCT CCAGCCTACACCAACAGCTTTACCAGAGGCGTGTACTACCCCGAC AAGGTGTTCAGATCCAGCGTGCTGCACTCTACCCAGGACCTGTTC CTGCCTTTCTTCAGCAACGTGACCTGGTTCCACGCCATCCACGTG TCCGGCACCAATGGCACCAAGAGATTCGACAACCCCGTGCTGCC CTTCAACGACGGGGTGTACTTTGCCAGCACCGAGAAGTCCAACAT CATCAGAGGCTGGATCTTCGGCACCACACTGGACAGCAAGACCC AGAGCCTGCTGATCGTGAACAACGCCACCAACGTGGTCATCAAAG TGTGCGAGTTCCAGTTCTGCAACGACCCCTTCCTGGGCGTCTACT ACCACAAGAACAACAAGAGCTGGATGGAAAGCGAGTTCCGGGTG TACAGCAGCGCCAACAACTGCACCTTCGAGTACGTGTCCCAGCCT TTCCTGATGGACCTGGAAGGCAAGCAGGGCAACTTCAAGAACCT GCGCGAGTTCGTGTTCAAGAACATCGACGGCTACTTCAAGATCTA CAGCAAGCACACCCCTATCAACCTCGTGCGGGATCTGCCTCAGG GCTTCTCTGCTCTGGAACCCCTGGTGGATCTGCCCATCGGCATCA ACATCACCCGGTTTCAGACACTGCTGGCCCTGCACAGAAGCTACC TGACACCTGGCGATAGCAGCAGCGGATGGACAGCTGGTGCCGCCGCTTACTATGTGGGCTACCTGCAGCCTAGAACCTTCCTGCTGAAG TACAACGAGAACGGCACCATCACCGACGCCGTGGATTGTGCCCT TGATCCTCTGAGCGAGACAAAGTGCACCCTGAAGTCCTTCACCGT GGAAAAGGGCATCTACCAGACCAGCAACTTCCGGGTGCAGCCCA CCGAATCCATCGTGCGGTTCCCCAATATCACCAATCTGTGCCCCT TCGGCGAGGTGTTCAATGCCACCAGATTCGCCTCTGTGTACGCCT GGAACCGGAAGCGGATCAGCAATTGCGTGGCCGACTACTCCGTG CTGTACAACTCCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTG TCCCCTACCAAGCTGAACGACCTGTGCTTCACAAACGTGTACGCC GACAGCTTCGTGATCCGGGGAGATGAAGTGCGGCAGATTGCCCC TGGACAGACAGGCAAGATCGCCGACTACAACTACAAGCTGCCCG ACGACTTCACCGGCTGTGTGATTGCCTGGAACAGCAACAACCTGG ACTCCAAAGTCGGCGGCAACTACAATTACCTGTACCGGCTGTTCC GGAAGTCCAATCTGAAGCCCTTCGAGCGGGACATCTCCACCGAG ATCTATCAGGCCGGCAGCACCCCTTGTAACGGCGTGGAAGGCTT CAACTGCTACTTCCCACTGCAGTCCTACGGCTTTCAGCCCACAAA Petição 870250095390, de 19 / 10 / 2025, pág. 84 / 166 81 / 115 TGGCGTGGGCTATCAGCCCTACAGAGTGGTGGTGCTGAGCTTCG AACTGCTGCATGCCCCTGCCACAGTGTGCGGCCCTAAGAAAAGC ACCAATCTCGTGAAGAACAAATGCGTGAACTTCAACTTCAACGGC CTGACCGGCACCGGCGTGCTGACAGAGAGCAACAAGAAGTTCCT GCCATTCCAGCAGTTTGGCCGGGATATCGCCGATACCACAGACG CCGTTAGAGATCCCCAGACACTGGAAATCCTGGACATCACCCCTT GCAGCTTCGGCGGAGTGTCTGTGATCACCCCTGGCACCAACACC AGCAATCAGGTGGCAGTGCTGTACCAGGACGTGAACTGTACCGA AGTGCCCGTGGCCATTCACGCCGATCAGCTGACACCTACATGGC GGGTGTACTCCACCGGCAGCAATGTGTTTCAGACCAGAGCCGGC TGTCTGATCGGAGCCGAGCACGTGAACAATAGCTACGAGTGCGA CATCCCCATCGGCGCTGGCATCTGTGCCAGCTACCAGACACAGA CAAACAGCCCCAGAGGATCCGGCAGTGGGTCAGGACGAGTCCAA CCAACAGAGTCAATCGTAAGATTCCCCAATATCACCAACCTCTGC CCCTTTGACGAAG IIIICAACGCTACCAGATTTGCAAGTGTGTAC GCCTGGAATAGGAAGCGGATCAGTAACTGCGTCGCCGACTACTC TGTACTTTATAACCTCGCGCCCTTCTTTACATTCAAGTGCTATGGC GTCTCCCCCACGAAACTTAATGACCTCTGTTTCACGAACGTCTAC GCCGATTCCTTTGTGATAAGAGGGGATGAGGTAAGACAAATAGCA CCTGGTCAGACAGGCAACATAGCAGACTATAACTATAAGTTGCCC GACGACTTTACAGGATGTGTAATTGCTTGGAACAGTAACAAGCTGGATTCAAAGGTTTCCGGCAATTATAACTACCTGTACAGACTGTTCA GAAAAAGTAATCTCAAACCCTTCGAGAGAGACATTTCAACCGAAAT CTATCAGGCCGGGAACAAACCATGCAACGGCGTCGCTGGATTCA ACTGTTACTTCCCCCTCCGATCATACTCCTTTAGGCCCACATATGG AGTGGGTCATCAACCTTACCGAGTTGTTGTCCTGTCTTTCGAGCT CTTGCACGCGCCGGCAACTGTGTGTGGACCTAAAAAGAGTACGA ACTTGGTGAAGAATAAGTGTGTAAACTTTAACTTTAATGGTTAG 4495_[S1_O micron_BtKY 72_RsSCHC 014] (SEQ ID NO: 29) ATGTTTGTGTTTCTAGTGCTACTACCACTAGTGTCCTCTCAGTGCG TGAACCTGATCACACGGACCCAGTCATACACCAACTCCTTCACCA GAGGAGTGTACTACCCTGACAAGGTGTTCAGATCTAGCGTGCTGC ATTCTACCCAGGACCTGTTTCTGCCTTTCTTCAGCAATGTGACCTG GTTCCACGCCATCCACGTGTCTGGCACAAACGGCACCAAGAGATT CGACAACCCTGTGCTGCCTTTCAACGATGGCGTGTACTTCGCCTC TACAGAGAAGTCCAACATCATCCGGGGCTGGATCTTCGGCACCAC ACTGGACTCGAAGACACAATCTCTGCTGATCGTGAACAACGCCAC Petição 870250095390, de 19 / 10 / 2025, pág. 85 / 166 / 115 CAACGTTGTCATCAAGGTGTGCGAGTTCCAGTTCTGCAACGACCC TTTCTTGGACGTGTACTACCACAAGAACAACAAGTCCTGGATGGA ATCCGAATTCAGAGTGTACTCCAGCGCCAACAACTGTACATTCGA GTACGTCAGCCAGCCCTTTCTGATGGACCTGGAAGGCAAGCAGG GAAATTTCAAGAACCTGAGAGAGTTCGTGTTCAAGAACATCGACG GCTACTTCAAGATCTACAGCAAGCACACCCCTATTAACCTGGGCA GAGATCTGCCCCAGGGCTTTTCCGCTCTGGAGCCCCTGGTGGAC CTGCCTATCGGCATCAACATCACCCGGTTTCAGACCCTCCTAGCC CTGCACAGATCCTATCTGACCCCTGGCGACAGCAGTTCCGGCTG GACCGCCGGGGCTGCTGCCTACTACGTGGGGTACCTGCAGCCTA GAACCTTCCTGCTGAAGTACAACGAGAACGGCACCATCACCGAC GCCGTGGACTGTGCTCTGGATCCACTGTCCGAGACCAAGTGCAC TCTCAAGAGCTTCACCGTGGAAAAGGGAATCTACCAGACCTCCAA CTTTAGAGTGCAGCCCACCGAGTCAATCGTGAGATTCCCCAACAT CACCAACCTGTGCCCTTTTGACGAGGTGTTCAACGCTACCAGATT TGCTTCTGTGTACGCCTGGAACCGGAAGAGAATCTCTAACTGCGT GGCCGATTACTCCGTGCTGTACAACTTCGCTCCTTTCTTCGCCTT CAAGTGTTACGGCGTGTCCCCTACCAAGCTGAACGACCTGTGTTT CACTAACGTGTACGCCGACTCTTTCGTGATCCGGGGCAACGAGG TGTCCCAGATCGCCCCAGGCCAGACAGGCAACATCGCTGACTAC AACTACAAGCTGCCTGACGATTTCACCGGCTGTGTGATCGCCTGGAACTCCAACAAGCTGGATTCCAAAGTGGGCGGCAACTACAACTAT CTGTACCGGCTGTTCAGAAAGTCCAATCTGAAGCCCTTCGAACGC GACATCTCCACCGAGATCTATCAGGCCGGCAACAAGCCTTGTAAC GGCGTCGCTGGCTTCAACTGCTACTTCCCTTTGCGATCTTATGGC TTCCGGCCTACCTACGGCGTGGGCCACCAGCCTTACCGGGTGGT GGTGCTGAGCTTTGAGCTGCTGCACGCTCCTGCTACAGTGTGCG GCCCTAAGAAGTCCACCAATCTGGTGAAAAATAAGTGCGTTAACT TCAACTTCAACGGCCTGACCGGCACCGGCGTGCTGACAGAGTCA AATAAGAAGTTCCTGCCTTTCCAGCAGTTTGGCAGGGACATCGCC GACACCACGGACGCTGTGCGGGACCCTCAGACCCTGGAAATCCT GGATATCACCCCTTGCTCCTTCGGCGGCGTGAGCGTGATTACCC CTGGAACCAACACCTCTAATCAAGTGGCCGTGCTGTACCAAGGCG TGAACTGCACCGAAGTGCCCGTGGCTATCCACGCCGATCAGCTG ACCCCTACATGGCGGGTATACAGTACCGGCTCTAACGTGTTCCAG ACCCGGGCTGGCTGCCTGATCGGCGCCGAGTACGTGAACAACTC CTACGAGTGCGACATCCCCATCGGCGCTGGCATTTGCGGATCTG Petição 870250095390, de 19 / 10 / 2025, pág. 86 / 166 83 / 115 GCTCTGGATCCAGAGTCTCTCCAAGCACCGAGGTGGTGCGGTTT CCTAATATCACCAACCTGTGCCCTTTCGGACAAGTGTTTAACGCCT CCAACTTCCCATCGGTGTACGCCTGGGAGAGACTGCGCATCTCC GACTGCGTCGCCGACTATGCCGTGCTGTACAATTCTTCCTCCTCT TTCTCCACCTTTAAGTGCTACGGCGTGAGCCCTACAAAGCTGAAC GACCTGTGCTTCTCCTCTGTGTACGCCGACTACTTCGTGGTGAAA GGCGATGATGTGAGACAGATCGCCCCTGCCCAGACCGGCGTGAT CGCCGATTACAACTACAAGCTCCCCGACGACTTCACAGGCTGCGT GCTGGCCTGGAATACCAACTCCGTAGATTCCAAATCCGGAAACAA CTTCTACTACCGGCTGTTCAGACACGGCAAGATCAAGCCCTACGA AAGAGACATCTCCAACGTGCTGTACAACTCCGCTGGCGGCACCT GTTCCTCCATCTCTCAGCTGGGCTGCTACGAGCCCCTGAAATCCT ATGGGTTCACCCCCACCGTGGGGGTGGGCTACCAGCCTTATAGG GTCGTGGTGTTATCCTTCGAACTGCTGAACGCTCCAGCTACCGTG TGCGGCCCCAAGAAATCAACCGAGCTGGTCAAGAACAAGTGCGT GAACTTCGGCTCTGGCAGCGGCTCTAGAGTGGCACCCTCTAAAG AAGTGGTCAGATTCCCCAATATCACCAATCTGTGTCC Illi GGCGA GGTCTTCAACGCCACCACCTTCCCTTCTGTGTACGCCTGGGAACG GAAACGGATCTCTAACTGCGTCGCCGACTACTCTGTTCTCTACAA CTCCACCTCTTTCTCCACCTTTAAATGTTACGGCGTCTCTGCTACA AAACTGAACGATCTGTGCTTCTCTAACGTGTACGCTGACTC IIIIGTGGTAAAGGGCGACGACGTGAGACAGATCGCCCCTGGCCAAACC GGAGTCATCGCTGATTATAACTACAAACTGCCTGATGACTTCCTG GGATGTGTGCTGGCTTGGAACACCAATAGCAAGGACAGCAGCAC ATCTGGCAACTACAACTACCTGTACAGATGGGTGAGGAGAAGCAA GCTCAACCCGTATGAACGGGACCTGTCTAACGACATCTACTCTCC AGGCGGACAGTCCTGCTCCGCTGTGGGCCCTAACTGCTACAATC CTCTGAGACCCTACGGCTTCTTCACCACCGCTGGCGTGGGACAT CAGCCTTACAGAGTTGTTGTGCTGAGCTTCGAGCTGCTGAACGCC CCTGCCACCGTGTGTGGCCCTAAGCTGTCTACTGATCTGATCAAA AACCAGTGCGTGAATTTCtgataataa 4498_[S1_O micron_HKU 3_BTKY72 (SEQ ID NO: ATGTTTGTGTTTCTAGTGCTACTACCACTAGTGTCCTCTCAGTGCG TGAACCTGATCACACGGACCCAGTCATACACCAACTCCTTCACCA GAGGAGTGTACTACCCTGACAAGGTGTTCAGATCTAGCGTGCTGC ATTCTACCCAGGACCTGTTTCTGCCTTTCTTCAGCAATGTGACCTG GTTCCACGCCATCCACGTGTCTGGCACAAACGGCACCAAGAGATT Petição 870250095390, de 19 / 10 / 2025, pág. 87 / 166 / 115 30) CGACAACCCTGTGCTGCCTTTCAACGATGGCGTGTACTTCGCCTC TACAGAGAAGTCCAACATCATCCGGGGCTGGATCTTCGGCACCAC ACTGGACTCGAAGACACAATCTCTGCTGATCGTGAACAACGCCAC CAACGTTGTCATCAAGGTGTGCGAGTTCCAGTTCTGCAACGACCC TTTCTTGGACGTGTACTACCACAAGAACAACAAGTCCTGGATGGA ATCCGAATTCAGAGTGTACTCCAGCGCCAACAACTGTACATTCGA GTACGTCAGCCAGCCCTTTCTGATGGACCTGGAAGGCAAGCAGG GAAATTTCAAGAACCTGAGAGAGTTCGTGTTCAAGAACATCGACG GCTACTTCAAGATCTACAGCAAGCACACCCTATTAACCTGGGCA GAGATCTGCCCCAGGGC Illi CCGCTCTGGAGCCCCTGGTGGAC CTGCCTATCGCATCAACATCACCCGGTTTCAGACCCTCCTAGCC CTGCACAGATCCTATCTGACCCCTGGCCAGCAGTTCCGGCTG GACCGCCGGGGCTGCTGCCTACTACGTGGGGTACCTGCAGCCTA GAACCTTCCTGCTGAAGTACAACGAGAACGGCACCATCACCGAC GCCGTGGACTGTGCTCTGGATCCACTGTCCGAGACCAAGTGCAC TCTCAAGAGCTTCACCGTGGAAAGGGAATCTACCGAGCTCCAA CTTTAGAGTGCAGCCCACGAGTCAATCGTGAGATTCCCCAACAT CACCAACCTGTGCC llll GACGAGGTGTTCAACGCTACCAGATT TGCTTCTGTGTACGCCTGGAACCGGAAGAATCTCTAACTGCGT GCCGATTACTCCGTGCTGTACAACTTCGCTCTTTCTTGCCTTT CAAGGTTTACGGCGTGTCCCCTACCAAGCTGAGGAACGACCTGTGTTTTCACTAACGTGTACGCCGACTCTTTCGTGATCCGGGGCAACGAGG TGTCCCAGATCGCCCCAGGCCAGACAGGCAACATCGCTGACTAC AACTACAAGCTGCCTGACGATTTCACCGGCTGTGTGATCGCCTGG AACTCCAACAAGCTGGATTCCAAAGTGGGCGGCAACTACAACTAT CTGTACCGGCTGTTCAGAAAGTCCAATCTGAAGCCCTTCGAACGC GACATCTCCACCGAGATCTATCAGGCCGGCAACAAGCCTTGTAAC GGCGTCGCTGGCTTCAACTGCTACTTCCCTTTGCGATCTTATGGC TTCCGGCCTACCTACGGCGTGGGCCACCAGCCTTACCGGGTGGT GGTGCTGAGCTTTGAGCTGCTGCACGCTCCTGCTACAGTGTGCG GCCCTAAGAAGTCCACCAATCTGGTGAAAAATAAGTGCGTTAACT TCAACTTCAACGGCCTGACCGGCACCGGCGTGCTGACAGAGTCA AATAAGAAGTTCCTGCCTTTCCAGCAGTTTGGCAGGGACATCGCC GACACCACGGACGCTGTGCGGGACCCTCAGACCCTGGAAATCCT GGATATCACCCCTTGCTCCTTCGGCGGCGTGAGCGTGATTACCC CTGGAACCAACACCTCTAATCAAGTGGCCGTGCTGTACCAAGGCG TGAACTGCACCGAAGTGCCCGTGGCTATCCACGCCGATCAGCTG Petição 870250095390, de 19 / 10 / 2025, pág. 88 / 166 85 / 115 ACCCCTACATGGCGGGTATACAGTACCGGCTCTAACGTGTTCCAG ACCCGGGCTGGCTGCCTGATCGGCGCCGAGTACGTGAACAACTC CTACGAGTGCGACATCCCCATCGGCGCTGGCATTTGCGGATCTG GCTCTGGATCCAGAGTCTCTCCAAGCACCGAGGTGGTGCGGTTT CCTAATATCACCAACCTGTGCCCTTTCGGACAAGTGTTTAACGCCT CCAACTTCCCATCGGTGTACGCCTGGGAGAGACTGCGCATCTCC GACTGCGTCGCCGACTATGCCGTGCTGTACAATTCTTCCTCCTCT TTCTCCACCTTTAAGTGCTACGGCGTGAGCCCTACAAAGCTGAAC GACCTGTGCTTCTCCTCTGTGTACGCCGACTACTTCGTGGTGAAA GGCGATGATGTGAGACAGATCGCCCCTGCCCAGACCGGCGTGAT CGCCGATTACAACTACAAGCTCCCCGACGACTTCACAGGCTGCGT GCTGGCCTGGAATACCAACTCCGTAGATTCCAAATCCGGAAACAA CTTCTACTACCGGCTGTTCAGACACGGCAAGATCAAGCCCTACGA AAGAGACATCTCCAACGTGCTGTACAACTCCGCTGGCGGCACCT GTTCCTCCATCTCTCAGCTGGGCTGCTACGAGCCCCTGAAATCCT ATGGGTTCACCCCCACCGTGGGGGTGGGCTACCAGCCTTATAGG GTCGTGGTGTTATCCTTCGAACTGCTGAACGCTCCAGCTACCGTG TGCGGCCCCAAGAAATCAACCGAGCTGGTCAAGAACAAGTGCGT GAACTTCGGCTCTGGCAGCGGCTCTAGAGTGGCACCCTCTAAAG AAGTGGTCAGATTCCCCAATATCACCAATCTGTGTCC Illi GGCGA GGTCTTCAACGCCACCACCTTCCCTTCTGTGTACGCCTGGGAACGGAAACGGATCTCTAACTGCGTCGCCGACTACTCTGTTCTCTACAA CTCCACCTCTTTCTCCACCTTTAAATGTTACGGCGTCTCTGCTACA AAACTGAACGATCTGTGCTTCTCTAACGTGTACGCTGACTC IIIIG TGGTAAAGGGCGACGACGTGAGACAGATCGCCCCTGGCCAAACC GGAGTCATCGCTGATTATAACTACAAACTGCCTGATGACTTCCTG GGATGTGTGCTGGCTTGGAACACCAATAGCAAGGACAGCAGCAC ATCTGGCAACTACAACTACCTGTACAGATGGGTGAGGAGAAGCAA GCTCAACCCGTATGAACGGGACCTGTCTAACGACATCTACTCTCC AGGCGGACAGTCCTGCTCCGCTGTGGGCCCTAACTGCTACAATC CTCTGAGACCCTACGGCTTCTTCACCACCGCTGGCGTGGGACAT CAGCCTTACAGAGTTGTTGTGCTGAGCTTCGAGCTGCTGAACGCC CCTGCCACCGTGTGTGGCCCTAAGCTGTCTACTGATCTGATCAAA AACCAGTGCGTGAATTTCtgataataa 4499_[WHS1 ATGTTTGTGTTTCTAGTGCTACTACCACTAGTGTCTTCCCAGTGCG _KHOSTA2R TCAATCTGACCACCAGAACCCAACTGCCCCCTGCTTACACTAACT Petição 870250095390, de 19 / 10 / 2025, pág. 89 / 166 86 / 115 BD_WIVIRB CTTTCACCAGAGGCGTGTACTACCCTGCAAGGTGTTCCGGTCGT D] (SEQ ID CCGTGCTGCATTCTACCCAGGATCTCTTCTTGCCTTTCTTCTCTAA NO: 31) CGTGACCTGGTTCCACGCCATCCATGTCTGGCACAAACGGCA CCAAGAGATTCGACAACCCTTGCTGCCTTTCAACGACGGCTGTT ATTTCGCCTCTACCGAAGTCTAACATCATCCGGGGCTGGATCT TCGGCACCACACTGGACAGCAAGACCACAGTCGCTGATCGTG AACAACGCCACCAACGTGGTCATCAAGGTCTGCGAATTCCAGTTC TGCAACGATCCTTTCCTGGGCGTATACTACCACAAGAACAACAAG TCCTGGATGGAATCCGAATTCAGAGTATACTCCTCCGCAATAAC TGCACATTCGAGTACGTGTCTCAGCCTTTCCTGATCTGGAAA GGCAAGCAGGGCAACTTCCAAAACCTGAGAGAGTTCGTGTTCAAG AACATCGACGGCTACTTCAAGATCTACAAGCACACCCCTATC AACCTGGTGCGGGATCTGCCACAGGGC They CCGCTCTGGAACC TCTGGTGGACCTGCCCATCGGCATCAATATCACCCGCCTTTCAAAC CCTGCTGGCCCTGCCACAGATCTTACCTGACACCAGGCACTCCTC CTCCGGCTGGACCGCCGGCGCTGCCCCTACTACGTGGGCTACC TCCAGCCTCGGACCTTTCTGCTCCAAGTACAACGAGAACGGCACAA TCACCGACGCCGTGGACTGCGCCCTGGACCCCCTGTCCGAGACA AAGTGTACCCTGAAGTCCTTACACCGTGGAAAAAGGAATCTATCAA ACCTCCAACTTTCGTGTGCAACCTACTGAATCTATCGTGAGATTTC CTAATATTACCAATCTGTGTC llll GGCGAGGTGTTCAACGCCACTCGGTTCGCTTCCGTGTACGCCTGGAACAGAAAGCGGATCAGCA ACTGCGTTGCTGACTACTCCGTGCTGTACAACTCCGCTTCCTTCA GCACCTTCAAGTGCTATGGGGTCTCCCCTACCAAGCTGAACGATC TGTGCTTCACCAACGTGTATGCAGACTCTTTCGTGATCAGAGGCG ACGAGGTCAGACAGATCGCCCCCGGCCAGACCGGAAAGATCGCT GACTACAACTACAAGCTGCCCGACGACTTCACAGGCTGTGTGATC GCGTGGAACTCTAACAACCTAGACTCTAAGGTAGGCGGCAACTAT AACTACCTGTACAGACTGTTTCGGAAGAGCAACCTGAAGCCTTTC GAGCGGGACATCTCGACCGAGATCTACCAGGCTGGCAGCACACC CTGCAACGGGGTGGAAGGATTTAACTGCTACTTCCCACTGCAGTC TTATGGCTTCCAGCCCACAAACGGCGTGGGCTACCAACCTTACCG GGTGGTGGTGCTGTCCTTCGAGCTGCTGCACGCTCCTGCTACCG TGTGTGGCCCAAAGAAATCTACCAACCTGGTGAAGAACAAGTGTG TCAACTTCAATTTCAACGGCCTGACCGGCACCGGCGTCCTGACCG AGTCTAATAAGAAGTTCCTGCCCTTTCAGCAGTTCGGCAGAGATA TCGCCGATACCACCGACGCTGTGCGGGACCCCCAGACGCTGGAA Petição 870250095390, de 19 / 10 / 2025, pág. 90 / 166 87 / 115 ATCCTGGATATCACGCCTTGCTCTTTCGGCGGCGTGTCCGTGATC ACACCCGGCACCAACACCAGCAACCAAGTGGCTGTGTTGTATCAG GACGTGAACTGCACCGAAGTGCCTGTGGCCATCCACGCCGATCA GCTGACCCCTACCTGGAGAGTGTACTCAACCGGCAGCAACGTGT TCCAGACCAGAGCGGGCTGCCTGATCGGCGCCGAGCACGTGAAC AACTCCTACGAGTGCGACATCCCTATCGGAGCCGGCATCTGCGC CAGCTACCAAACACAGACCAACTCCCCTCGGGGATCTGGCTCTG GTTCCAGAGTGTCTCCTTCTCTGGACGTGGTGAGGTTTCCAAACA TGACCAACATCTGCCCTTTCGACCAGGTGTTCAACAAGACCCAGT TCCCTTCCGTCTACGCTTGGGAACGGGTGAGAATCTCCGACTGTG TGTCCGACTACACCGTGCTGTACAACAGCTCTGCTTCTTTCTCCA CCTTCAAGTGTTACGGCGTGTCTCCTACCAAGCTGAACGACCTGT GCTTCTCAGGCGTGTACGCCGACTACTTCGTGGTCAAAGGCGATC ACGTGCACCAGATCGCCCCTGGCCAGACCGGCGTGATCGCCGAC TACAATTACAAACTGCCTTCCGAGTTCGTAGGCTGCATCCTGGCT TGGAACACAAGAACCATCGACTCCAAGAGAGGATTCTACTACCGG CTGTTCAGACACGGCAATATCCGGCCGTACGAGAGAGACACCTC CAATGTGCCCTACAATGCTGCTGGAGGCACCTGCAACCAGCCTG GCACCCACAACTGCTACGAGCCTCTGCAGGACTACGGCTTCACAT CCACATCGGGAGTGGGCTACCAGCCATTCCGCGTGGTGGTCTTA TCCTTTGAGCTGCTGAACGCCCCTGCCACCGTGTGTGGCCCCAAGCAGAGCACCGATCTAGTGAAAAACAAGTGCGTCAATTTCGGCTC CGGAAGCGGCTCCAGAGTGGCTCCCTCTAAAGAGGTGGTGAGAT TCCCCAACATTACCAACCTGTGCCC Illi GGAGAGGTCTTCAATG CTACCACCTTCCCTAGCGTATACGCTTGGGAGCGGAAGCGGATCT CCAACTGCGTGGCCGACTACTCTGTGCTGTACAACTCCACCAGCT TTTCTACCTTCAAATGCTACGGCGTGTCCGCCACCAAGCTGAACG ATCTGTGC ΗΗ CCAACGTGTACGCCGATTCCTTCGTGGTTAAGG GCGACGATGTGAGACAGATCGCCCCTGGCCAGACAGGTGTAATC GCTGATTACAACTACAAGCTGCCTGACGACTTCACCGGCTGTGTG CTGGCCTGGAACACCAGAAACATCGATGCTACACAGACCGGCAA CTACAACTACAAGTACCGGAGCCTGCGGCATGGCAAGCTGAGAC CTTTCGAGAGAGATATCTCCAACGTGCCATTCTCTCCCGATGGCA AACCTTGTACCCCACCTGCTTTCAACTGCTACTGGCCCCTGAACG ACTACGGCTTCTATATCACTAACGGCATCGGCTACCAGCCATACA GAGTGGTGGTTCTGAGTTTCGAACTGCTCAATGCTCCAGCCACCG TGTGCGGACCTAAGCTTTCCACCGACCTGATAAAAAACCAGTGTG Petição 870250095390, de 19 / 10 / 2025, pág. 91 / 166 88 / 115 TGAACTTCtgataataa 4500_[WHS1 _Pang17RB D_WIV1RBD ] (SEQ ID NO: 32) ATGTTTGTGTTTCTAGTGCTACTACCACTAGTGTCCTCCCAGTGTG TGAATCTGACAACCAGAACCCAGCTGCCTCCAGCCTACACCAATT CCTTCACCAGAGGAGTCTACTACCCTGACAAAGTGTTCAGATCCT CTGTGCTCCACTCAACACAGGATCTGTTTCTGCCCTTCTTCTCCAA CGTCACTTGGTTCCACGCTATCCATGTGTCCGGAACAAACGGCAC AAAGAGATTCGACAACCCCGTGTTGCCTTTCAACGACGGCGTGTA CTTCGCCTCTACCGAGAAGTCCAACATCATCAGAGGCTGGATCTT CGGCACCACACTCGATTCTAAGACCCAGTCTCTGCTGATCGTTAA CAACGCCACCAACGTGGTCATCAAGGTGTGCGAGTTCCAGTTCTG CAACGACCCCTTCCTGGGCGTCTACTACCACAAGAACAACAAGTC TTGGATGGAATCCGAGTTCCGTGTTTACAGCTCCGCCAACAACTG TACCTTCGAGTACGTCTCTCAGCCCTTCCTAATGGACCTGGAAGG TAAACAGGGCAATTTCAAGAACCTGAGAGAGTTCGTGTTCAAGAA CATCGACGGATAII IIAAGATCTACTCTAAGCACACCCCTATCAAC CTGGTGCGGGACCTGCCTCAAGGCTTCTCCGCTCTGGAGCCTCT AGTGGACCTGCCTATTGGCATCAACATCACCAGATTCCAGACCCT ACTGGCTCTGCACAGATCTTACCTGACTCCTGGCGACAGCTCCAG CGGCTGGACCGCCGGCGCTGCCGCTTACTACGTGGGCTACCTGC AGCCTCGGACCTTCCTGCTGAAGTACAACGAGAACGGAACCATCA CCGACGCTGTGGACTGCGCCCTGGATCCTCTGTCTGAAACTAAGTGCACCCTGAAGTCGTTTACCGTGGAAAAGGGCATCTACCAGACCT CCAACTTCAGAGTGCAGCCAACCGAATCTATCGTGCGCTTCCCCA ACATCACAAACCTGTGCCCCTTCGGCGAAGTGTTCAACGCTACAC GGTTCGCCTCCGTATACGCTTGGAACAGAAAAAGAATCTCCAACT GTGTGGCTGATTACTCCGTGCTGTATAACAGCGCCTCTTTTTCCA CCTTCAAGTGCTACGGGGTGTCTCCTACCAAACTGAACGACCTGT GCTTTACCAACGTGTACGCCGACTCCTTTGTGATCCGGGGCGATG AGGTGCGGCAGATCGCCCCTGGCCAGACCGGCAAGATCGCCGA CTATAATTACAAGCTGCCTGACGACTTCACCGGCTGCGTGATCGC ATGGAACTCCAACAATCTGGACTCCAAGGTGGGCGGCAACTACAA CTATCTGTATAGACTGTTCAGAAAGTCCAACCTGAAACCTTTCGAG AGAGACATCAGCACCGAGATCTACCAGGCCGGCTCTACCCCTTG CAACGGCGTAGAGGGCTTCAACTGCTACTTCCCCCTGCAGTCCTA CGGCTTTCAACCTACCAACGGAGTGGGCTACCAACCTTACCGGGT GGTGGTGCTGTCCTTCGAGCTGCTGCACGCCCCTGCTACTGTGT Petição 870250095390, de 19 / 10 / 2025, pág. 92 / 166 89 / 115 GCGGACCTAAGAAATCTACCAATCTGGTGAAAAACAAGTGCGTGA ACTTCAACTTCAACGGCCTGACAGGCACTGGCGTCCTGACCGAGT CCAACAAGAAGTTCCTGCCTTTCCAGCAGTTCGGCAGAGACATCG CCGACACCACCGACGCCGTTAGAGATCCTCAGACCCTGGAGATC CTGGACATCACCCCTTGCTCCTTTGGCGGCGTGTCCGTGATCACC CCTGGCACCAACACCAGTAATCAGGTGGCCGTGCTGTACCAGGA CGTGAACTGCACCGAAGTGCCTGTGGCCATCCACGCCGACCAGC TGACACCTACATGGCGGGTTTACTCCACAGGATCCAACGTGTTCC AGACCCGGGCTGGCTGCCTGATCGGCGCCGAGCACGTGAACAAC TCCTACGAGTGCGACATCCCTATCGGCGCTGGCATCTGCGCTTCT TACCAAACCCAGACCAACTCCCCCCGCGGCTCTGGCTCCGGCAG TCGGGTGCAACCTACCATCTCCATCGTGCGGTTTCCTAACATCAC CAACCTGTGCCCTTTCGGCGAGGTCTTCAACGCCAGCAAGTTCGC TTCCGTGTATGCCTGGAACAGAAAGAGAATCTCCAACTGCGTCGC CGACTACTCCGTGCTGTACAATTCTACAAGTTTCTCCACCTTCAAG TGCTACGGCGTGTCCCCTACCAAGCTGAACGACCTGTGCTTCACC AACGTCTACGCCGACTCCTTCGTGGTGAAGGGCGATGAAGTGAG ACAGATCGCTCCAGGACAGACAGGCGTAATTGCCGACTATAATTA TAAACTCCCCGATGACTTCACCGGCTGCGTGATTGCCTGGAACTC TGTCAAGCAGGACGCTTTGACCGGCGGAAACTACGGCTACCTGT ACCGGCTGTTCAGAAAGTCCAAGCTGAAACCTTTTGAACGGGACATCTCTACCGAAATCTACCAGGCTGGGAGCACCCCTTGTAACGGAC AAGTGGGCCTGAACTGTTACTACCCCCTGGAAAGATACGGCTTCC ATCCTACCACCGGCGTGAATTACCAGCCTTTCCGGGTTGTGGTTC TGAGCTTTGAGCTGCTGAACGGCCCAGCTACGGTGTGCGGCCCC AAGCTCTCTACCACCCTTGTGAAGGACAAGTGCGTCAATTTCGGC TCTGGCTCTGGGTCCAGAGTGGCTCCTTCCAAAGAGGTGGTGAG ATTTCCTAATATCACCAACCTGTGTCCTTTCGGCGAAGTGTTCAAC GCCACCACCTTCCCATCTGTGTACGCCTGGGAGAGAAAGCGGAT CAGCAACTGTGTGGCTGATTATTCTGTGCTGTACAACTCCACCTC CTTCTCCACCTTTAAGTGTTACGGCGTGTCTGCTACCAAGCTGAA CGATCTCTGTTTTAGTAACGTGTACGCCGACTCCTTCGTGGTGAA GGGCGACGATGTGCGGCAGATCGCCCCTGGCCAGACCGGCGTG ATCGCTGATTACAACTACAAGCTGCCTGACGACTTTACAGGCTGT GTGCTGGCTTGGAACACCCGGAACATCGATGCCACCCAGACCGG CAACTACAACTACAAGTACCGCTCTCTGCGGCACGGCAAGCTGAG GCCCTTTGAGCGGGATATCTCTAACGTGCCTTTCAGCCCTGATGG Petição 870250095390, de 19 / 10 / 2025, pág. 93 / 166 90 / 115 CAAGCCCTGCACCCCTCCAGCCTTCAATTGTTACTGGCCTCTGAA CGACTACGGCTTCTACATCACCAACGGAATCGGCTACCAGCCCTA TAGAGTGGTGGTGCTGTCGTTCGAGCTGCTGAATGCTCCCGCCA CCGTGTGTGGCCCAAAGCTGTCCACCGACCTGATCAAGAACCAG TGCGTGAACTTCtgataataa 4501_[WHS1 _Khosta2RB D_RsSHC01 4RBD_WIV1 RBD] (SEQ ID NO: 33) ATGTTTGTGTTTCTAGTGCTACTACCACTAGTGTCCTCCCAGTGCG TGAACCTGACCACAAGAACCCAGCTGCCTCCTGCGTACACCAACT CCTTCACCAGAGGCGTGTACTACCCTGACAAGGTGTTTCGTTCCT CCGTCTTGCACTCCACACAGGATCTGTTTCTGCCTTTCTTCTCTAA CGTGACGTGGTTCCACGCCATCCACGTGTCCGGTACCAACGGCA CAAAGAGATTCGACAACCCCGTGCTGCCTTTCAACGACGGCGTTT ACTTCGCCTCCACTGAGAAGTCTAACATCATCAGAGGATGGATCT TCGGTACCACCCTCGACAGCAAGACCCAATCCCTGCTGATAGTGA ACAACGCTACAAACGTGGTGATCAAGGTGTGCGAGTTCCAGTTCT GCAACGATCC Illi CTGGGAGTGTACTACCACAAGAATAACAAGT CCTGGATGGAAAGTGAATTCAGAGTGTACTCTAGCGCCAACAACT GTACCTTTGAGTACGTGTCCCAACCTTTCCTGATGGACCTGGAAG GAAAGCAGGGCAACTTCAAGAACCTGAGAGAGTTCGTGTTCAAGA ACATCGATGGCTACTTCAAGATCTACTCCAAGCACACACCTATCAA CTTGGTTAGAGACCTCCCGCAGGGCTTCTCCGCTCTGGAACCTCTGGTCGACCTGCCCATTGGCATCAACATCACACGGTTCCAGACCCT GCTGGCTCTGCACAGATCCTACCTGACCCCAGGAGATTCCTCTTC TGGCTGGACCGCCGGCGCTGCCGCTTACTACGTGGGCTACCTGC AGCCTCGGACATTCCTGCTGAAGTACAACGAGAACGGCACCATCA CCGACGCTGTGGACTGTGCCCTGGATCCCCTGAGCGAGACAAAG TGTACCCTGAAATC Illi ACCGTGGAAAAGGGCATTTACCAGACCT CCAACTTCAGGGTGCAGCCTACTGAGTCCATCGTGCGGTTCCCTA ACATCACCAACCTGTGCCCCTTCGGCGAAGTGTTTAACGCCACCA GATTTGCTTCTGTGTACGCTTGGAACAGAAAGAGAATCAGCAACT GCGTGGCTGATTACTCCGTCCTGTACAATTCAGCAAGCTTCTCCA CCTTCAAATGCTACGGAGTGTCTCCAACCAAGCTGAACGACCTGT GTTTCACCAACGTGTACGCCGACTCTTTCGTGATCCGGGGCGAC GAAGTCCGGCAAATCGCCCCCGGCCAGACCGGCAAGATCGCCGA CTACAACTACAAGCTGCCTGACGATTTCACCGGATGTGTCATCGC TTGGAACTCCAACAACCTGGATAGTAAAGTGGGCGGCAACTATAA TTATTTGTACCGGCTGTTCCGGAAGTCTAATCTGAAGCCTTTCGAG Petição 870250095390, de 19 / 10 / 2025, pág. 94 / 166 91 / 115 AGAGACATCTCTACCGAGATCTACCAGGCCGGCTCTACACCTTGC AACGGCGTAGAGGGCTTCAACTGCTACTTCCCCCTGCAGAGCTAC GGCTTCCAGCCTACTAACGGCGTTGGCTACCAGCCTTACAGAGTG GTGGTGCTGTCTTTCGAGCTGCTGCATGCTCCAGCCACAGTGTGC GGCCCTAAGAAGTCCACGAACCTGGTGAAGAACAAATGCGTGAA CTTCAACTTCAATGGCCTGACCGGCACCGGCGTGCTGACAGAGT CTAACAAGAAGTTCCTGCCATTCCAGCAGTTCGGCAGAGATATTG CTGACACCACTGATGCCGTACGGGACCCTCAGACCCTGGAAATC CTGGATATCACCCCTTGTTCCTTCGGCGGCGTCTCCGTGATCACT CCTGGAACCAACACCTCCAACCAGGTGGCCGTGCTGTACCAGGA CGTGAACTGCACCGAGGTGCCTGTGGCCATCCATGCCGACCAGC TGACGCCCACCTGGCGGGTGTACTCCACCGGATCTAATGTGTTCC AAACCCGGGCTGGCTGCCTGATCGGCGCCGAGCACGTGAATAAC TCCTACGAGTGCGACATCCCTATCGGGGCCGGAATCTGCGCGTC ATACCAGACCCAGACAAACTCTCCTAGAGGCTCTGGCTCTGGCAG CAGAGTTTCGCCTTCTCTGGACGTGGTCAGATTCCCTAACATGAC CAACATCTGCCCTTTCGACCAGGTGTTCAACAAAACCCAGTTCCC CTCCGTGTACGCCTGGGAACGGGTGAGAATTTCCGACTGCGTCT CAGATTACACCGTGCTCTATAACAGCTCTGCCTCTTTCTCTACCTT TAAGTGCTACGGCGTGAGCCCTACCAAGTTAAATGACCTGTGCTT TAGCGGCGTGTACGCCGATTATTTCGTGGTAAAGGGTGACCACGTGCACCAGATAGCCCCCGGCCAGACCGGCGTGATCGCTGACTACA ATTATAAGCTGCCCAGCGAGTTCGTGGGCTGCATCCTGGCCTGG AACACTAGAACAATCGACTCCAAGAGAGGCTTCTACTACCGGCTG TTCCGGCATGGCAACATCAGACCTTACGAGCGCGATACCTCCAAT GTGCCCTACAACGCTGCTGGCGGGACCTGCAACCAGCCTGGCAC CCACAACTGCTACGAGCCTCTGCAGGACTACGGCTTCACCTCCAC ATCTGGCGTCGGCTACCAACCATTCAGAGTGGTGGTGCTGTCTTT CGAGCTGCTGAACGCTCCAGCTACCGTGTGTGGCCCTAAGCAAT CCACAGATCTGGTGAAGAACAAGTGTGTGAATTTCGGTTCCGGCT CCGGCTCTAGAGTGGCTCCTTCTAAAGAGGTTGTGCGGTTTCCTA ACATCACCAACCTGTGTCCTTTCGGCGAGGTGTTCAACGCCACCA CGTTCCCCTCTGTGTACGCCTGGGAGAGAAAGAGGATCTCCAACT GTGTTGCTGACTACTCGGTGCTGTATAACTCCACCTCTTTTTCCAC CTTCAAGTGCTACGGCGTCTCCGCCACCAAGCTCAATGACCTGTG CTTCTCGAACGTGTACGCAGACTCCTTCGTGGTCAAGGGCGACG ACGTGAGACAGATCGCCCCTGGCCAGACTGGCGTGATCGCCGAC Petição 870250095390, de 19 / 10 / 2025, pág. 95 / 166 / 115 TATAATTACAAACTGCCGGACGACTTTCTGGGCTGCGTGCTGGCT TGGAACACCAACTCTAAGGACTCTTCCACCTCTGGCAACTACAAC TACCTGTATAGATGGGTGCGTAGGAGTAAACTCAACCCTTACGAG CGGGACCTGTCCAACGATATCTATTCCCCTGGCGGCCAGTCCTG CTCCGCTGTGGGCCCCAATTGCTACAACCCCCTGCGGCCTTACG GCTTCTTCACAACCGCTGGAGTGGGCCACCAGCCTTACCGGGTG GTGGTGCTGTC Illi GAACTGCTGAATGCTCCTGCTACCGTGTGC GGCCCCAAGCTGTCCACCGACCTGATAAAAAACCAGTGTGTGAAC TTCGGCTCTGGCAGCGGTTCTAGAGTCGCCCCTAGTAAAGAAGTG GTGAGATTCCCCAACATCACCAACCTGTGCCCTTTCGGCGAAGTG TTCAACGCCACCACCTTCCCTTCTGTGTACGCTTGGGAGCGGAAG CGGATCTCCAACTGTGTGGCCGACTATAGCGTGTTATACAACTCT ACCTCTTTTTCCACCTTCAAGTGCTATGGCGTGTCTGCCACCAAAC TGAACGACCTGTGCTTCTCGAACGTGTACGCTGATAGCTTTGTGG TGAAAGGCGACGACGTGAGACAGATCGCACCTGGACAGACCGGA GTGATCGCCGACTATAACTACAAGCTTCCAGATGACTTCACCGGC TGTGTGCTGGCTTGGAACACCCGGAACATCGACGCCACCCAGAC AGGAAACTACAACTACAAGTACCGCTCCCTGAGACACGGCAAGCT GAGACCCTTCGAGCGGGACATCTCCAACGTGCCTTTCTCTCCTGA TGGCAAGCCCTGCACCCCTCCAGCCTTCAACTGTTACTGGCCTCT GAACGACTACGGC UH ACATCACCAATGGCATCGGATATCAGCCTTACAGAGTGGTGGTCCTGTCCTTTGAGCTGCTGAACGCCCCTGC CACCGTGTGCGGCCCTAAGCTGTCCACCGACCTGATCAAGAACC AGTGCGTGAACTTTtgataataa 4502_[WHS1 _KHOSTA2R BD_RSCH01 4RBD_URBA NIRBD] (SEQ ID NO: 34) ATGTTTGTGTTTCTAGTGCTACTACCACTAGTCTCTTCCCAGTGTG TGAACCTGACCACCAGAACCCAGCTGCCTCCTGCCTACACAAATT Cllll ACACGCGGAGTGTACTACCCTGACAAGGTGTTCAGATCCT CTGTACTGCATAGTACACAGGACCTGTTTCTGCCCTTCTTCAGCAA CGTGACCTGGTTCCACGCTATTCATGTTTCTGGCACCAATGGAAC CAAGAGATTCGACAATCCTGTGCTGCCATTCAACGACGGCGTGTA CTTCGCCTCCACGGAGAAGTCCAACATCATCAGGGGCTGGATCTT CGGCACCACCCTGGATTCAAAGACCCAGTCTCTGCTGATCGTGAA TAATGCTACCAACGTGGTCATCAAAGTATGCGAGTTCCAGTTCTG CAACGACCC UH CTGGGCGTGTACTACCACAAGAACAATAAGTC CTGGATGGAATCCGAGTTCAGAGTATACTCTTCTGCCAACAACTG TACCTTCGAGTACGTCTCTCAGCCTTTCCTGATGGACCTTGAGGG Petição 870250095390, de 19 / 10 / 2025, pág. 96 / 166 93 / 115 CAAGCAGGGCAACTTCAAAAACCTGAGAGAGTTCGTGTTCAAAAA CATCGACGGCTACTTCAAGATCTACTCTAAGCACACCCCTATCAA CCTGGTGCGCGACCTGCCCCAAGGC Illi CCGCTCTGGAACCTC TGGTGGATCTGCCTATCGGCATCAACATCACCCGCTTCCAAACCC TGCTCGCTCTGCACCGCTCCTACCTGACCCCTGGCGATTCCTCCT CCGGCTGGACCGCCGGCGCTGCCGCCTACTACGTAGGATATCTG CAGCCTCGGACCTTCCTGCTGAAGTACAATGAGAACGGCACCATC ACCGACGCCGTGGACTGCGCCCTGGACCCCCTGTCCGAGACAAA GTGCACCCTAAAGTCCTTCACAGTGGAAAAGGGAATCTACCAGAC ATCCAACTTCAGAGTGCAGCCTACCGAGTCCATCGTGAGATTCCC TAACATCACCAACCTGTGTCCTTTCGGCGAGGTGTTCAACGCCAC TAGATTCGCCTCCGTGTACGCTTGGAACCGGAAGCGGATCAGCA ATTGTGTTGCCGACTACTCCGTCCTGTACAACTCCGCGAGTTTCT CCACTTTCAAGTGCTACGGCGTGTCACCTACCAAGTTGAACGATC TGTGCTTCACTAACGTCTATGCCGACAGCTTTGTGATCAGAGGCG ACGAGGTGCGGCAGATTGCACCTGGCCAGACCGGCAAGATCGCC GATTACAACTACAAGCTGCCCGATGAT H TACCGGCTGTGTGATC GCCTGGAACTCCAACAACCTGGACTCTAAGGTCGGAGGCAACTA CAACTACCTGTACAGACTGTTTAGAAAGTCTAACCTGAAGCCCTTC GAGCGGGACATCTCCACTGAGATCTACCAGGCCGGATCCACACC TTGTAACGGCGTGGAAGGCTTCAACTGCTACTTCCCTCTGCAGTCTTATGGCTTCCAGCCTACCAACGGCGTCGGCTACCAGCCTTACAG AGTGGTCGTCCTCTCCTTCGAGCTGCTGCACGCCCCAGCCACCG TGTGTGGGCCTAAGAAATCGACAAACCTGGTGAAGAACAAGTGCG TGAACTTCAACTTCAACGGTCTGACCGGAACCGGAGTTCTTACCG AATCCAACAAGAAGTTCCTGCCTTTCCAGCAGTTTGGCAGAGACA TCGCCGACACCACCGATGCTGTGAGAGATCCTCAGACACTGGAA ATCCTGGATATCACCCCATGCTCCTTCGGCGGCGTGAGTGTGATC ACCCCTGGCACCAACACATCCAACCAAGTGGCCGTGCTGTACCA GGACGTGAACTGTACCGAGGTTCCCGTGGCCATCCACGCCGACC AGCTGACCCCTACCTGGCGGGTGTACTCCACCGGCTCCAACGTG TTCCAAACTAGAGCCGGCTGCCTGATCGGGGCCGAGCACGTGAA CAACTCTTACGAGTGCGACATCCCCATCGGCGCTGGCATCTGCG CTTCCTACCAGACACAGACCAACTCTCCTAGAGGCTCCGGCTCCG GCTCTAGAGTGTCTCCCTCCCTCGACGTGGTTCGATTCCCCAACA TGACCAACATCTGCCCTTTCGACCAGGTGTTCAACAAAACCCAGT TTCCAAGCGTGTACGCCTGGGAGAGAGTCAGAATCTCTGACTGTG Petição 870250095390, de 19 / 10 / 2025, pág. 97 / 166 / 115 TCAGCGACTACACCGTGCTGTACAACAGTTCTGCCTCCTTCTCCA CATTTAAGTGCTACGGCGTGTCCCCTACAAAGCTGAACGACCTGT GCTTCTCTGGCGTCTACGCCGACTACTTCGTCGTGAAGGGCGAC CACGTGCACCAGATCGCTCCAGGCCAGACCGGCGTTATTGCCGA CTACAACTACAAGCTGCCTTCCGAGTTCGTGGGATGCATCCTGGC CTGGAACACTCGGACCATCGACTCCAAGCGGGGCTTCTACTACC GGCTGTTCCGGCACGGTAACATCCGCCCCTACGAGAGAGACACC TCTAATGTACCCTACAATGCCGCCGGCGGCACCTGTAACCAGCCC GGTACCCACAACTGCTACGAGCCTCTGCAGGACTACGGCTTCAC CTCTACCAGCGGAGTGGGCTACCAACCATTCAGAGTGGTGGTGC TGAGTTTTGAACTGCTGAACGCTCCTGCTACAGTGTGCGGCCCTA AGCAGTCAACCGATCTGGTGAAGAACAAGTGCGTGAATTTCGGCT CCGGATCTGGATCTAGAGTGGCCCCCTCTAAAGAGGTCGTGAGG TTCCCTAACATCACCAATCTGTGCCCTTTCGGCGAAGTGTTCAAC GCTACAACGTTCCCCTCCGTTTATGCCTGGGAGAGAAAGCGGATC TCCAACTGCGTGGCTGATTATTCCGTGCTGTACAATTCGACATCTT TCTCCACCTTTAAGTGTTACGGCGTGTCCGCCACCAAACTGAACG ACCTTTGCTTTTCCAACGTGTATGCTGACAGTTTCGTGGTGAAGG GCGACGATGTGCGACAGATAGCGCCCGGCCAGACCGGCGTGAT CGCTGACTACAACTACAAGCTGCCTGATGACTTCCTCGGCTGCGT GCTGGCCTGGAATACCAACTCCAAGGACTCCTCAACCTCTGGCAACTATAATTACCTGTACAGATGGGTGAGACGGAGCAAACTGAACCC GTACGAACGGGATCTTTCTAATGACATCTACTCTCCCGGTGGACA GTCCTGCTCCGCCGTGGGCCCAAATTGTTACAACCCACTGCGGC CTTACGGCTTCTTCACCACCGCTGGCGTGGGCCATCAGCCTTACA GAGTGGTGGTGCTGTCCTTTGAGCTGCTGAACGCTCCTGCTACC GTGTGCGGCCCTAAATTGTCTACCGACCTGATCAAGAACCAGTGC GTGAATTTCGGCAGCGGCTCTGGATCCAGAGTGGTGCCTTCCGG CGACGTCGTTAGATTTCCGAACATCACCAATCTGTGTCCTTTCGG CGAAGTGTTCAACGCCACCAAGTTCCCTTCTGTGTACGCTTGGGA ACGGAAGAAAATCTCCAACTGTGTGGCCGACTACTCTGTGTTGTA TAACTCTACCTTCTTTTCCACCTTCAAGTGCTACGGCGTGTCTGCC ACCAAGCTGAACGATCTCTGCTTCTCCAACGTGTACGCAGACTCC TTCGTGGTGAAAGGCGACGACGTCAGACAGATCGCTCCCGGACA GACCGGCGTGATCGCCGATTACAACTACAAGCTGCCCGACGACT TCATGGGCTGTGTGCTGGCTTGGAATACCAGAAACATCGATGCCA CCTCTACTGGCAACTACAACTACAAGTACCGCTACCTGAGACACG Petição 870250095390, de 19 / 10 / 2025, pág. 98 / 166 95 / 115 GCAAACTGCGGCC Illi GAACGGGACATCTCCAACGTGCCATTCA GCCCTGATGGCAAGCCTTGCACGCCCCCTGCTCTGAACTGCTACT GGCCTCTGAACGACTACGGATTCTACACAACCACCGGCATCGGAT ATCAGCCTTACCGGGTGGTAGTGCTGAGCTTCGAGCTGCTGAAC GCCCCAGCTACCGTGTGCGGCCCCAAGCTGTCTACCGACCTCAT CAAGAACCAGTGCGTGAA llll tgataataa 4503_[Wuha nS1_RATG1 3RBD_BTKY 72RBD_WIV 1RBD] (SEQ ID NO: 35) ATGTTTGTGTTTCTAGTGCTACTACCACTAGTCAGTTCTCAGTGCG TGAACCTGACAACGAGAACCCAGCTGCCTCCAGCCTACACCAACT CATTCACAAGAGGCGTGTACTACCCCGACAAGGTGTTCAGAAGCT CTGTGCTGCACTCCACCCAGGATCTGTTCCTGCCCTTCTTCTCCA ACGTGACCTGGTTTCACGCCATCCACGTCTCCGGCACCAATGGCA CCAAGCGGTTCGACAACCCAGTGCTCCCATTCAACGACGGCGTG TACTTCGCCTCCACCGAGAAGTCTAACATCATCAGAGGTTGGATC TTCGGCACCACCCTGGACTCCAAGACCCAATCCCTGCTGATCGTG AACAACGCCACTAATGTGGTCATCAAAGTGTGCGAGTTCCAGTTC TGCAACGACCCCTTCCTGGGTGTGTACTACCACAAGAACAACAAG TCTTGGATGGAAAGCGAGTTCAGAGTGTACTCATCTGCTAACAATT GCACCTTCGAGTACGTGAGTCAGCCIIIICTGATGGACCTGGAAG GAAAGCAGGGCAACTTCAAAAACCTGAGAGAGTTCGTGTTCAAAA ATATCGACGGCTACTTCAAGATCTACTCTAAGCACACCCCTATCAACCTGGTCCGGGATCTGCCTCAGGGCTTTAGCGCCCTCGAGCCTC TGGTGGACCTGCCCATCGGCATCAACATCACCCGGTTCCAGACTC TGTTAGCTCTGCACAGATCCTACCTCACCCCCGGCGATTCCTCTT CTGGCTGGACCGCTGGCGCTGCTGCCTACTACGTGGGCTACCTG CAGCCTCGAACGTTTCTGCTGAAGTACAACGAGAACGGCACCATC ACAGACGCCGTAGACTGTGCCCTGGATCCTCTGTCTGAGACAAAG TGCACGCTGAAGTCCTTCACCGTGGAAAAGGGCATCTACCAGACA TCCAACTTCCGGGTGCAGCCTACCGAGTCTATCGTGCGGTTCCCC AACATAACCAACCTGTGTCCTTTCGGCGAGGTATTTAACGCTACC AGATTCGCCTCCGTGTACGCCTGGAACAGAAAACGGATCTCTAAC TGCGTTGCCGACTACAGTGTGCTGTACAACTCCGCTTCATTCAGC ACCTTCAAGTGCTACGGCGTGTCCCCTACCAAGCTGAATGATCTG TGCTTCACCAACGTGTACGCTGACTCTTTCGTGATCCGGGGCGAC GAAGTGAGACAGATCGCCCCTGGCCAGACAGGCAAGATCGCCGA CTATAACTACAAGCTGCCTGACGACTTCACCGGATGCGTGATTGC CTGGAACTCCAATAACCTGGATTCTAAGGTGGGCGGCAACTACAA Petição 870250095390, de 19 / 10 / 2025, pág. 99 / 166 96 / 115 CTACCTGTATCGTCTGTTCCGGAAGTCCAATCTGAAGCCATTCGA AAGAGATATTTCCACCGAGATCTACCAGGCTGGAAGCACCCCTTG CAACGGCGTCGAAGGCTTCAACTGCTACTTCCCCCTGCAGTCTTA CGGCTTTCAGCCTACCAACGGCGTTGGATACCAACCTTACAGAGT GGTCGTGCTGTCTTTTGAGCTGCTGCATGCTCCAGCAACCGTGTG CGGACCCAAGAAGTCCACCAATCTGGTGAAGAACAAGTGCGTGA ACTTCAACTTCAACGGCCTGACGGGTACCGGCGTACTGACAGAGT CCAACAAAAAGTTTCTGCCTTTCCAGCAGTTCGGCAGAGATATCG CCGACACCACCGACGCCGTGAGAGATCCTCAGACCCTGGAGATC CTGGATATCACCCCTTGTAGCTTCGGCGGAGTGTCCGTGATCACA CCCGGCACAAACACCTCTAACCAGGTGGCCGTCCTGTACCAGGA CGTGAACTGCACCGAAGTGCCTGTGGCAATCCACGCCGACCAGC TGACCCCCACCTGGCGGGTTTACTCTACCGGCAGCAACGTGTTTC AGACCAGAGCTGGCTGCCTGATTGGCGCCGAGCACGTGAACAAC TCGTACGAGTGCGACATCCCTATCGGAGCCGGCATCTGCGCCTC CTACCAGACCCAGACCAACTCTCCTAGAGGCTCCGGATCCGGCT CTCGGGTGCAGCCCACCGACTCCATCGTCAGATTCCCTAACATCA CCAACCTCTGCCCTTTTGGAGAAGTGTTCAACGCCACCACGTTCG CCTCTGTGTACGCTTGGAACAGAAAGCGGATCTCCAACTGCGTGG CGGACTACTCTGTCCTGTACAATTCCACCTCCTTTTCCACCTTCAA GTGCTACGGCGTGTCCCCTACAAAGCTGAACGATCTGTGCTTCACCAATGTGTACGCCGATAGCTTCGTTATCACCGGCGACGAGGTGC GCCAGATCGCTCCTGGCCAGACCGGCAAGATCGCCGACTACAAC TACAAGTTGCCCGATGACTTCACCGGCTGTGTGATCGCTTGGAAC AGCAAGCACATCGATGCCAAGGAAGGTGGCAACTTCAACTACCTG TACAGACTGTTTAGAAAGGCCAACCTTAAGCCATTTGAGAGAGAC ATCTCCACAGAAATCTACCAGGCTGGCTCCAAACCTTGCAATGGC CAGACAGGCCTGAACTGCTACTATCCTCTGTACCGCTACGGCTTC TACCCTACCGATGGCGTGGGCCACCAGCCTTATAGAGTCGTGGT GCTGTCTTTCGAACTGCTGAACGCCCCTGCCACCGTGTGTGGCC CTAAGAAGTCTACAAACCTGGTGAAAAATAAGTGCGTGAACTTCG GCTCTGGCTCTGGCTCTCGGGTGTCCCCAAGCACGGAGGTGGTC CGGTTCCCAAACATCACCAACCTGTGCCCTTTTGGCCAAGTGTTC AATGCTTCAAACTTTCCTTCTGTGTACGCTTGGGAGCGGCTGAGG ATCTCCGACTGCGTGGCTGATTACGCCGTGCTCTACAACTCTAGC AGCTCTTTCTCTACCTTCAAGTGCTACGGCGTGTCTCCAACCAAG CTGAACGACCTGTGTTTCTCCTCCGTGTACGCCGACTACTTCGTG Petição 870250095390, de 19 / 10 / 2025, pág. 100 / 166 97 / 115 GTGAAGGGCGACGACGTGAGACAGATCGCTCCTGCTCAGACCGG AGTGATCGCCGATTACAACTACAAGCTGCCTGATGACTTCACCGG CTGCGTGCTGGCCTGGAACACCAACTCCGTGGACTCCAAGAGTG GGAACACTTCTACTACAGACTGTTTAGACATGGCAAGATCAAGC CTTACGAGCGCGACATCTCCAACGTGCTGTACAACTCTGCCGGC GGCACCTGCTCCTCCATTAGCCAGCTGGGATGTTACGAGCCCCT GAAAAGCTACGGCTTTACCCCTACTGTAGGCGTCGCTATCAGCCC TTACCGGGTTGTGGTGCTGTCCTTCGAACTGCTGAACGCCCCTGC TACCGTGTGTGGCCCTAAGAAATCCACCGAGCTGGTGAAGAACAA GTGCGTGAACTTCGGCTCCGGCTCCGGCTCCAGAGTGGCACCG CTAAAGAGGTGGTGCGGTCCCAAACATCACCAACCTGTGTCCTT TCGGCGAAGTCTTCAACGCCACCACGTTCCCTAGCGTTTACGCCT GGGAACGGAAGAGAATCTCTAACTGTGTGGCCGACTACAGCGTG CTGTACAACTCCACCTCG They CCACCTTCAAGTGTTATGGCGTGT CCGCCACCAAGTTGAACGACCGCTTGCTTCAGCAATGTGTATGCCG ACTCCTTCGTGGTCAAAGGCGACGGTGCGGCAGATCGCCCCT GGACAAACTGGCGTGATCGCCCGACTATAACTACAAACTGCCTGAC GATTTCACCGGCTGTGTGCTGGCTTGGCTTGGATACCCGGAACATCGAT GCTACACAGACCGGCAACTACAACTACAAGTACAGTACAGGAGCCTGGAGA CACGGCAAGCTTAGGCCTTTCGAGAGAGACATTTCCAACGTGCCC TTTCCCCCTGACGGCAAGCCCTGCACCCCCTGCGTTCAACTGT TACTGGCCCTTGAACGACTATGGC llllACATCACCAACGGGATC GGCTATCAACCGTACCGGGTGGTGGTGCTGTC Illi GAGCTGCTG AACGCGCCTGCCACAGTGTGCGGCCCCAAGCTCTCCACCGACTT GATCAAGAACCAATGTGTGAACTTCtgataataa 4495_BA2S1 (SEQ ID NO: 36) atgtttgtgtttctagtgctactaccactagtgtcctctcagtgcgtgaacctgatcacacggacccag tcatacaccaactccttcaccagaggagtgtactaccctgacaaggtgttcagatctagcgtgctg cattctacccaggacctgtttctgcctttcttcagcaatgtgacctggttccacgccatccacgtgtctg gcacaaacggcaccaagagattcgacaaccctgtgctgcctttcaacgatggcgtgtacttcgcc tctacagagaagtccaacatcatccggggctggatcttcggcaccacactggactcgaagacac aatctctgctgatcgtgaacaacgccaccaacgttgtcatcaaggtgtgcgagttccagttctgcaa cgaccctttcttggacgtgtactaccacaagaacaacaagtcctggatggaatccgaattcagagt gtactccagcgccaacaactgtacattcgagtacgtcagccagccctttctgatggacctggaag gcaagcagggaaatttcaagaacctgagagagttcgtgttcaagaacatcgacggctacttcaa gatctacagcaagcacacccctattaacctgggcagagatctgccccagggcttttccgctctgga gcccctggtggacctgcctatcggcatcaacatcacccggtttcagaccctcctagccctgcacag Petição 870250095390, de 19 / 10 / 2025, pág. 101 / 166 98 / 115atcctatctgacccctggcgacagcagttccggctggaccgccggggctgctgcctactacgtgg ggtacctgcagcctagaaccttcctgctgaagtacaacgagaacggcaccatcaccgacgccgt ggactgtgctctggatccactgtccgagaccaagtgcactctcaagagcttcaccgtggaaaagg gaatctaccagacctccaactttagagtgcagcccaccgagtcaatcgtgagattccccaacatc accaacctgtgcccttttgacgaggtgttcaacgctaccagatttgcttctgtgtacgcctggaaccg gaagagaatctctaactgcgtggccgattactccgtgctgtacaacttcgctcctttcttcgccttcaa gtgttacggcgtgtcccctaccaagctgaacgacctgtgtttcactaacgtgtacgccgactctttcg tgatccggggcaacgaggtgtcccagatcgccccaggccagacaggcaacatcgctgactac aactacaagctgcctgacgatttcaccggctgtgtgatcgcctggaactccaacaagctggattcc aaagtgggcggcaactacaactatctgtaccggctgttcagaaagtccaatctgaagcccttcga acgcgacatctccaccgagatctatcaggccggcaacaagccttgtaacggcgtcgctggcttca actgctacttccctttgcgatcttatggcttccggcctacctacggcgtgggccaccagccttaccgg gtggtggtgctgagctttgagctgctgcacgctcctgctacagtgtgcggccctaagaagtccacc aatctggtgaaaaataagtgcgttaacttcaacttcaacggcctgaccggcaccggcgtgctgac agagtcaaataagaagttcctgcctttccagcagtttggcagggacatcgccgacaccacggacgctgtgcgggaccctcagaccctggaaatcctggatatcaccccttgctccttcggcggcgtgagc gtgattacccctggaaccaacacctctaatcaagtggccgtgctgtaccaaggcgtgaactgcac cgaagtgcccgtggctatccacgccgatcagctgacccctacatggcgggtatacagtaccggct ctaacgtgttccagacccgggctggctgcctgatcggcgccgagtacgtgaacaactcctacga gtgcgacatccccatcggcgctggcatttgc 4498_BA2S1 (SEQ ID NO: atgtttgtgtttctagtgctactaccactagtgtccagccagtgcgtcaatctcatcacccgcacaca atcctacacaaactccttcaccagaggcgtgtactaccctgataaggtgttcagatcctccgtgctg 37) cactccacccaggacctgttcctgccgttcttcagcaacgtgacctggttccacgccatccacgtgt caggaacaaacggcaccaagagattcgacaaccccgtcctgcctttcaacgacggcgtctactt cgcctccacagagaagtctaatatcatcagaggctggatcttcggcactaccctggactccaaga cacagtctctgctcatcgtgaacaacgccaccaacgtcgtcatcaaggtgtgcgagttccagttct gcaacgacccatttctggacgtgtactaccacaagaacaacaagtcctggatggaatccgagttc agagtgtactcttccgccaacaactgcaccttcgagtacgtgtctcaacctttcctgatggacctgg aaggcaagcagggtaacttcaagaatctgagagagtttgtgttcaagaacatcgatggctacttta agatctacagcaagcacacccctatcaacctgggcagagatttaccccagggattctccgctctagaacccctggtggacctgcccatcggcatcaacatcacaagattccaaaccctgctggctctgca cagatcttatctgacccccggcgactcctctagcggctggaccgctggtgctgccgcctactacgt gggctacctccagcctagaaccttcctgctgaagtacaacgagaacggcaccatcaccgatgct gtggactgcgccctggatcctctgtccgaaaccaaatgtaccctgaagagcttcaccgtggaaaa gggcatctaccagacaagcaactttcgggtgcagcccaccgaatccatcgtgcggttcccaaat atcaccaatctgtgtcctttcgacgaggtgttcaatgctaccagattcgcctctgtgtacgcctggaa Petição 870250095390, de 19 / 10 / 2025, pág. 102 / 166 99 / 115 ccggaagagaatcagcaactgcgtggccgattactctgtactgtataatttcgctcccttcttcgcctt caagtgctacggagtgtcgcctacaaaacttaacgatctgtgcttcaccaacgtgtacgccgaca gcttcgtgatccggggcaatgaagtgtctcagatcgccccaggacagaccggcaacatcgcgg actacaactacaaactgccagacgactttaccggctgcgtgatcgcttggaactccaacaaactg gacagcaaagtgggcggcaactacaactacctgtacagactgtttagaaagtctaacctgaagc cctttgaaagagatatctctacagagatctaccaggctggcaacaagccttgtaatggcgttgctg gcttcaactgctacttccctctgcggtcttacggcttccggcctacctacggcgtgggccaccagcct taccgggtagtcgtactcagcttcgagctgctacatgctcccgctacagtgtgcggccccaagaa gtccacgaacctggtcaagaacaagtgtgtgaactttaacttcaacggcctgaccggcacgggc gtcctgaccgagtccaataaaaagttcctacccttccagcagttcggcagagatatcgctgacac caccgacgccgtgcgggaccctcagaccctggaaatcctggacatcaccccttgctccttcggtg gcgtttccgtgattacccctggcaccaacacctccaatcaagtggccgtgctgtaccagggcgtga actgtaccgaagtgcctgtggcgatccacgccgaccagctgaccccaacctggagagtgtattct accggatccaacgtgtttcagaccagagctggatgcctgatcggagccgagtacgtgaacaaca gctacgagtgcgacattcccatcggcgccggcatctgc 4296_Wuhan S1 (SEQ ID NO: 38)atgttcgtgtttctggtgctgctgcctctggtgtccagccagtgtgtgaacctgaccaccagaacaca gctgcctccagcctacaccaacagctttaccagaggcgtgtactaccccgacaaggtgttcagat ccagcgtgctgcactctacccaggacctgttcctgcctttcttcagcaacgtgacctggttccacgcc atccacgtgtccggcaccaatggcaccaagagattcgacaaccccgtgctgcccttcaacgacg gggtgtactttgccagcaccgagaagtccaacatcatcagaggctggatcttcggcaccacactg gacagcaagacccagagcctgctgatcgtgaacaacgccaccaacgtggtcatcaaagtgtgc gagttccagttctgcaacgaccccttcctgggcgtctactaccacaagaacaacaagagctggat ggaaagcgagttccgggtgtacagcagcgccaacaactgcaccttcgagtacgtgtcccagcct ttcctgatggacctggaaggcaagcagggcaacttcaagaacctgcgcgagttcgtgttcaaga acatcgacggctacttcaagatctacagcaagcacacccctatcaacctcgtgcgggatctgcct cagggcttctctgctctggaacccctggtggatctgcccatcggcatcaacatcacccggtttcaga cactgctggccctgcacagaagctacctgacacctggcgatagcagcagcggatggacagctg gtgccgccgcttactatgtgggctacctgcagcctagaaccttcctgctgaagtacaacgagaac ggcaccatcaccgacgccgtggattgtgcccttgatcctctgagcgagacaaagtgcaccctga agtccttcaccgtggaaaagggcatctaccagaccagcaacttccgggtgcagcccaccgaatccatcgtgcggttccccaatatcaccaatctgtgccccttcggcgaggtgttcaatgccaccagattc gcctctgtgtacgcctggaaccggaagcggatcagcaattgcgtggccgactactccgtgctgta caactccgccagcttcagcaccttcaagtgctacggcgtgtcccctaccaagctgaacgacctgt gcttcacaaacgtgtacgccgacagcttcgtgatccggggagatgaagtgcggcagattgcccct ggacagacaggcaagatcgccgactacaactacaagctgcccgacgacttcaccggctgtgtg attgcctggaacagcaacaacctggactccaaagtcggcggcaactacaattacctgtaccggc Petição 870250095390, de 19 / 10 / 2025, pág. 103 / 166 100 / 115 tgttccggaagtccaatctgaagcccttcgagcgggacatctccaccgagatctatcaggccggc agcaccccttgtaacggcgtggaaggcttcaactgctacttcccactgcagtcctacggctttcagc ccacaaatggcgtgggctatcagccctacagagtggtggtgctgagcttcgaactgctgcatgcc cctgccacagtgtgcggccctaagaaaagcaccaatctcgtgaagaacaaatgcgtgaacttca acttcaacggcctgaccggcaccggcgtgctgacagagagcaacaagaagttcctgccattcc agcagtttggccgggatatcgccgataccacagacgccgttagagatccccagacactggaaat cctggacatcaccccttgcagcttcggcggagtgtctgtgatcacccctggcaccaacaccagca atcaggtggcagtgctgtaccaggacgtgaactgtaccgaagtgcccgtggccattcacgccgat cagctgacacctacatggcgggtgtactccaccggcagcaatgtgtttcagaccagagccggct gtctgatcggagccgagcacgtgaacaatagctacgagtgcgacatccccatcggcgctggcat ctgtgccagctaccagacacagacaaacagccccaga 4304_Wuhan S1 (SEQ ID NO: 39) atgttcgtgtttctggtgctgctgcctctggtgtccagccagtgtgtgaacctgaccaccagaacaca gctgcctccagcctacaccaacagctttaccagaggcgtgtactaccccgacaaggtgttcagat ccagcgtgctgcactctacccaggacctgttcctgcctttcttcagcaacgtgacctggttccacgcc atccacgtgtccggcaccaatggcaccaagagattcgacaaccccgtgctgcccttcaacgacggggtgtactttgccagcaccgagaagtccaacatcatcagaggctggatcttcggcaccacactg gacagcaagacccagagcctgctgatcgtgaacaacgccaccaacgtggtcatcaaagtgtgc gagttccagttctgcaacgaccccttcctgggcgtctactaccacaagaacaacaagagctggat ggaaagcgagttccgggtgtacagcagcgccaacaactgcaccttcgagtacgtgtcccagcct ttcctgatggacctggaaggcaagcagggcaacttcaagaacctgcgcgagttcgtgttcaaga acatcgacggctacttcaagatctacagcaagcacacccctatcaacctcgtgcgggatctgcct cagggcttctctgctctggaacccctggtggatctgcccatcggcatcaacatcacccggtttcaga cactgctggccctgcacagaagctacctgacacctggcgatagcagcagcggatggacagctg gtgccgccgcttactatgtgggctacctgcagcctagaaccttcctgctgaagtacaacgagaac ggcaccatcaccgacgccgtggattgtgcccttgatcctctgagcgagacaaagtgcaccctga agtccttcaccgtggaaaagggcatctaccagaccagcaacttccgggtgcagcccaccgaatc catcgtgcggttccccaatatcaccaatctgtgccccttcggcgaggtgttcaatgccaccagattc gcctctgtgtacgcctggaaccggaagcggatcagcaattgcgtggccgactactccgtgctgta caactccgccagcttcagcaccttcaagtgctacggcgtgtcccctaccaagctgaacgacctgt gcttcacaaacgtgtacgccgacagcttcgtgatccggggagatgaagtgcggcagattgcccctggacagacaggcaagatcgccgactacaactacaagctgcccgacgacttcaccggctgtgtg attgcctggaacagcaacaacctggactccaaagtcggcggcaactacaattacctgtaccggc tgttccggaagtccaatctgaagcccttcgagcgggacatctccaccgagatctatcaggccggc agcaccccttgtaacggcgtggaaggcttcaactgctacttcccactgcagtcctacggctttcagc ccacaaatggcgtgggctatcagccctacagagtggtggtgctgagcttcgaactgctgcatgcc cctgccacagtgtgcggccctaagaaaagcaccaatctcgtgaagaacaaatgcgtgaacttca Petição 870250095390, de 19 / 10 / 2025, pág. 104 / 166 101 / 115 acttcaacggcctgaccggcaccggcgtgctgacagagagcaacaagaagttcctgccattcc agcagtttggccgggatatcgccgataccacagacgccgttagagatccccagacactggaaat cctggacatcaccccttgcagcttcggcggagtgtctgtgatcacccctggcaccaacaccagca atcaggtggcagtgctgtaccaggacgtgaactgtaccgaagtgcccgtggccattcacgccgat cagctgacacctacatggcgggtgtactccaccggcagcaatgtgtttcagaccagagccggct gtctgatcggagccgagcacgtgaacaatagctacgagtgcgacatccccatcggcgctggcat ctgtgccagctaccagacacagacaaacagccccaga 4371_Wuhan (SEQ ID NO: atgcagtgtgtgaacctgaccaccagaacacagctgcctccagcctacaccaacagctttacca gaggcgtgtactaccccgacaaggtgttcagatccagcgtgctgcactctacccaggacctgttcc 40) tgcctttcttcagcaacgtgacctggttccacgccatccacgtgtccggcaccaatggcaccaaga gattcgacaaccccgtgctgcccttcaacgacggggtgtactttgccagcaccgagaagtccaac atcatcagaggctggatcttcggcaccacactggacagcaagacccagagcctgctgatcgtga acaacgccaccaacgtggtcatcaaagtgtgcgagttccagttctgcaacgaccccttcctgggc gtctactaccacaagaacaacaagagctggatggaaagcgagttccgggtgtacagcagcgc caacaactgcaccttcgagtacgtgtcccagcctttcctgatggacctggaaggcaagcagggcaacttcaagaacctgcgcgagttcgtgttcaagaacatcgacggctacttcaagatctacagcaa gcacacccctatcaacctcgtgcgggatctgcctcagggcttctctgctctggaacccctggtggat ctgcccatcggcatcaacatcacccggtttcagacactgctggccctgcacagaagctacctgac acctggcgatagcagcagcggatggacagctggtgccgccgcttactatgtgggctacctgcag cctagaaccttcctgctgaagtacaacgagaacggcaccatcaccgacgccgtggattgtgccct tgatcctctgagcgagacaaagtgcaccctgaagtccttcaccgtggaaaagggcatctaccag accagcaacttccgggtgcagcccaccgaatccatcgtgcggttccccaatatcaccaatctgtg ccccttcggcgaggtgttcaatgccaccagattcgcctctgtgtacgcctggaaccggaagcgga tcagcaattgcgtggccgactactccgtgctgtacaactccgccagcttcagcaccttcaagtgcta cggcgtgtcccctaccaagctgaacgacctgtgcttcacaaacgtgtacgccgacagcttcgtgat ccggggagatgaagtgcggcagattgcccctggacagacaggcaagatcgccgactacaact acaagctgcccgacgacttcaccggctgtgtgattgcctggaacagcaacaacctggactccaa agtcggcggcaactacaattacctgtaccggctgttccggaagtccaatctgaagcccttcgagc gggacatctccaccgagatctatcaggccggcagcaccccttgtaacggcgtggaaggcttcaa ctgctacttcccactgcagtcctacggctttcagcccacaaatggcgtgggctatcagccctacagagtggtggtgctgagcttcgaactgctgcatgcccctgccacagtgtgcggccctaagaaaagca ccaatctcgtgaagaacaaatgcgtgaacttcaacttcaacggcctgaccggcaccggcgtgct gacagagagcaacaagaagttcctgccattccagcagtttggccgggatatcgccgataccaca gacgccgttagagatccccagacactggaaatcctggacatcaccccttgcagcttcggcggag tgtctgtgatcacccctggcaccaacaccagcaatcaggtggcagtgctgtaccaggacgtgaa ctgtaccgaagtgcccgtggccattcacgccgatcagctgacacctacatggcgggtgtactcca Petição 870250095390, de 19 / 10 / 2025, pág. 105 / 166 102 / 115 ccggcagcaatgtgtttcagaccagagccggctgtctgatcggagccgagcacgtgaacaatag ctacgagtgcgacatccccatcggcgctggcatctgtgccagctaccagacacagacaaacag ccccaga 4372_Wuhan (SEQ ID NO: atgcagtgtgtgaacctgaccaccagaacacagctgcctccagcctacaccaacagctttacca gaggcgtgtactaccccgacaaggtgttcagatccagcgtgctgcactctacccaggacctgttcc 41) tgcctttcttcagcaacgtgacctggttccacgccatccacgtgtccggcaccaatggcaccaaga gattcgacaaccccgtgctgcccttcaacgacggggtgtactttgccagcaccgagaagtccaac atcatcagaggctggatcttcggcaccacactggacagcaagacccagagcctgctgatcgtga acaacgccaccaacgtggtcatcaaagtgtgcgagttccagttctgcaacgaccccttcctgggc gtctactaccacaagaacaacaagagctggatggaaagcgagttccgggtgtacagcagcgc caacaactgcaccttcgagtacgtgtcccagcctttcctgatggacctggaaggcaagcagggc aacttcaagaacctgcgcgagttcgtgttcaagaacatcgacggctacttcaagatctacagcaa gcacacccctatcaacctcgtgcgggatctgcctcagggcttctctgctctggaacccctggtggat ctgcccatcggcatcaacatcacccggtttcagacactgctggccctgcacagaagctacctgac acctggcgatagcagcagcggatggacagctggtgccgccgcttactatgtgggctacctgcagcctagaaccttcctgctgaagtacaacgagaacggcaccatcaccgacgccgtggattgtgccct tgatcctctgagcgagacaaagtgcaccctgaagtccttcaccgtggaaaagggcatctaccag accagcaacttccgggtgcagcccaccgaatccatcgtgcggttccccaatatcaccaatctgtg ccccttcggcgaggtgttcaatgccaccagattcgcctctgtgtacgcctggaaccggaagcgga tcagcaattgcgtggccgactactccgtgctgtacaactccgccagcttcagcaccttcaagtgcta cggcgtgtcccctaccaagctgaacgacctgtgcttcacaaacgtgtacgccgacagcttcgtgat ccggggagatgaagtgcggcagattgcccctggacagacaggcaagatcgccgactacaact acaagctgcccgacgacttcaccggctgtgtgattgcctggaacagcaacaacctggactccaa agtcggcggcaactacaattacctgtaccggctgttccggaagtccaatctgaagcccttcgagc gggacatctccaccgagatctatcaggccggcagcaccccttgtaacggcgtggaaggcttcaa ctgctacttcccactgcagtcctacggctttcagcccacaaatggcgtgggctatcagccctacag agtggtggtgctgagcttcgaactgctgcatgcccctgccacagtgtgcggccctaagaaaagca ccaatctcgtgaagaacaaatgcgtgaacttcaacttcaacggcctgaccggcaccggcgtgct gacagagagcaacaagaagttcctgccattccagcagtttggccgggatatcgccgataccaca gacgccgttagagatccccagacactggaaatcctggacatcaccccttgcagcttcggcggagtgtctgtgatcacccctggcaccaacaccagcaatcaggtggcagtgctgtaccaggacgtgaa ctgtaccgaagtgcccgtggccattcacgccgatcagctgacacctacatggcgggtgtactcca ccggcagcaatgtgtttcagaccagagccggctgtctgatcggagccgagcacgtgaacaatag ctacgagtgcgacatccccatcggcgctggcatctgtgccagctaccagacacagacaaacag ccccaga Petition 870250095390, dated 10 / 19 / 2025, pp. 106 / 166 103 / 115 4499_Wuhan S1 (SEQ ID NO: 42) atgtttgtgtttctagtgctactaccactagtgtcttcccagtgcgtcaatctgaccaccagaacccaa ctgccccctgcttacactaactctttcaccagaggcgtgtactaccctgacaaggtgttccggtcgtc cgtgctgcattctacccaggatctcttcttgcctttcttctctaacgtgacctggttccacgccatccatg tgtctggcacaaacggcaccaagagattcgacaaccctgtgctgcctttcaacgacggcgtgtatt tcgcctctaccgagaagtctaacatcatccggggctggatcttcggcaccacactggacagcaa gacccagtcgctgctgatcgtgaacaacgccaccaacgtggtcatcaaggtctgcgaattccagt tctgcaacgatcctttcctgggcgtatactaccacaagaacaacaagtcctggatggaatccgaat tcagagtatactcctccgccaataactgcacattcgagtacgtgtctcagcctttcctgatggacctg gaaggcaagcagggcaacttcaaaaacctgagagagttcgtgttcaagaacatcgacggctac ttcaagatctacagcaagcacacccctatcaacctggtgcgggatctgccacagggcttttccgct ctggaacctctggtggacctgcccatcggcatcaatatcacccgctttcaaaccctgctggccctg cacagatcttacctgacaccaggcgactcctcctccggctggaccgccggcgctgccgcctacta cgtgggctacctccagcctcggacctttctgctcaagtacaacgagaacggcacaatcaccgac gccgtggactgcgccctggaccccctgtccgagacaaagtgtaccctgaagtccttcaccgtggaaaaaggaatctatcaaacctccaactttcgtgtgcaacctactgaatctatcgtgagatttcctaata ttaccaatctgtgtccttttggcgaggtgttcaacgccactcggttcgcttccgtgtacgcctggaaca gaaagcggatcagcaactgcgttgctgactactccgtgctgtacaactccgcttccttcagcacctt caagtgctatggggtctcccctaccaagctgaacgatctgtgcttcaccaacgtgtatgcagactct ttcgtgatcagaggcgacgaggtcagacagatcgcccccggccagaccggaaagatcgctga ctacaactacaagctgcccgacgacttcacaggctgtgtgatcgcgtggaactctaacaacctag actctaaggtaggcggcaactataactacctgtacagactgtttcggaagagcaacctgaagcct ttcgagcgggacatctcgaccgagatctaccaggctggcagcacaccctgcaacggggtggaa ggatttaactgctacttcccactgcagtcttatggcttccagcccacaaacggcgtgggctaccaac cttaccgggtggtggtgctgtccttcgagctgctgcacgctcctgctaccgtgtgtggcccaaagaa atctaccaacctggtgaagaacaagtgtgtcaacttcaatttcaacggcctgaccggcaccggcg tcctgaccgagtctaataagaagttcctgccctttcagcagttcggcagagatatcgccgatacca ccgacgctgtgcgggacccccagacgctggaaatcctggatatcacgccttgctctttcggcggc gtgtccgtgatcacacccggcaccaacaccagcaaccaagtggctgtgttgtatcaggacgtga actgcaccgaagtgcctgtggccatccacgccgatcagctgacccctacctggagagtgtactcaaccggcagcaacgtgttccagaccagagcgggctgcctgatcggcgccgagcacgtgaacaa ctcctacgagtgcgacatccctatcggagccggcatctgcgccagctaccaaacacagaccaa ctcccctcgg 4500_Wuhan S1 (SEQ ID NO: 43) atgtttgtgtttctagtgctactaccactagtgtcctcccagtgtgtgaatctgacaaccagaacccag ctgcctccagcctacaccaattccttcaccagaggagtctactaccctgacaaagtgttcagatcct ctgtgctccactcaacacaggatctgtttctgcccttcttctccaacgtcacttggttccacgctatcca tgtgtccggaacaaacggcacaaagagattcgacaaccccgtgttgcctttcaacgacggcgtgt Petição 870250095390, de 19 / 10 / 2025, pág. 107 / 166 104 / 115 acttcgcctctaccgagaagtccaacatcatcagaggctggatcttcggcaccacactcgattcta agacccagtctctgctgatcgttaacaacgccaccaacgtggtcatcaaggtgtgcgagttccagt tctgcaacgaccccttcctgggcgtctactaccacaagaacaacaagtcttggatggaatccgag ttccgtgtttacagctccgccaacaactgtaccttcgagtacgtctctcagcccttcctaatggacctg gaaggtaaacagggcaatttcaagaacctgagagagttcgtgttcaagaacatcgacggatattt taagatctactctaagcacacccctatcaacctggtgcgggacctgcctcaaggcttctccgctctg gagcctctagtggacctgcctattggcatcaacatcaccagattccagaccctactggctctgcac agatcttacctgactcctggcgacagctccagcggctggaccgccggcgctgccgcttactacgt gggctacctgcagcctcggaccttcctgctgaagtacaacgagaacggaaccatcaccgacgct gtggactgcgccctggatcctctgtctgaaactaagtgcaccctgaagtcgtttaccgtggaaaag ggcatctaccagacctccaacttcagagtgcagccaaccgaatctatcgtgcgcttccccaacat cacaaacctgtgccccttcggcgaagtgttcaacgctacacggttcgcctccgtatacgcttggaa cagaaaaagaatctccaactgtgtggctgattactccgtgctgtataacagcgcctctttttccacctt caagtgctacggggtgtctcctaccaaactgaacgacctgtgctttaccaacgtgtacgccgactcctttgtgatccggggcgatgaggtgcggcagatcgcccctggccagaccggcaagatcgccga ctataattacaagctgcctgacgacttcaccggctgcgtgatcgcatggaactccaacaatctgga ctccaaggtgggcggcaactacaactatctgtatagactgttcagaaagtccaacctgaaaccttt cgagagagacatcagcaccgagatctaccaggccggctctaccccttgcaacggcgtagagg gcttcaactgctacttccccctgcagtcctacggctttcaacctaccaacggagtgggctaccaac cttaccgggtggtggtgctgtccttcgagctgctgcacgcccctgctactgtgtgcggacctaagaa atctaccaatctggtgaaaaacaagtgcgtgaacttcaacttcaacggcctgacaggcactggcg tcctgaccgagtccaacaagaagttcctgcctttccagcagttcggcagagacatcgccgacacc accgacgccgttagagatcctcagaccctggagatcctggacatcaccccttgctcctttggcggc gtgtccgtgatcacccctggcaccaacaccagtaatcaggtggccgtgctgtaccaggacgtga actgcaccgaagtgcctgtggccatccacgccgaccagctgacacctacatggcgggtttactcc acaggatccaacgtgttccagacccgggctggctgcctgatcggcgccgagcacgtgaacaac tcctacgagtgcgacatccctatcggcgctggcatctgcgcttcttaccaaacccagaccaactcc ccccgc 4501_Wuhan S1 (SEQ ID NO: 44) atgtttgtgtttctagtgctactaccactagtgtcctcccagtgcgtgaacctgaccacaagaacccagctgcctcctgcgtacaccaactccttcaccagaggcgtgtactaccctgacaaggtgtttcgttcct ccgtcttgcactccacacaggatctgtttctgcctttcttctctaacgtgacgtggttccacgccatcca cgtgtccggtaccaacggcacaaagagattcgacaaccccgtgctgcctttcaacgacggcgttt acttcgcctccactgagaagtctaacatcatcagaggatggatcttcggtaccaccctcgacagc aagacccaatccctgctgatagtgaacaacgctacaaacgtggtgatcaaggtgtgcgagttcc agttctgcaacgatccttttctgggagtgtactaccacaagaataacaagtcctggatggaaagtg aattcagagtgtactctagcgccaacaactgtacctttgagtacgtgtcccaacctttcctgatggac Petição 870250095390, de 19 / 10 / 2025, pág. 108 / 166 105 / 115 ctggaaggaaagcagggcaacttcaagaacctgagagagttcgtgttcaagaacatcgatggct acttcaagatctactccaagcacacacctatcaacttggttagagacctcccgcagggcttctccg ctctggaacctctggtcgacctgcccattggcatcaacatcacacggttccagaccctgctggctct gcacagatcctacctgaccccaggagattcctcttctggctggaccgccggcgctgccgcttacta cgtgggctacctgcagcctcggacattcctgctgaagtacaacgagaacggcaccatcaccgac gctgtggactgtgccctggatcccctgagcgagacaaagtgtaccctgaaatcttttaccgtggaa aagggcatttaccagacctccaacttcagggtgcagcctactgagtccatcgtgcggttccctaac atcaccaacctgtgccccttcggcgaagtgtttaacgccaccagatttgcttctgtgtacgcttggaa cagaaagagaatcagcaactgcgtggctgattactccgtcctgtacaattcagcaagcttctccac cttcaaatgctacggagtgtctccaaccaagctgaacgacctgtgtttcaccaacgtgtacgccga ctctttcgtgatccggggcgacgaagtccggcaaatcgcccccggccagaccggcaagatcgc cgactacaactacaagctgcctgacgatttcaccggatgtgtcatcgcttggaactccaacaacct ggatagtaaagtgggcggcaactataattatttgtaccggctgttccggaagtctaatctgaagcctt tcgagagagacatctctaccgagatctaccaggccggctctacaccttgcaacggcgtagagggcttcaactgctacttccccctgcagagctacggcttccagcctactaacggcgttggctaccagcct tacagagtggtggtgctgtctttcgagctgctgcatgctccagccacagtgtgcggccctaagaagt ccacgaacctggtgaagaacaaatgcgtgaacttcaacttcaatggcctgaccggcaccggcgt gctgacagagtctaacaagaagttcctgccattccagcagttcggcagagatattgctgacacca ctgatgccgtacgggaccctcagaccctggaaatcctggatatcaccccttgttccttcggcggcgt ctccgtgatcactcctggaaccaacacctccaaccaggtggccgtgctgtaccaggacgtgaact gcaccgaggtgcctgtggccatccatgccgaccagctgacgcccacctggcgggtgtactccac cggatctaatgtgttccaaacccgggctggctgcctgatcggcgccgagcacgtgaataactcct acgagtgcgacatccctatcggggccggaatctgcgcgtcataccagacccagacaaactctcc taga 4502_Wuhan S1 (SEQ ID NO: 45) atgtttgtgtttctagtgctactaccactagtctcttcccagtgtgtgaacctgaccaccagaacccag ctgcctcctgcctacacaaattcttttacacgcggagtgtactaccctgacaaggtgttcagatcctct gtactgcatagtacacaggacctgtttctgcccttcttcagcaacgtgacctggttccacgctattcat gtttctggcaccaatggaaccaagagattcgacaatcctgtgctgccattcaacgacggcgtgtac ttcgcctccacggagaagtccaacatcatcaggggctggatcttcggcaccaccctggattcaaagacccagtctctgctgatcgtgaataatgctaccaacgtggtcatcaaagtatgcgagttccagttct gcaacgacccttttctgggcgtgtactaccacaagaacaataagtcctggatggaatccgagttca gagtatactcttctgccaacaactgtaccttcgagtacgtctctcagcctttcctgatggaccttgagg gcaagcagggcaacttcaaaaacctgagagagttcgtgttcaaaaacatcgacggctacttcaa gatctactctaagcacacccctatcaacctggtgcgcgacctgccccaaggcttttccgctctgga acctctggtggatctgcctatcggcatcaacatcacccgcttccaaaccctgctcgctctgcaccgc tcctacctgacccctggcgattcctcctccggctggaccgccggcgctgccgcctactacgtagga Petição 870250095390, de 19 / 10 / 2025, pág. 109 / 166 106 / 115 tatctgcagcctcggaccttcctgctgaagtacaatgagaacggcaccatcaccgacgccgtgg actgcgccctggaccccctgtccgagacaaagtgcaccctaaagtccttcacagtggaaaagg gaatctaccagacatccaacttcagagtgcagcctaccgagtccatcgtgagattccctaacatc accaacctgtgtcctttcggcgaggtgttcaacgccactagattcgcctccgtgtacgcttggaacc ggaagcggatcagcaattgtgttgccgactactccgtcctgtacaactccgcgagtttctccactttc aagtgctacggcgtgtcacctaccaagttgaacgatctgtgcttcactaacgtctatgccgacagct ttgtgatcagaggcgacgaggtgcggcagattgcacctggccagaccggcaagatcgccgatt acaactacaagctgcccgatgattttaccggctgtgtgatcgcctggaactccaacaacctggact ctaaggtcggaggcaactacaactacctgtacagactgtttagaaagtctaacctgaagcccttcg agcgggacatctccactgagatctaccaggccggatccacaccttgtaacggcgtggaaggctt caactgctacttccctctgcagtcttatggcttccagcctaccaacggcgtcggctaccagccttac agagtggtcgtcctctccttcgagctgctgcacgccccagccaccgtgtgtgggcctaagaaatcg acaaacctggtgaagaacaagtgcgtgaacttcaacttcaacggtctgaccggaaccggagttc ttaccgaatccaacaagaagttcctgcctttccagcagtttggcagagacatcgccgacaccacc gatgctgtgagagatcctcagacactggaaatcctggatatcaccccatgctccttcggcggcgtgagtgtgatcacccctggcaccaacacatccaaccaagtggccgtgctgtaccaggacgtgaact gtaccgaggttcccgtggccatccacgccgaccagctgacccctacctggcgggtgtactccacc ggctccaacgtgttccaaactagagccggctgcctgatcggggccgagcacgtgaacaactctt acgagtgcgacatccccatcggcgctggcatctgcgcttcctaccagacacagaccaactctcct aga 4503_Wuhan S1 (SEQ ID NO: 46) atgtttgtgtttctagtgctactaccactagtcagttctcagtgcgtgaacctgacaacgagaaccca gctgcctccagcctacaccaactcattcacaagaggcgtgtactaccccgacaaggtgttcagaa gctctgtgctgcactccacccaggatctgttcctgcccttcttctccaacgtgacctggtttcacgccat ccacgtctccggcaccaatggcaccaagcggttcgacaacccagtgctcccattcaacgacgg cgtgtacttcgcctccaccgagaagtctaacatcatcagaggttggatcttcggcaccaccctgga ctccaagacccaatccctgctgatcgtgaacaacgccactaatgtggtcatcaaagtgtgcgagtt ccagttctgcaacgaccccttcctgggtgtgtactaccacaagaacaacaagtcttggatggaaa gcgagttcagagtgtactcatctgctaacaattgcaccttcgagtacgtgagtcagccttttctgatg gacctggaaggaaagcagggcaacttcaaaaacctgagagagttcgtgttcaaaaatatcgac ggctacttcaagatctactctaagcacacccctatcaacctggtccgggatctgcctcagggctttagcgccctcgagcctctggtggacctgcccatcggcatcaacatcacccggttccagactctgttag ctctgcacagatcctacctcacccccggcgattcctcttctggctggaccgctggcgctgctgccta ctacgtgggctacctgcagcctcgaacgtttctgctgaagtacaacgagaacggcaccatcaca gacgccgtagactgtgccctggatcctctgtctgagacaaagtgcacgctgaagtccttcaccgtg gaaaagggcatctaccagacatccaacttccgggtgcagcctaccgagtctatcgtgcggttccc caacataaccaacctgtgtcctttcggcgaggtatttaacgctaccagattcgcctccgtgtacgcct Petição 870250095390, de 19 / 10 / 2025, pág. 110 / 166 107 / 115 ggaacagaaaacggatctctaactgcgttgccgactacagtgtgctgtacaactccgcttcattca gcaccttcaagtgctacggcgtgtcccctaccaagctgaatgatctgtgcttcaccaacgtgtacgc tgactctttcgtgatccggggcgacgaagtgagacagatcgcccctggccagacaggcaagatc gccgactataactacaagctgcctgacgacttcaccggatgcgtgattgcctggaactccaataa cctggattctaaggtgggcggcaactacaactacctgtatcgtctgttccggaagtccaatctgaag ccattcgaaagagatatttccaccgagatctaccaggctggaagcaccccttgcaacggcgtcg aaggcttcaactgctacttccccctgcagtcttacggctttcagcctaccaacggcgttggatacca accttacagagtggtcgtgctgtcttttgagctgctgcatgctccagcaaccgtgtgcggacccaag aagtccaccaatctggtgaagaacaagtgcgtgaacttcaacttcaacggcctgacgggtaccg gcgtactgacagagtccaacaaaaagtttctgcctttccagcagttcggcagagatatcgccgac accaccgacgccgtgagagatcctcagaccctggagatcctggatatcaccccttgtagcttcgg cggagtgtccgtgatcacacccggcacaaacacctctaaccaggtggccgtcctgtaccaggac gtgaactgcaccgaagtgcctgtggcaatccacgccgaccagctgacccccacctggcgggttt actctaccggcagcaacgtgtttcagaccagagctggctgcctgattggcgccgagcacgtgaa caactcgtacgagtgcgacatccctatcggagccggcatctgcgcctcctaccagacccagaccaactctcctaga 4495_BTKY7 2 (SEQ ID NO: 47) agagtctctccaagcaccgaggtggtgcggtttcctaatatcaccaacctgtgccctttcggacaa gtgtttaacgcctccaacttcccatcggtgtacgcctgggagagactgcgcatctccgactgcgtcg ccgactatgccgtgctgtacaattcttcctcctctttctccacctttaagtgctacggcgtgagccctac aaagctgaacgacctgtgcttctcctctgtgtacgccgactacttcgtggtgaaaggcgatgatgtg agacagatcgcccctgcccagaccggcgtgatcgccgattacaactacaagctccccgacgac ttcacaggctgcgtgctggcctggaataccaactccgtagattccaaatccggaaacaacttctac taccggctgttcagacacggcaagatcaagccctacgaaagagacatctccaacgtgctgtaca actccgctggcggcacctgttcctccatctctcagctgggctgctacgagcccctgaaatcctatgg gttcacccccaccgtgggggtgggctaccagccttatagggtcgtggtgttatccttcgaactgctg aacgctccagctaccgtgtgcggccccaagaaatcaaccgagctggtcaagaacaagtgcgtg aacttc 4495_RsSH C014 (SEQ ID NO: 48) agagtggcaccctctaaagaagtggtcagattccccaatatcaccaatctgtgtccttttggcgagg tcttcaacgccaccaccttcccttctgtgtacgcctgggaacggaaacggatctctaactgcgtcgc cgactactctgttctctacaactccacctctttctccacctttaaatgttacggcgtctctgctacaaaactgaacgatctgtgcttctctaacgtgtacgctgactcttttgtggtaaagggcgacgacgtgagac agatcgcccctggccaaaccggagtcatcgctgattataactacaaactgcctgatgacttcctgg gatgtgtgctggcttggaacaccaatagcaaggacagcagcacatctggcaactacaactacct gtacagatgggtgaggagaagcaagctcaacccgtatgaacgggacctgtctaacgacatcta ctctccaggcggacagtcctgctccgctgtgggccctaactgctacaatcctctgagaccctacgg Petition 870250095390, dated 10 / 19 / 2025, pp. 111 / 166 108 / 115 cttcttcaccaccgctggcgtgggacatcagccttacagagttgttgtgctgagcttcgagctgctga acgcccctgccaccgtgtgtggccctaagctgtctactgatctgatcaaaaaccagtgcgtgaattt c 4498_HKU3 (SEQ ID NO: 49) cgcgtgtcccctacccaagaggtgattcgttttcctaacatcaccaacagatgtcctttcgacaagg tgttcaatgccacccggttccctaacgtgtacgcctgggaacggacaaaaatctccgactgcgtg gccgactacaccgtgctgtacaattctacatctttttctactttcaaatgctacggcgtgtccccatcta agctgatcgacctgtgttttacctctgtgtatgccgatactttcctgatccggtcctcggaggtgagac aggtcgcccctggcgagacaggggtgatcgccgactacaactacaagctgcctgacgattttac cggctgcgtgatcgcctggaataccgccaagcacgacacgggcaattactactatagatcccac cggaagaccaagctgaaacctttcgagcgcgatctgagcagcgacgacggcaacggcgtttac accctgtccacctatgacttcaaccctaacgtacccgtggcctaccaggccacccgggtggtggt gctgtctttcgagctgctgaacgcccctgccaccgtgtgtggccctaagctgtctaccgaactggtg aagaaccagtgcgtgaacttc 4498_BTKY7 2 (SEQ ID NO: 50) agagtttccccttccaccgaggtggtcagattccccaacatcacaaacctgtgcccattcggccag gtgttcaatgcttccaacttcccatctgtgtacgcctgggagcggctgaggatctctgactgcgtggccgactacgccgtgctgtacaactcttcctccagcttctctaccttcaagtgttacggcgtgtctcctac caagctgaatgatctgtgcttcagctctgtgtacgccgactacttcgtggtgaagggtgatgatgtac ggcaaatcgcccctgctcagaccggcgtgattgccgactacaattacaagctgccagacgacttc accggctgtgtcctggcttggaacaccaactccgtggacagcaagtccggaaacaacttctacta cagactgttcagacacggcaagatcaagccttacgagcgggacatctcgaacgtgctgtacaac tccgccggcggaacctgtagctctatctcccagctgggctgctacgagcctctgaagagctacgg cttcactcccaccgtgggcgtcggctatcagccttacagggtggttgtgctgtcctttgagctgctga acgcccctgctaccgtgtgcggccccaagaaatccacagagctggtgaagaacaagtgcgtga acttc 4498_WIV1 (SEQ ID NO: 51) cgggtggctccttctaaagaggtggtgagattccctaacatcaccaacctgtgcccttttggcgagg tcttcaacgctaccaccttcccatccgtgtacgcttgggagagaaaacggatcagcaattgcgtgg ctgattattccgtgctgtacaactctacctctttttccaccttcaagtgctacggcgtatctgctactaag ctgaacgacctgtgcttctccaacgtgtatgctgactctttcgtggtcaagggcgacgacgtgcggc agatcgctcctggccagaccggcgtgatcgccgactataactacaagctgcctgatgacttcaca ggctgtgttctggcctggaacaccagaaacatcgacgccacccagaccggcaattacaactacaagtacagatctctgcggcatggaaagctgaggcctttcgagcgggatatctccaacgtcccctttt cccctgatggcaagccttgcacccctcctgctttcaactgctactggcctctgaacgactacggcttc tacatcaccaacggcatcggctaccagccttatagagtggtggtgctgtctttcgagctgctgaacg ctcctgccaccgtgtgtggacctaagctgtcaaccgacctgatcaagaaccagtgcgtgaacttc Petição 870250095390, de 19 / 10 / 2025, pág. 112 / 166 109 / 115 4499_Khosta 2 (SEQ ID NO: 52) agagtgtctccttctctggacgtggtgaggtttccaaacatgaccaacatctgccctttcgaccaggt gttcaacaagacccagttcccttccgtctacgcttgggaacgggtgagaatctccgactgtgtgtcc gactacaccgtgctgtacaacagctctgcttctttctccaccttcaagtgttacggcgtgtctcctacc aagctgaacgacctgtgcttctcaggcgtgtacgccgactacttcgtggtcaaaggcgatcacgtg caccagatcgcccctggccagaccggcgtgatcgccgactacaattacaaactgccttccgagtt cgtaggctgcatcctggcttggaacacaagaaccatcgactccaagagaggattctactaccgg ctgttcagacacggcaatatccggccgtacgagagagacacctccaatgtgccctacaatgctg ctggaggcacctgcaaccagcctggcacccacaactgctacgagcctctgcaggactacggctt cacatccacatcgggagtgggctaccagccattccgcgtggtggtcttatcctttgagctgctgaac gcccctgccaccgtgtgtggccccaagcagagcaccgatctagtgaaaaacaagtgcgtcaatt tc 4499_WIV1 (SEQ ID NO: 53) agagtggctccctctaaagaggtggtgagattccccaacattaccaacctgtgcccttttggagag gtcttcaatgctaccaccttccctagcgtatacgcttgggagcggaagcggatctccaactgcgtg gccgactactctgtgctgtacaactccaccagcttttctaccttcaaatgctacggcgtgtccgccac caagctgaacgatctgtgcttttccaacgtgtacgccgattccttcgtggttaagggcgacgatgtgagacagatcgcccctggccagacaggtgtaatcgctgattacaactacaagctgcctgacgactt caccggctgtgtgctggcctggaacaccagaaacatcgatgctacacagaccggcaactacaa ctacaagtaccggagcctgcggcatggcaagctgagacctttcgagagagatatctccaacgtg ccattctctcccgatggcaaaccttgtaccccacctgctttcaactgctactggcccctgaacgacta cggcttctatatcactaacggcatcggctaccagccatacagagtggtggttctgagtttcgaactg ctcaatgctccagccaccgtgtgcggacctaagctttccaccgacctgataaaaaaccagtgtgt gaacttc 4500_Pang1 7 (SEQ ID NO: 54) cgggtgcaacctaccatctccatcgtgcggtttcctaacatcaccaacctgtgccctttcggcgagg tcttcaacgccagcaagttcgcttccgtgtatgcctggaacagaaagagaatctccaactgcgtcg ccgactactccgtgctgtacaattctacaagtttctccaccttcaagtgctacggcgtgtcccctacc aagctgaacgacctgtgcttcaccaacgtctacgccgactccttcgtggtgaagggcgatgaagt gagacagatcgctccaggacagacaggcgtaattgccgactataattataaactccccgatgact tcaccggctgcgtgattgcctggaactctgtcaagcaggacgctttgaccggcggaaactacggc tacctgtaccggctgttcagaaagtccaagctgaaaccttttgaacgggacatctctaccgaaatct accaggctgggagcaccccttgtaacggacaagtgggcctgaactgttactaccccctggaaagatacggcttccatcctaccaccggcgtgaattaccagcctttccgggttgtggttctgagctttgagct gctgaacggcccagctacggtgtgcggccccaagctctctaccacccttgtgaaggacaagtgc gtcaatttc 4500_WIV1 (SEQ ID NO: agagtggctccttccaaagaggtggtgagatttcctaatatcaccaacctgtgtcctttcggcgaag tgttcaacgccaccaccttcccatctgtgtacgcctgggagagaaagcggatcagcaactgtgtg Petição 870250095390, de 19 / 10 / 2025, pág. 113 / 166 110 / 115 55) gctgattattctgtgctgtacaactccacctccttctccacctttaagtgttacggcgtgtctgctaccaa gctgaacgatctctgttttagtaacgtgtacgccgactccttcgtggtgaagggcgacgatgtgcgg cagatcgcccctggccagaccggcgtgatcgctgattacaactacaagctgcctgacgactttac aggctgtgtgctggcttggaacacccggaacatcgatgccacccagaccggcaactacaacta caagtaccgctctctgcggcacggcaagctgaggccctttgagcgggatatctctaacgtgccttt cagccctgatggcaagccctgcacccctccagccttcaattgttactggcctctgaacgactacgg cttctacatcaccaacggaatcggctaccagccctatagagtggtggtgctgtcgttcgagctgctg aatgctcccgccaccgtgtgtggcccaaagctgtccaccgacctgatcaagaaccagtgcgtga acttc 4501_Khosta 2 (SEQ ID NO: 56) agagtttcgccttctctggacgtggtcagattccctaacatgaccaacatctgccctttcgaccaggt gttcaacaaaacccagttcccctccgtgtacgcctgggaacgggtgagaatttccgactgcgtctc agattacaccgtgctctataacagctctgcctctttctctacctttaagtgctacggcgtgagccctac caagttaaatgacctgtgctttagcggcgtgtacgccgattatttcgtggtaaagggtgaccacgtg caccagatagcccccggccagaccggcgtgatcgctgactacaattataagctgcccagcgagt tcgtgggctgcatcctggcctggaacactagaacaatcgactccaagagaggcttctactaccggctgttccggcatggcaacatcagaccttacgagcgcgatacctccaatgtgccctacaacgctgct ggcgggacctgcaaccagcctggcacccacaactgctacgagcctctgcaggactacggcttc acctccacatctggcgtcggctaccaaccattcagagtggtggtgctgtctttcgagctgctgaacg ctccagctaccgtgtgtggccctaagcaatccacagatctggtgaagaacaagtgtgtgaatttc 4501_RsShC 014 (SEQ ID NO: 57) agagtggctccttctaaagaggttgtgcggtttcctaacatcaccaacctgtgtcctttcggcgaggt gttcaacgccaccacgttcccctctgtgtacgcctgggagagaaagaggatctccaactgtgttgc tgactactcggtgctgtataactccacctctttttccaccttcaagtgctacggcgtctccgccaccaa gctcaatgacctgtgcttctcgaacgtgtacgcagactccttcgtggtcaagggcgacgacgtgag acagatcgcccctggccagactggcgtgatcgccgactataattacaaactgccggacgactttc tgggctgcgtgctggcttggaacaccaactctaaggactcttccacctctggcaactacaactacct gtatagatgggtgcgtaggagtaaactcaacccttacgagcgggacctgtccaacgatatctattc ccctggcggccagtcctgctccgctgtgggccccaattgctacaaccccctgcggccttacggctt cttcacaaccgctggagtgggccaccagccttaccgggtggtggtgctgtcttttgaactgctgaat gctcctgctaccgtgtgcggccccaagctgtccaccgacctgataaaaaaccagtgtgtgaacttc 4501_WIV1 (SEQ ID NO: 58)agagtcgcccctagtaaagaagtggtgagattccccaacatcaccaacctgtgccctttcggcga agtgttcaacgccaccaccttcccttctgtgtacgcttgggagcggaagcggatctccaactgtgtg gccgactatagcgtgttatacaactctacctctttttccaccttcaagtgctatggcgtgtctgccacca aactgaacgacctgtgcttctcgaacgtgtacgctgatagctttgtggtgaaaggcgacgacgtga gacagatcgcacctggacagaccggagtgatcgccgactataactacaagcttccagatgactt caccggctgtgtgctggcttggaacacccggaacatcgacgccacccagacaggaaactaca Petição 870250095390, de 19 / 10 / 2025, pág. 114 / 166 111 / 115 actacaagtaccgctccctgagacacggcaagctgagacccttcgagcgggacatctccaacgt gcctttctctcctgatggcaagccctgcacccctccagccttcaactgttactggcctctgaacgact acggcttttacatcaccaatggcatcggatatcagccttacagagtggtggtcctgtcctttgagctg ctgaacgcccctgccaccgtgtgcggccctaagctgtccaccgacctgatcaagaaccagtgcg tgaacttt 4502_Khosta 2 (SEQ ID NO: 59) agagtgtctccctccctcgacgtggttcgattccccaacatgaccaacatctgccctttcgaccagg tgttcaacaaaacccagtttccaagcgtgtacgcctgggagagagtcagaatctctgactgtgtca gcgactacaccgtgctgtacaacagttctgcctccttctccacatttaagtgctacggcgtgtcccct acaaagctgaacgacctgtgcttctctggcgtctacgccgactacttcgtcgtgaagggcgacca cgtgcaccagatcgctccaggccagaccggcgttattgccgactacaactacaagctgccttccg agttcgtgggatgcatcctggcctggaacactcggaccatcgactccaagcggggcttctactac cggctgttccggcacggtaacatccgcccctacgagagagacacctctaatgtaccctacaatgc cgccggcggcacctgtaaccagcccggtacccacaactgctacgagcctctgcaggactacgg cttcacctctaccagcggagtgggctaccaaccattcagagtggtggtgctgagttttgaactgctg aacgctcctgctacagtgtgcggccctaagcagtcaaccgatctggtgaagaacaagtgcgtga atttc 4502_RsShC 014 (SEQ IDNO: 60) agagtggccccctctaaagaggtcgtgaggttccctaacatcaccaatctgtgccctttcggcgaa gtgttcaacgctacaacgttcccctccgtttatgcctgggagagaaagcggatctccaactgcgtg gctgattattccgtgctgtacaattcgacatctttctccacctttaagtgttacggcgtgtccgccacca aactgaacgacctttgcttttccaacgtgtatgctgacagtttcgtggtgaagggcgacgatgtgcg acagatagcgcccggccagaccggcgtgatcgctgactacaactacaagctgcctgatgacttc ctcggctgcgtgctggcctggaataccaactccaaggactcctcaacctctggcaactataattac ctgtacagatgggtgagacggagcaaactgaacccgtacgaacgggatctttctaatgacatcta ctctcccggtggacagtcctgctccgccgtgggcccaaattgttacaacccactgcggccttacgg cttcttcaccaccgctggcgtgggccatcagccttacagagtggtggtgctgtcctttgagctgctga acgctcctgctaccgtgtgcggccctaaattgtctaccgacctgatcaagaaccagtgcgtgaattt c 4502_Urbani (SEQ ID NO: 61) agagtggtgccttccggcgacgtcgttagatttccgaacatcaccaatctgtgtcctttcggcgaagt gttcaacgccaccaagttcccttctgtgtacgcttgggaacggaagaaaatctccaactgtgtggc cgactactctgtgttgtataactctaccttcttttccaccttcaagtgctacggcgtgtctgccaccaag ctgaacgatctctgcttctccaacgtgtacgcagactccttcgtggtgaaaggcgacgacgtcagacagatcgctcccggacagaccggcgtgatcgccgattacaactacaagctgcccgacgacttca tgggctgtgtgctggcttggaataccagaaacatcgatgccacctctctggcaactacaactaca agtaccgctacctgagacacggcaaactgcggccttttgaacgggacatctccaacgtgccattc agccctgatggcaagccttgcacgccccctgctctgaactgctactggcctctgaacgactacgg Petition 870250095390, dated 10 / 19 / 2025, pp. 115 / 166 112 / 115 attctacacaaccaccggcatcggatatcagccttaccgggtggtagtgctgagcttcgagctgct gaacgccccagctaccgtgtgcggccccaagctgtctaccgacctcatcaagaaccagtgcgtg aatttttga 4503_RatG1 3 (SEQ ID NO: 62) cgggtgcagcccaccgactccatcgtcagattccctaacatcaccaacctctgcccttttggagaa gtgttcaacgccaccacgttcgcctctgtgtacgcttggaacagaaagcggatctccaactgcgtg gcggactactctgtcctgtacaattccacctccttttccaccttcaagtgctacggcgtgtcccctaca aagctgaacgatctgtgcttcaccaatgtgtacgccgatagcttcgttatcaccggcgacgaggtg cgccagatcgctcctggccagaccggcaagatcgccgactacaactacaagttgcccgatgact tcaccggctgtgtgatcgcttggaacagcaagcacatcgatgccaaggaaggtggcaacttcaa ctacctgtacagactgtttagaaaggccaaccttaagccatttgagagagacatctccacagaaa tctaccaggctggctccaaaccttgcaatggccagacaggcctgaactgctactatcctctgtacc gctacggcttctaccctaccgatggcgtgggccaccagccttatagagtcgtggtgctgtctttcga actgctgaacgcccctgccaccgtgtgtggccctaagaagtctacaaacctggtgaaaaataagt gcgtgaacttc 4503_BTKY7 2 (SEQ ID NO: 63) cgggtgtccccaagcacggaggtggtccggttcccaaacatcaccaacctgtgcccttttggccaagtgttcaatgcttcaaactttccttctgtgtacgcttgggagcggctgaggatctccgactgcgtggc tgattacgccgtgctctacaactctagcagctctttctctaccttcaagtgctacggcgtgtctccaac caagctgaacgacctgtgtttctcctccgtgtacgccgactacttcgtggtgaagggcgacgacgt gagacagatcgctcctgctcagaccggagtgatcgccgattacaactacaagctgcctgatgact tcaccggctgcgtgctggcctggaacaccaactccgtggactccaagagtgggaacaacttcta ctacagactgtttagacatggcaagatcaagccttacgagcgcgacatctccaacgtgctgtaca actctgccggcggcacctgctcctccattagccagctgggatgttacgagcccctgaaaagctac ggctttacccctactgtaggcgtcggctatcagccttaccgggttgtggtgctgtccttcgaactgctg aacgcccctgctaccgtgtgtggccctaagaaatccaccgagctggtgaagaacaagtgcgtga acttc 4503_WIV1 (SEQ ID NO: 64) agagtggcaccgtctaaagaggtggtgcggttcccaaacatcaccaacctgtgtcctttcggcga agtcttcaacgccaccacgttccctagcgtttacgcctgggaacggaagagaatctctaactgtgt ggccgactacagcgtgctgtacaactccacctcgttttccaccttcaagtgttatggcgtgtccgcca ccaagttgaacgacctgtgcttcagcaatgtgtatgccgactccttcgtggtcaaaggcgacgacg tgcggcagatcgcccctggacaaactggcgtgatcgccgactataactacaaactgcctgacgatttcaccggctgtgtgctggcttggaatacccggaacatcgatgctacacagaccggcaactaca actacaagtacaggagcctgagacacggcaagcttaggcctttcgagagagacatttccaacgt gcccttctcccctgacggcaagccctgcacaccccctgcgttcaactgttactggcctctgaacga ctatggcttttacatcaccaacgggatcggctatcaaccgtaccgggtggtggtgctgtcttttgagct gctgaacgcgcctgccacagtgtgcggccccaagctctccaccgacttgatcaagaaccaatgt Petição 870250095390, de 19 / 10 / 2025, pág. 116 / 166 113 / 115 gtgaacttc OmicronRBD cgagtccaaccaacagagtcaatcgtaagattccccaatatcaccaacctctgcccctttgacga (SEQ ID NO: agttttcaacgctaccagatttgcaagtgtgtacgcctggaataggaagcggatcagtaactgcgt 65) cgccgactactctgtactttataacctcgcgcccttctttacattcaagtgctatggcgtctcccccac gaaacttaatgacctctgtttcacgaacgtctacgccgattcctttgtgataagaggggatgaggta agacaaatagcacctggtcagacaggcaacatagcagactataactataagttgcccgacgac tttacaggatgtgtaattgcttggaacagtaacaagctggattcaaaggtttccggcaattataacta cctgtacagactgttcagaaaaagtaatctcaaacccttcgagagagacatttcaaccgaaatct atcaggccgggaacaaaccatgcaacggcgtcgctggattcaactgttacttccccctccgatcat actcctttaggcccacatatggagtgggtcatcaaccttaccgagttgttgtcctgtctttcgagctctt gcacgcgccggcaactgtgtgtggacctaaaaagagtacgaacttggtgaagaataagtgtgta aactttaactttaatggt BetaRBD atgttcgtgtttctggtgctgctgcctctggtgtccagccgggtgcagcccaccgaatccatcgtgcg (SEQ ID NO: gttccccaatatcaccaatctgtgccccttcggcgaggtgttcaatgccaccagattcgcctctgtgt 66) acgcctggaaccggaagcggatcagcaattgcgtggccgactatagtgtactgtataactcagcatccttttccacgtttaagtgctacggggtcagtcctacaaagttgaatgacttgtgctttacaaacgt atatgctgattcctttgtcatacgaggcgatgaggtcagacagattgctccgggacaaaccggaa atattgccgactacaactacaaacttcccgacgattttactgggtgtgtaattgcctggaacagtaa caatcttgactcaaaagtggggggaaattacaattacctttatagactcttccgcaagagcaatctc aagccttttgaacgcgatatatctaccgaaatataccaggccggttctactccatgcaatggagtta agggatttaattgttactttcctctccaatcttatgggttccagccaacttatggagtcggttatcagcc atatcgagtcgttgtgctcagcttcgaactgcttcatgccccagctactgtttgtgggccgaaaaagt ccactaatctcgtgaagaataagtgcgtaaacttt DeltaRBD agggttcagcccacagagtccatagtacggttccctaatattaccaacctgtgtccgttcggtgaag (SEQ ID NO: tcttcaatgccacaagattcgccagcgtttatgcctggaaccgaaagagaattagtaattgtgttgc 67) ggattattctgtcctttacaatagtgcaagcttctccaccttcaagtgttacggggtttccccgacgaa actcaacgacctttgttttacaaatgtgtatgcagattcatttgttatccgaggagatgaggtacggca aatagcccccggacaaacaggaaagatagccgattacaactataaactgcctgatgacttcact gggtgcgtcatcgcatggaatagcaacaaccttgattccaaagtagggggcaattataattaccgctatcgacttttccgcaagtccaacctcaaacccttcgagcgcgatatcagcacggaaatttacca agcgggcagcaaaccatgcaacggagtcgaaggatttaattgttacttcccgttgcaatcctatgg ctttcaaccaaccaacggtgttggttaccaaccttatagagttgtcgttctcagttttgagctcctccat gccccggccaccgtatgcggcccaaagaaatcaacaaacctcgttaagaacaaatgtgtcaac tttaatttcaatggg Petition 870250095390, dated 10 / 19 / 2025, pp. 117 / 166 114 / 115

[0195] In the present description, all terms mentioned in the singular shall encompass plural forms thereof. Likewise, all terms mentioned in the plural shall encompass singular forms thereof. Unless otherwise defined, all technical and scientific terms used herein have the same meaning commonly understood by a person of ordinary skill in the art to which this disclosure relates.

[0196] As used herein, the term “about” refers to a variation of approximately + / -10% of a given value. It should be understood that such variation is always included in any value given herein, whether specifically mentioned or not.

[0197] As used herein, the term “substantially” refers to a variation of approximately + / -5% of a given value. If a value is not used, substantially means almost completely, but perhaps with some variation, contamination and / or additional component. In some embodiments, “substantially” may include completely.

[0198] It should be understood that the polypeptides, immunogenic compositions, uses and methods are described in terms of comprising, containing or including various components or steps; the polypeptides, immunogenic compositions, uses and methods may also consist essentially of or consist of the various components and steps. Furthermore, the indefinite articles “a” or “an”, as used in the claims, are defined herein to mean one or more of the elements it introduces.

[0199] For the sake of brevity, only certain intervals are explicitly disclosed here. However, intervals of any lower bound can be combined with any upper bound to recite an interval not explicitly recited, just as intervals of any lower bound can be combined with any other lower bound to recite an interval not explicitly recited, similarly, intervals of any upper bound can be combined with any other upper bound to recite an interval not explicitly recited. Furthermore, whenever a numerical interval with a lower bound and an upper bound is disclosed, any number and any interval included within the interval are specifically disclosed. In particular, each interval of values ​​(of the form Petition 870250095390, dated 10 / 19 / 2025, pp. 118 / 166 115 / 115 of approximately aa approximately b or, equivalently, of approximately aab or, equivalently, of approximately ab or of aab) disclosed here should be understood as establishing each number and interval covered within the broader range of values, even if not explicitly recited. Thus, each individual point or value can serve as its own lower or upper limit, combined with any other individual point or value or any other lower or upper limit, to recite an interval not explicitly recited.

[0200] Therefore, the present disclosure is well suited to achieve the aforementioned purposes and advantages, as well as those inherent thereto. The particular embodiments disclosed above are merely illustrative, as the present disclosure may be modified and practiced in different but equivalent ways apparent to those skilled in the art who benefit from the teachings contained herein. Although individual embodiments are discussed, the disclosure encompasses all combinations of all such embodiments. Furthermore, no intended limitations are made to the details of construction or design shown herein, except as described in the claims below. In addition, the terms in the claims have their simple and common meaning unless otherwise explicitly and clearly defined by the patent holder.Therefore, it is evident that the particular illustrative embodiments disclosed above may be altered or modified, and all such variations are considered within the scope and spirit of this disclosure. If there is any conflict in the use of a word or term in this specification and one or more patents or other documents that may be referenced herein, the definitions that are consistent with this specification shall prevail.

[0201] Many obvious variations of the embodiments presented here will appear to those skilled in the art in light of the present disclosure. Such obvious variations are within the intended scope of the appended claims. Petition 870250095390, dated 10 / 19 / 2025, pp. 119 / 166

Claims

1 / 13 CLAIMS 1. Fusion polypeptide characterized by comprising an amino acid sequence encoding, in sequence, a first antigen, a ligand and at least one additional antigen.

2. Fusion polypeptide according to claim 1, characterized in that at least one additional antigen comprises a plurality of antigens and each antigen of the plurality of antigens is linked to the preceding antigen with a linker peptide comprising the ligand.

3. Fusion polypeptide according to claim 1 or 2, characterized in that the sequence of the first antigen comprises a greater number of amino acids than the sequence of at least one of the other antigens.

4. Fusion polypeptide according to any one of claims 1 to 3 characterized in that the first antigen comprises an antigenic peptide or fragment thereof from a first pathogen.

5. Fusion polypeptide according to claim 4 characterized in that the first antigen comprises a first prokaryotic antigen, a first viral antigen or a first fungal antigen.

6. Fusion polypeptide according to claim 5 characterized in that the first viral antigen comprises a component of a surface glycoprotein of a virus, a lipoprotein or an extracellular domain of a transmembrane protein.

7. Fusion polypeptide according to claim 5 or 6 characterized in that the first viral antigen comprises a first coronavirus antigen comprising a MERS-CoV antigen, a SARS-CoV-1 antigen, a SARS-CoV-2 antigen (such as Wuhan coronavirus antigens, BA.1 coronavirus antigens, BA.2 coronavirus antigens or B.1.351 coronavirus antigens), an HCoV-HKU1 antigen, an HCoV-OC43 antigen, a BtCoV-RaTG13 antigen, a BtSL-CoV-WIV1 antigen, an HKU4CoV antigen, an HKU5-CoV antigen, a PDF-2108 CoV antigen, an SHC014-CoV antigen, a BtSCoV-RsSHC014 antigen, a BtSCoV-Rs3367 antigen, a BANAL-52 antigen, a BANAL-236 antigen, a Pangolin-CoV GX / P2V antigen, a bat CDPHE15 coronavirus antigen, a coronavirus antigen Bat HKU10, an alphacoronavirus HuB-2013 antigen from Petition 870250095390, dated 10 / 19 / 2025, p. 120 / 166 2 / 13 Rhinolophus ferrumequinum, a human coronavirus antigen 229E,a coronavirus antigen of mouse Lucheng Rn, a coronavirus 1 antigen of mink , a coronavirus antigen of fur, a coronavirus 1 antigen of Miniopterus carcass, a coronavirus HKU8 antigen of Miniopterus carcass, a Sax-2011 alphacoronavirus antigen of Myotis ricketti, an antigen of alphacoronavirus SC-2013 of Nyctalus velutinus, an antigen of coronavirus 3398 of Pipistrellus kuhlii, an antigen of swine epidemic diarrhea virus, an antigen of coronavirus 512 of morcego Scotophilus, an antigen of coronavirus HKU2 of Rhinolophus morsel, an antigen of human coronavirus NL63, an antigen of coronavirus strain BtKYNL63-9b related to NL63, an antigen of coronavirus T14 of Sorex araneus, an antigen of coronavirus X74 Suncus murinus, an antigen of Alphacoronavirus 1, a canine coronavirus antigen, a feline coronavirus antigen, a human CCoV-HuPn-2018 antigen, a swine transmissible gastroenteritis coronavirus antigen,an antigen of the porcine acute diarrhea syndrome coronavirus (SADS-CoV), an HCoV-NL63 antigen, an antigen of the NL63-related bat coronavirus strain BtKYNL63-9b, an HCoV-229E antigen, a Khosta2 sarbecovirus antigen, an antigen of the Kenyan bat coronavirus BtKY72, an antigen of the bat SARS coronavirus HKU3, or any combination thereof.

8. Fusion polypeptide according to claim 7 characterized in that the first coronavirus antigen comprises a Spike (S) protein, or a fragment thereof.

9. Fusion polypeptide according to claim 7 or 8 characterized in that the first coronavirus antigen comprises a SARS-CoV-2 Spike protein or a protein encoded by a nucleotide sequence with at least 70% identity to the SARS-CoV-2 Spike protein.

10. Fusion polypeptide according to any one of claims 1 to 9 characterized in that the linkage sequence comprises from 6 to 24 amino acids.

11. Fusion polypeptide according to claim 10 characterized in that the linkage sequence comprises glycine (G), serine (S), alanine (A) or any combination thereof. Petition 870250095390, dated 10 / 19 / 2025, pp. 121 / 166 3 / 13 12. Fusion polypeptide according to claim 10 or 11 characterized by an amino acid sequence of the linker comprising GSGSGS or GAAASG.

13. Fusion polypeptide according to any one of claims 1 to 12 characterized in that the at least one additional antigen comprises at least one additional antigenic peptide or fragment thereof from at least one additional pathogen.

14. Fusion polypeptide according to any one of claims 1 to 13 characterized in that at least one additional antigen comprises an amino acid sequence of at least 8 amino acids.

15. Fusion polypeptide according to any one of claims 1 to 14 characterized in that at least one additional antigen protein comprises at least one additional prokaryotic antigen, at least one additional viral antigen, at least one additional fungal antigen, or any combination thereof.

16. Fusion polypeptide according to claim 15 characterized in that at least one additional viral antigen comprises at least one coronavirus antigen.

17. Fusion polypeptide according to claim 16 characterized in that at least one coronavirus antigen comprises a MERS-CoV antigen, a SARS-CoV-1 antigen, a SARS-CoV-2 antigen, an HCoV-HKU1 antigen, an HCoV-OC43 antigen, a BtCoV-RaTG13 antigen, a BtSL-CoV-WIV1 antigen, an HKU4-CoV antigen, an HKU5-CoV antigen, a PDF-2108 CoV antigen, an SHC014-CoV antigen, a BtSCoV-RsSHC014 antigen, a BtSCoV-Rs3367 antigen, a BANAL-52 antigen, a BANAL236 antigen, a Pangolin-CoV GX / P2V antigen, a bat coronavirus CDPHE15 antigen, a bat coronavirus HKU10 antigen, a Rhinolophus ferrumequinum alphacoronavirus HuB-2013 antigen, a human coronavirus 229E antigen, a Lucheng Rn mouse coronavirus antigen, a mink coronavirus 1 antigen, a ferret coronavirus antigen, a Miniopterus bat coronavirus 1 antigen, a Miniopterus bat coronavirus HKU8 antigen,an alphacoronavirus antigen Sax-2011 from Myotis ricketti, an alphacoronavirus antigen SC-2013 from Nyctalus velutinus, an antigen from coronavirus 3398 from Pipistrellus kuhlii, an antigen from the virus of Petition 87025350, 10 / 19 / 2025, p. 122 / 166 4 / 13 swine epidemic diarrhea, a Scotophilus bat coronavirus 512 antigen, a Rhinolophus bat HKU2 coronavirus antigen, a human coronavirus NL63 antigen, an antigen of the bat coronavirus BtK6-L strain related ao NL63, a Sorex araneus coronavirus T14 antigen, a Suncus murine X74 coronavirus antigen, an Alphacoronavirus 1 antigen, a canine coronavirus antigen, a feline coronavirus antigen, a human CCoV-HuPn-2018 antigen, a gastrointestinal coronavirus antibody transmissible swine, a swine acute diarrhea syndrome coronavirus (SADS-CoV) antigen, an HCoV-NL63 antigen, an NL63-related bat coronavirus strain BtKYNL63-9b antigen,an HCoV-229E antigen, a Khosta2 sarbecovirus antigen, Kenyan bat coronavirus BtKY72 antigen, HKU3 SARS bat coronavirus antigen HKU3, Wuhan coronavirus antigen, BA.1 coronavirus antigen, BA.2 coronavirus antigen, B.1.351 coronavirus antigen, or any combination thereof.

18. Fusion polypeptide according to claim 17 characterized in that at least one coronavirus antigen comprises a receptor-binding domain, a fragment thereof, or a protein encoded by a nucleotide sequence with at least 70% identity to a Coronaviridae receptor-binding domain.

19. Fusion polypeptide according to any one of claims 1 to 18 characterized in that the first antigen and at least one additional antigen each independently comprise a prokaryotic antigen, a viral antigen, or a fungal antigen.

20. Fusion polypeptide according to any one of claims 1 to 19 characterized by further comprising, sequentially, a third antigen and the upstream binding sequence of the first antigen.

21. Fusion polypeptide according to any one of claims 2 to 20 characterized in that the plurality of antigens comprise prokaryotic antigens, viral antigens, fungal antigens or any combination thereof.

22. Fusion polypeptide according to claim 21 characterized in that the viral antigens comprise coronavirus antigens. Petition 870250095390, dated 10 / 19 / 2025, pp. 123 / 166 5 / 13 23. Fusion polypeptide according to claim 22 characterized in that the coronavirus antigens comprise MERS-CoV antigens, SARS-CoV-1 antigens, SARS-CoV-2 antigens, HCoV-HKU1 antigens, HCoV-0043 antigens, BtCoV-RaTG13 antigens, BtSL-CoV-WIV1 antigens, HKU4-CoV antigens, HKU5-CoV antigens, PDF-2108 CoV antigens, SHC014-CoV antigens, BtSCoV-RsSHC014 antigens, BtSCoVRs3367 antigens, BANAL-52 antigens, BANAL-236 antigens, Pangolin CoV GX / P2V antigens, bat coronavirus CDPHE15 antigens, bat coronavirus HKU10 antigens, Rhinolophus ferrumequinum alphacoronavirus HuB-2013 antigens, coronavirus antigens 229E human, Lucheng Rn rat coronavirus antigens, mink coronavirus 1 antigens, ferret coronavirus antigens, Miniopterus bat coronavirus 1 antigens, Miniopterus bat coronavirus HKU8 antigens, Myotis ricketti Sax-2011 alphacoronavirus antigens,Nyctalus velutinus alphacoronavirus SC-2013 antigens, Pipistrellus kuhlii coronavirus 3398 antigens, porcine epidemic diarrhea virus antigens, Scotophilus bat coronavirus 512 antigens, Rhinolophus bat coronavirus HKU2 antigens, human NL63 coronavirus antigens, BtKYNL63-9b strain antigens of the related bat coronavirus NL63, Sorex araneus coronavirus T14 antigens, Suncus murinus coronavirus BtKYNL63-9b strain of bat coronavirus related to NL63, HCoV-229E antigens, Khosta2 sarbecovirus antigens, Kenyan bat coronavirus BtKY72 antigens, HKU3 SARS bat coronavirus antigens,Wuhan coronavirus antigens, BA.1 coronavirus antigens, BA.2 coronavirus antigens, B.1.351 coronavirus antigens or any combination of these.

24. Fusion polypeptide according to claim 23 characterized in that the coronavirus antigen comprises a receptor-binding domain, a fragment thereof or a protein encoded by a sequence of nucleotides with at least 70% identity to a Coronaviridae receptor-binding domain.

25. Fusion polypeptide according to any one of claims 1 to 24 characterized in that the first antigen and at least one additional antigen, each independently, comprise a prokaryotic antigen, a viral antigen or a fungal antigen.

26. Fusion polypeptide characterized by comprising an amino acid sequence encoding a plurality of antigens in series, wherein each of the plurality of antigens is linked to a preceding antigen-binding sequence.

27. Fusion polypeptide according to claim 26 characterized in that the plurality of antigens comprises three or more antigens.

28. Fusion polypeptide according to claim 26 or 27 characterized in that each of the plurality of antigens independently comprises a prokaryotic antigen, a viral antigen or a fungal antigen.

29. Fusion polypeptide according to any one of claims 26 to 28 characterized in that the linkage sequence comprises 6 to 24 amino acids.

30. Fusion polypeptide according to claim 29 characterized in that the linkage sequence comprises glycine (G), serine (S), alanine (D) or any combination thereof.

31. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a Wuhan coronavirus antigen and a B.1.617.2 coronavirus antigen.

32. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a Wuhan coronavirus antigen and a BA.1 coronavirus antigen.

33. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a coronavirus antigen B.1.351, a Wuhan coronavirus antigen and a coronavirus antigen BA.

1.

34. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen and a Bt SL-CoV-WIV1 antigen. Petition 870250095390, dated 10 / 19 / 2025, pp. 125 / 166 7 / 13 35. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a BA.2 coronavirus antigen, a Kenyan bat coronavirus antigen BtKY72, and a BtSCoVRsSHC014 antigen.

36. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a Wuhan coronavirus antigen, a pangolin CoV GX / P2V antigen and a Bt SL-CoV-WIV1 antigen.

37. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen, a BtSCoV-RsSHC014 antigen and a Bt SL-CoV-WIV1 antigen.

38. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a BA.2 coronavirus antigen, a bat SARS HKU3 coronavirus antigen, a Kenyan bat BtKY72 coronavirus antigen and a Bt SL-CoV-WIV1 antigen.

39. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a Wuhan coronavirus antigen, a Khosta2 sarbecovirus antigen, a BtSCoV-RsSHC014 antigen and a SARS-CoV-1 antigen.

40. Fusion polypeptide according to any one of claims 1-30 characterized by comprising a Wuhan coronavirus antigen, a BtCoV-RaTG13 antigen, a Kenya bat coronavirus BtKY72 antigen and a Bt SL-CoV-WIV1 antigen.

41. Fusion polypeptide according to any one of claims 1-40 characterized in that the antigen comprises either a receptor-binding domain or an S1 domain.

42. Fusion polypeptide according to any one of claims 1-41 characterized in that the antigen comprises a sequence selected from the group consisting of SEQ ID NOs: 12-24 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with a sequence selected from the group consisting of SEQ ID NOs: 12-24. Petition 870250095390, dated 10 / 19 / 2025, pp. 126 / 166 8 / 13 43. Fusion polypeptide characterized by having SEQ ID NO:1 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

1.

44. Fusion polypeptide characterized by possessing SEQ ID NO:2 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

2.

45. Fusion polypeptide characterized by possessing SEQ ID NO:3 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

3.

46. ​​Fusion polypeptide characterized by possessing SEQ ID NO:4 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

4.

47. Fusion polypeptide characterized by having SEQ ID NO:5 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

5.

48. Fusion polypeptide characterized by possessing SEQ ID NO:6 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

6.

49. Fusion polypeptide characterized by having SEQ ID NO: 7 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

7.

50. Fusion polypeptide characterized by having SEQ ID NO:8 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

8.

51. Fusion polypeptide characterized by having SEQ ID NO:9 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

9.

52. Fusion polypeptide characterized by having SEQ ID NO:10 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

10.

53. Fusion polypeptide characterized by possessing SEQ ID NO:11 or a sequence with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with SEQ ID NO:

11. Petition 870250095390, dated 10 / 19 / 2025, pp. 128 / 166 10 / 13 54. Immunogenic composition characterized by comprising the fusion polypeptide of any one of claims 1 to 53, and a pharmaceutically acceptable salt, carrier or adjuvant.

55. Immunogenic composition according to claim 54, characterized in that it is for use in the treatment or prevention of a pathogenic infection in a subject in need thereof.

56. Use of the polypeptide of any of claims 1 to 53 or of the immunogenic composition of claim 54 characterized in being in the manufacture of a medicament for the treatment or prevention of a pathogenic infection in a subject in need.

57. Use of the polypeptide of any of claims 1 to 53 or of the immunogenic composition of claim 54, characterized in that it is for the treatment or prevention of a pathogenic infection in a subject in need thereof.

58. A method for treating or preventing a pathogenic infection, characterized by comprising administering an effective amount of the fusion polypeptide of any of claims 1 to 53 or of the immunogenic composition of claim 54 to a subject in need thereof.

59. Use as defined in claim 56 or 57 or of the method of claim 58 characterized in that the pathogenic infection comprises a viral infection, a bacterial infection or a fungal infection.

60. Use or method as defined in claim 59, characterized in that the pathogenic infection comprises a viral infection.

61. Use or method as defined in claim 60, characterized in that the viral infection comprises a coronavirus.

62. Uses or methods according to claim 61, characterized by the fact that the coronavirus comprises MERS-CoV, SARS-CoV-1 SARSCoV-2, HCoV-HKUI, HCoV-OC43, BtCoV-RaTG13, Bt SL-CoV-WIV1, HKU4CoV, HKU5-CoV, 63; PDF-2108 CoV, SHC014-CoV, BtSCoV-RsSHC014, BtSCoVRs3367, BANAL-52, BANAL-236, Pangolin-CoV GX / P2V, morsel CDPHE15 coronavirus, morsel HKU10 coronavirus, Rhinolophus alphacoronavirus HuB2013 ferrumequinum, human coronavirus 229E, Lucheng Rn mouse coronavirus, mink coronavirus 1, furan coronavirus, Miniopterus morsel Coronavirus 1, Miniopterus morsel HKU8 coronavirus, Petition 870250095390, 10 / 19 / 2025, p. 129 / 166 11 / 13 alphacoronavirus Sax-2011 of Myotis ricketti, alphacoronavirus SC-2013 of Nyctalus velutinus, Coronavirus 3398 of Pipistrellus kuhlii, virus of swine epidemic diarrhea, coronavirus 512 of Scotophilus strain , coronavirus HKLI2 of Rhinolophus, human coronavirus NL63,strain BtKYNL63-9b of ao-related morsel coronavirus NL63, Sorex araneus coronavirus T14, Suncus murinus coronavirus X74, Alphacoronavirus 1, canine coronavirus, feline coronavirus, human CCoV-HuPn-2018, swine transmissible gastroenteritis coronavirus, da swine acute diarrhea syndrome (SADS-CoV), HCoV-NL63, BtKYNL63-9b strain of NL63-related morsel coronavirus, HCoV-229E, Khosta2 sarbecovirus, WIV1 SARS-like morsel coronavirus, BtKY72 morsel coronavirus of Kenya, morsel coronavirus SHC014, pangolim coronavirus Pang17, morsel HKU3 SARS coronavirus, SARS Urbani coronavirus, morsel RaTG13 coronavirus, Wuhan coronavirus, coronavirus BA.1, coronavirus BA.2, coronavirus B.1,351 or any combination thereof; or virus with at least 60% nucleotide identity with MERS-CoV, SARS-CoV-1, SARS-CoV2, HCoV-HKLH, HCoV-0043, BtCoV-RaTG13, Bt SL-CoV-WIV1, HKU4-CoV, HKU5-CoV, PDF-2108 CoV, SHC014-CoV, BtSCoV-RsSHC014,BtSCoVRs3367, BANAL-52, BANAL-236, Pangolin-CoV GX / P2V, morsel CDPHE15 coronavirus, morsel HKU10 coronavirus, Rhinolophus ferrumequinum alphacoronavirus HuB2013, human coronavirus 229E, Lucheng Rn mouse coronavirus, 1 de mink, furrow coronavirus, Miniopterus brood coronavirus 1, Miniopterus brood coronavirus HKU8, Myotis ricketti alphacoronavirus Sax-2011, Nyctalus velutinus alphacoronavirus SC-2013, Pipistrellus kuhlii coronavirus 3398, swine epidemic diarrhea virus, coronavirus 512 of the Scotophilus brood, HKU2 coronavirus of the Rhinolophus brood, human coronavirus NL63, BtKYNL63-9b strain of NL63-related brood coronavirus, coronavirus T14 of Sorex araneus, coronavirus X74 of Suncus murinus, Alphacoronavirus 1, canine coronavirus, coronavirus feline, CCoV-HuPn-2018 human, swine transmissible gastroenteritis coronavirus, swine acute diarrhea syndrome coronavirus (SADS-CoV), HCoV-NL63,strain BtKYNL63-9b of bat coronavirus related to NL63, HCoV-229E, sarbecovirus Khosta2, bat SARS-like coronavirus WIV1, Kenyan bat coronavirus BtKY72, coronavirus Petition 870250095390, dated 19 / 10 / 2025, p. 130 / 166 12 / 13 SHC014 bat coronavirus, Pang17 pangolin coronavirus, HKU3 SARS bat coronavirus, SARS Urbani coronavirus, RaTG13 bat coronavirus, Wuhan coronavirus, BA.1 coronavirus, BA.2 coronavirus, B.1.351 coronavirus or any combination thereof.

63. Use or method as defined in any of claims 56 to 62 characterized in that the fusion polypeptide or immunogenic composition is for administration one or more times.

64. Use or method as defined in any one of claims 56 to 63 characterized in that the fusion polypeptide or immunogenic composition neutralizes two or more different pathogens, two or more different antigens, or both in the subject.

65. The use or method of claim 64 characterized in that the two or more different pathogens comprise two or more protein variants derived from the same parental or ancestral pathogen.

66. Use or method according to claim 65 characterized in that the two or more pathogens comprise two or more coronaviruses, two or more coronavirus variants, or any combination thereof.

67. Use or method according to any of claims 56 to 66 characterized by the fusion polypeptide or immunogenic composition reducing the amount of pathogen in the subject.

68. Nucleic acid encoding the fusion polypeptide defined in any one of claims 1 to 53 characterized by comprising a sequence selected from the group consisting of: SEQ ID NO:25-67; ​​or encoding a fusion polypeptide with at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity with the fusion polypeptide of any one of claims 1 to 53.

69. Transformed cell characterized by being transformed with the nucleic acid defined in claim 68 or expressing the fusion polypeptide of any of claims 1 to 53. Petition 870250095390, dated 10 / 19 / 2025, pp. 131 / 166 13 / 13 70. Cell according to claim 69 characterized in that the cell comprises a mammalian cell, a yeast cell, a plant cell, a bacterial cell or an insect / arthropod cell.

71. The cell according to claim 70 characterized in that the mammalian cell comprises a Chinese Hamster Ovary (CHO) cell. Petition 870250095390, dated 10 / 19 / 2025, pp. 132 / 166

Images